Interferon induction by paramyxoviruses : investigations into specific RNA:protein interactions by Dominguez Palao, Francisco
INTERFERON INDUCTION BY
PARAMYXOVIRUSES: INVESTIGATIONS INTO
SPECIFIC RNA:PROTEIN INTERACTIONS
Francisco Dominguez
A Thesis Submitted for the Degree of PhD
at the
University of St Andrews
2017
Full metadata for this item is available in
St Andrews Research Repository
at:
http://research-repository.st-andrews.ac.uk/
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10023/10750
This item is protected by original copyright
This item is licensed under a
Creative Commons Licence
Interferon induction by 
paramyxoviruses: investigations into 
specific RNA:protein interactions 
Francisco Dominguez 
 
 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of 
Philosophy at the University of St Andrews 
 
January 2017 
 
  
 
I 
ABSTRACT 
RNA:protein interactions are central in many cellular processes, including 
activation of innate immune responses against microbial infection. Their study 
is essential to better understand the diverse biological events that occur within 
cells. However, isolation of RNA:protein complexes is often laborious and 
requires specialized techniques. This thesis is concerned with attempts to 
develop an improved purification protocol to isolate specific RNA:protein 
complexes. Taking advantage of the specific interaction of the Pseudomonas 
aeruginosa PP7 protein with its cognate RNA binding site, termed the PP7 
recognition sequence (PRS), the aim was to identify cellular proteins involved 
in activating cell-signalling pathways, including the interferon-induction 
cascade, following viral infection with stocks of parainfluenza virus 5 (PIV5) 
rich in copyback defective interfering (DI) particles. Copyback DI genomes are 
powerful inducers of IFN and, here, I show they also activate the induction of 
IL-6, IL-8 and TNFα; cytokines that also have antiviral properties. 
Following the successful cloning of the PRS into a copyback DI genome, we 
investigated conditions for optimal in vitro capture of DI-PRS:protein complexes 
by PP7 on Dynabeads. When tested, the protocol led to the successful capture of 
ILF3 and PKR, two dsRNA binding proteins induced by IFN. We further 
developed a tap-tagging system to minimize the presence of non-specifically 
bound proteins to Dynabeads that may interfere with future mass spectrometry 
analysis. To isolate DI-PRS RNA:protein complexes from infected cells, 
attempts were made to rescue replicating DI-PRS genomes in the context of 
wild type PIV5. Similarly, efforts were made to isolate influenza A virus RNPs 
that contained the PRS in the neuraminidase (NA) gene from infected cells 
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using the PP7-based protocol developed. However, for reasons discussed, 
unfortunately RNA:protein complexes were not successfully purified from 
infected cells in either case. 
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CHAPTER 1: INTRODUCTION 
1.1. General introduction to innate immunity 
Eukaryotic organisms rely on their immune system to detect and eliminate 
microbes (Reikine et al., 2014). To facilitate understanding of how the immune 
system carries out its diverse actions, it has generally been divided into the 
innate and the adaptive immune system. Nevertheless, this separation is only 
conceptual, as both 'arms' of the immune response act cooperatively to 
eliminate infection. The innate immune response is the first line of defence 
against infection and is essential to activate the adaptive immune response. It 
includes a diversity of cellular receptors that detect the presence of foreign 
invaders (e.g. viruses), initiating a series of signalling cascades in cells that 
culminate with the production of hundreds of molecules, many of them with 
antimicrobial properties. 
The innate immune system is as ancient as is the bacterial 'immune' response to 
bacteriophages (Kotwal et al., 2012). No thorough attention had been paid to it 
until relatively recently, when some studies showed that the innate immune 
system possesses a high degree of specificity and is able to discriminate 
between self and foreign pathogens (Akira, 2009). The innate immune system is 
initiated by the interaction of stereotypical pathogen components with germ-
line encoded receptors (Akira, 2009; Kotwal et al., 2012). These host pattern 
recognition receptors (PRRs) constitute different ways to detect the presence of 
an invading microorganism and they are constantly surveying the extracellular 
space, endolysosomal compartments and cytoplasm in search of signs of 
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infection (Barton and Kagan, 2009). PRRs detect widely conserved chemical 
patterns or structures in microbes, or pathogen-associated molecular patterns 
(PAMPs), including bacterial cell wall elements and microbial nucleic acids 
(Reikine et al., 2014). 
PRRs are divided into a number of families, including Toll-like receptors 
(TLRs), C-type lectin receptors (CLRs), nucleotide-binding oligomerization 
domain (NOD) leucine-rich repeat-containing molecules (NOD-like receptors, 
NLRs), deoxyribonucleic acid (DNA)-binding factors and RIG-I-like receptors 
(RLRs) (Reikine et al., 2014; Wilkins and Gale, 2010). RLRs are cytosolic 
receptors and are the main detectors of ribonucleic acid (RNA) virus infection. 
The RLR family includes proteins encoded by the retinoic acid-inducible gene-I 
(RIG-I), the melanoma differentiation-associated gene 5 (Mda5) and the 
laboratory of genetics and physiology protein 2 gene (LGP2) (Kotwal et al., 
2012). Upon viral infection, RLRs recognize characteristic features that are 
present in non-self RNA (e.g. viral RNA) but not in host, self RNA. Following 
recognition, RIG-I and Mda5 are activated, triggering the induction of 
signalling pathways that end with the production of proteins with antiviral 
action, including type I interferon (IFN). IFNs include a broad family of 
multifunctional secreted cytokines involved in antiviral defence, cell growth 
regulation and immune activation (Goodbourn et al., 2000). They are divided 
into type I, type II and type III IFNs. Type I IFNs are directly induced by viral 
infection. Once generated, they are secreted and act in an autocrine and 
paracrine manner, inducing the activation of signalling pathways in cells that 
culminate with the production of hundreds of proteins with antiviral activity. 
The overall result is the induction of an antiviral response in cells that inhibits 
virus replication and spread (Hayden and Ghosh, 2004) (Fig. 1.1). 
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Fig. 1.1. IFN induction by viruses. Type I IFN (IFNα/β) is released from infected cells and, 
together with type II IFN (IFNγ), acts in neighbouring cells, and also in infected cells, to 
establish an antiviral state in them. Adapted from Randall and Goodbourn, 2007. 
1.2. IFNs play an essential role in innate immunity 
IFNs are the first known members of the fundamental family of biological 
regulatory proteins called cytokines (Sen, 2001). They were discovered by Alick 
Isaacs and Jean Lindenmann when they were infecting chorio-allantoic 
membranes of chick embryos with influenza viruses (Isaacs and Lindenmann, 
1957). Isaacs and Lindenmann observed that cells that had previously been 
challenged with a stock of inactivated viruses were more resistant to further 
infections with live viruses. They discovered that cells pre-infected with a stock 
of inactivated viruses secreted a substance that 'interfered' with the outcome of 
future viral infections. 
The IFN system is an exceptionally powerful antiviral response that can control 
most, if not all, virus infections (Randall and Goodbourn, 2008). All viruses 
need to have ways to counteract, at least in part, the IFN response in order to 
efficiently replicate and survive in cells. According to their amino acid 
sequence, IFNs are classified into three subfamilies: type I, II and III IFNs. Type 
I IFNs consist of a large group of evolutionary related molecules generated 
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from distinct IFNα genes, an IFNβ gene and other genes including IFNω, IFNε, 
IFNτ, IFNδ and IFNκ (Pestka et al., 2004). Induction of high levels of type I IFNs 
is the main initial response of mammalian cells to many viral infections (Biron 
and Sen, 2001). The IFNα family is a group of polypeptides that share high 
homology and are encoded by more than 13 genes in humans (Hervas-Stubbs et 
al., 2011; Sen, 2001), whereas the IFNβ family involves only 1 single molecule in 
most species (Hervas-Stubbs et al., 2011). The IFNα/β genes are induced directly 
in response to viral infection, whereas IFNω, ε, δ and κ play diverse roles, such 
as regulators of maternal recognition in pregnancy (Randall and Goodbourn, 
2008). The IFNα/β genes are coordinately regulated because the upstream 
regulatory regions of these genes are highly homologous (Sen, 2001). They are 
produced by almost every cell in the body in response to viral infection, 
although leukocytes are the main producers of IFNα, whereas IFNβ is 
predominantly produced by non-hematopoietic cells, being particularly 
synthesised by fibroblasts (Goodbourn et al., 2000). IFNα/β signal through a 
unique heterodimeric receptor, the cell-surface IFNα receptor (IFNAR). IFNAR 
is composed of 2 subunits, termed IFNAR1 and IFNAR2, which are present in 
nearly all tissues (Mogensen et al., 1999). All type I IFNs generally induce the 
same set of genes, although there are also IFNα/β-specific genes (Rani et al., 
1999). 
IFNγ, or 'immune IFN', is the only type II IFN and it is particularly synthesised 
by activated T cells and natural killer cells upon recognition of infected cells 
(Biron and Sen, 2001). IFNγ has functional, but not structural, homology with 
type I IFNs (Sen, 2001). IFNγ binds the cell-surface IFNγ receptor (IFNGR) that 
also includes 2 different subunits, IFNGR1 and IFNGR2 (Pestka et al., 2004). 
IFNγ induces a specific set of genes partially overlapping with those induced by 
type I IFNs (Sen, 2001). Type III IFNs have been more recently discovered and 
Chapter 1: 
Introduction 
 
 
5 
include the products of the IFNλ1 (interleukin, IL-29), IFNλ2 (IL-28A) and 
IFNλ3 (IL-28B) genes in humans (Randall and Goodbourn, 2008). Although 
type III IFNs are induced by the same cellular pathways as IFNα/β, the type III 
IFN receptor has a more limited tissue distribution than the IFNα/β receptor 
(Onoguchi et al., 2007). The IFNλ receptor is primarily expressed on epithelial 
cells and specific subsets of immune cells, therefore acting predominantly at 
mucosal surfaces (Bierne et al., 2012). 
Since they were discovered, an extensive research has been made in IFNs to 
elucidate how they 'interfere' with the normal replication of different viruses. 
IFNs are also widely used for therapeutical applications. For example, 
pegylated IFNα, together with ribavirin, is the standard treatment for chronic 
hepatitis C virus infections (NHS, 2016). IFNα has also been widely used to 
treat genital warts caused by papilloma virus infection (Yang et al., 2009). Both 
IFNα and IFNβ have proved to be effective in vitro in inhibiting the replication 
of severe acute respiratory syndrome coronavirus (SARS-CoV) (De Clercq, 
2006). IFN is also used to treat patients suffering from some non-infectious 
illnesses. For example, solid and hematologic malignancies are frequently 
treated with type I IFN systemic injections (Kirkwood, 2002), and multiple 
sclerosis is normally treated with controlled doses of IFNβ (Airas et al., 2007). 
1.3. RLRs and the IFN response in viral infection 
1.3.1. Overview of PRRs and introduction to RLRs 
PRRs are divided into several families, each of them located at specific cellular 
compartments or in the cytoplasm and showing different recognition 
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specificities. Nucleic acids are the largest and possibly the most important class 
of ligands for PRRs (Reikine et al., 2014). Cells possess endogenous nucleic 
acids in both the cytoplasm and nucleus. Therefore, cellular receptors have 
evolved to recognize particular features in nucleic acids that can only be found 
in foreign, non-self, RNA or DNA. Restricted location of these cellular receptors 
is also a way to minimize their activation by host nucleic acids (Janeway and 
Medzhitov, 2002). Innate immune receptors from all families nucleate the 
assembly of broad multimeric protein complexes with their signalling adaptors 
(i.e. MAVS, MyD88, TRIF or ASC) to activate the signalling cascades that lead 
to an effective innate immune response (Ferrao et al., 2012) (Fig. 1.2). 
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Fig. 1.2. Recognition of viral RNA by PRRs. TLRs recognize foreign RNA in endosomal 
compartments and signal through the adaptor molecules TRIF or MyD88, whereas RLRs 
recognize viral RNA in the cytoplasm and signal through MAVS. NLRP3 is part of the 
inflammasome complex and, together with ASC, activate the pro-inflammatory proteins IL-1β 
and IL-18. Adapted from Horner, 2016. 
TLRs were the first receptors discovered that play a role in pathogen 
recognition. They are transmembrane receptors (10 in humans) located at the 
cell surface or within endosome compartments (Barbalat et al., 2011; Wilkins 
and Gale, 2010). A subfamily of TLRs (TLRs 3, 7, 8 and 9) recognizes foreign 
RNA and DNA ligands (Nishiya et al., 2005; Rigby et al., 2014). TLR3 was the 
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first TLR involved in recognition of viral nucleic acids. TLR3 detects double-
stranded (ds) RNA, whereas TLR7 and 8 detect single-stranded (ss) RNA, all of 
them within endosomal compartments (Barbalat et al., 2011). TLR9 was one of 
the first non-self DNA sensors shown to play a role in innate immunity (Hemmi 
et al., 2000). 
Viral nucleic acids are mainly recognized by cytosolic PRRs. Cytosolic PRRs are 
composed of several families, including the DNA-binding factors, the NLRs 
and the RLRs (Wilkins and Gale, 2010). The first reported cytoplasmic DNA 
receptor was DNA-dependent activator of IFN-regulatory factors (DAI) 
(Takaoka et al., 2007). DAI recognizes intracytosolic viral DNA (Ishii et al., 
2006). Another molecule, cyclic guanosine monophosphate-adenosine 
monophosphate (cGAMP) synthase (cGAS), is also a cytosolic DNA receptor 
producing cGAMP that binds and activates the adaptor molecule stimulator of 
IFN genes (STING) (Sun et al., 2013). NLRs have been shown to be important in 
sensing cytosolic DNA and triggering inflammasome-dependent innate 
immune signalling (Petrilli et al., 2007). Apart from type I IFN, viruses also 
trigger the expression of pro-inflammatory cytokines in infected cells, including 
IL-1β and IL-18. Activation of IL-1β and IL-18 is dependent on a complex that 
includes specific NLRs and is called the inflammasome complex. Stimulated 
NLRs oligomerize and recruit caspase1. Interactions with NLRs induce self-
cleavage of caspase1 that is activated and, in turn, cleaves pro-IL-1β and pro-IL-
18 that are released as mature pro-inflammatory proteins (Bryant and 
Fitzgerald, 2009). NLRs are formed by four inflammasome subfamilies: NLRP1, 
NLRP3, IPAF and AIM2 (Petrilli et al., 2007). NLRP3 (also known as NALP3 or 
cryopyrin) is part of the inflammasome complex, that also includes its adaptor 
molecule apoptotic speck-like protein containing a CARD (ASC) and caspase1 
(Cassel et al., 2009). The IFN-inducible protein absent in melanoma 2 (AIM2) 
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also recognizes cytosolic dsDNA and acts as a regulator of DNA-mediated 
inflammatory responses (Hornung et al., 2009). 
RLRs are cytoplasmic receptors that recognize characteristic signatures in viral 
dsRNA (Kato et al., 2006). The RLR family consists of three members in 
mammals, all of them expressed in virtually every cell in the body: RIG-I (also 
known as DDX58), Mda5 (also known as IFIH1) and LGP2 (also known as 
DHX58) (Yoneyama and Fujita, 2010). RIG-I is the founding member of the RLR 
family and was originally identified as a gene induced in retinoic acid-treated 
acute promyelocytic leukemia cells (Yu et al., 1997). Mda5 was originally 
identified as a gene induced by IFN in a melanoma cell-line (Kang et al., 2002) 
and was later observed to have similar properties to RIG-I, playing a critical 
role in the IFN response to viral infection (Andrejeva et al., 2004). 
RIG-I, Mda5 and LGP2 structures are depicted in Fig. 1.3. RIG-I contains two N-
terminal domains (NTDs) in tandem which are essential for signalling activity, 
the caspase activator and recruitment domains (CARDs). It also contains a 
central internal death domain fold, the DExD/H-box helicase domain, with 
ATPase activity that is activated by ligand binding and is essential for 
signalling. DExD/H-box is connected with the C-terminal domain (CTD) via a 
flexible linker (Anchisi et al., 2015). The DExD/H-box helicase domain consists 
of two RecA-like helicase domains, termed Hel1 and Hel2, and also an insert 
domain, termed Hel2i (Kowalinski et al., 2011). Part of the CTD of RIG-I acts as 
a repressor domain (RD) that keeps the molecule inactive in the absence of 
infection (Wilkins and Gale, 2010). Mda5 also contains two tandem N-terminal 
CARDs and an internal DExD/H-box helicase domain. However, the CTD in 
Mda5 does not function as an inhibitory domain as in RIG-I (Saito et al., 2007). 
LGP2, in contrast, does not possess CARD domains, although it still contains a 
Chapter 1: 
Introduction 
 
 
10 
DExD/H-box helicase domain and a RD in the CTD (Yoneyama and Fujita, 
2009). All RLRs possess a zinc-binding region in their CTD (Cui et al., 2008). 
 
 
 
 
 
 
 
 
Fig. 1.3. Structure of RLRs. Both RIG-I and Mda5 contain two tandem N-terminal CARDs. 
Together with LGP2, they also possess a central DExD/H-box helicase domain. The CTDs of 
RIG-I and LGP2 act as RDs whereas the CTD of Mda5 does not show an inhibitory function. 
Adapted from Yoneyama et al., 2015. 
1.3.2. Structural features in viral RNA for recognition by RLRs 
When first characterized, RIG-I and Mda5 were both implicated in recognition 
of the synthetic dsRNA analog polyinosinic:polycytidylic acid (poly[I:C]). It 
was soon observed that long polymers of poly(I:C) (>2 kbp) were preferentially 
detected by Mda5 whereas smaller polymers (as short as 70 bp) were mainly 
recognized by RIG-I (Kato et al., 2008). It was also observed that RIG-I detected 
the synthetic ligand short, uncapped 5'-triphosphate (5'ppp) ssRNA (Pichlmair 
et al., 2006), although further research showed that 5'ppp ssRNA must contain 
small regions of base pairing to activate RIG-I (Schlee et al., 2009). 
It is now generally believed that RIG-I can be activated by short (≥10 bp) 
triphosphorylated or diphosphorylated (5'pp) dsRNA structures (Weber, 2015), 
although RIG-I-mediated sensing of viral ssRNA bearing 5'-phosphates has also 
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been reported (Pichlmair et al., 2006). The most prominent known ligand, 
however, is a 5'ppp dsRNA with blunt ends and with a minimum length of 
around 10 bp (Schmidt et al., 2009). 
The requirement of RNA to contain a 5'ppp so as it can be detected by RIG-I 
allows discrimination between self and non-self RNA (Hornung et al., 2006). All 
RNA transcripts generated in the nucleus of eukaryotic cells initially contain a 
5'-triphosphate, but host RNAs do not have 5'-triphosphates free in the cytosol. 
Host RNA, e.g. mRNA, is capped with a 7-methyl-guanosine group at its 5' end 
and contains a polyadenylate tail (poly-A) at its 3' end. This makes self mRNA 
lacking free 5'-phosphates (Pichlmair et al., 2006). The 5'-phosphate group is 
also highly inaccessible in rRNA and tRNA as a result of association with 
ribosomal proteins or formation of cloverleaf structures containing 3' 
overhangs. The mRNAs of viruses commonly contain 5' end capped structures 
and 3' poly-A tails, but RNA synthesis often leads to transient cytosolic viral 
RNA intermediates with an uncapped 5'-triphosphate end that makes them 
susceptible to be recognized by cytosolic receptors (Hornung et al., 2006; 
Pichlmair et al., 2006). 
The ligand for Mda5 is less well known. Mda5 is the primary sensor of poly(I:C) 
and preferentially recognizes long dsRNAs (>1 kbp), whereas RIG-I is involved 
in the recognition of short dsRNAs (≤1kbp) (Kato et al., 2008). 
Even when RIG-I and Mda5 are structurally similar proteins, they detect 
different sets of viruses. For example, respiratory syncytial virus (RSV), 
Hepatitis C virus (HCV), vesicular stomatitis virus (VSV) and influenza A virus 
are recognized by RIG-I, whereas Mda5 mainly recognizes picornaviruses (e.g. 
poliovirus and encephalomyocarditis virus). Some viruses are recognized by 
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both RIG-I and Mda5 (e.g. viruses from paramyxovirus, reovirus and flavivirus 
families) (Kato et al., 2006). This differential recognition may be due to certain 
viruses lacking appropriate ligands for RIG-I or Mda5, or have evolved evasion 
strategies for specific RLRs (Barbalat et al., 2011). 
1.3.3. RLR (RIG-I/Mda5)-dependent induction cascade 
1.3.3.1. Activation of RLRs 
RLRs are in an inactive state and only get activated upon recognition of foreign 
RNA. In this respect, the RD regions in RIG-I and LGP2 play an important role. 
RD in RIG-I keeps the molecule inactive until RNA binding triggers a 
conformation change (Wilkins and Gale, 2010). A region in the CTD of RIG-I 
overlapping with RD is responsible for the specific recognition of viral RNA 
(Yoneyama and Fujita, 2009). In uninfected cells, RIG-I is in an auto-repressed 
conformation, with the CTD exposed and scanning the cytoplasm in search of 
RNA ligands (Weber, 2015). The open conformation of the domains in the 
helicase region, with the second CARD (2CARD) bound to the Hel2i domain, 
sterically blocks CARDs interactions with polyubiquitin or CARDs from other 
binding partners, and thus prevents signalling to the signalling adaptor MAVS 
(Kowalinski et al., 2011). 
An adenosine-5'-triphosphate (ATP)-dependent conformational change occurs 
in RIG-I after RNA binding that releases the CARD domains for signalling 
(Wilkins and Gale, 2010). Lack of CARDs in LGP2 prevents further signalling 
upon activation of the molecule. In the past, it was assumed that LGP2 acted as 
an inhibitor of RIG-I/Mda5 activation, but recent studies have shown that LGP2 
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plays a more extensive role in modulating RIG-I/Mda5 activation 
(Venkataraman et al., 2007). Mda5 CTD does not contain RD and this allows the 
molecule to signal constitutively when expressed in abundance, reflecting an 
important role for Mda5 in amplifying IFN production and the host response 
(Saito et al., 2007). 
RIG-I activation in infected cells, when the CTD recognizes a specific RNA 
ligand, is shown in Fig. 1.4. 3 steps are required: RNA recognition, ATPase 
activity, and exposure of the CARDs for signalling (Anchisi et al., 2015). First, 
CTD in RIG-I recognizes and binds 5'ppp dsRNA independently of ATP 
binding (Patel et al., 2013), and the recognition is helped by zinc coordination in 
cysteine residues in RD (Cui et al., 2008). RIG-I surrounds dsRNA, adopting a 
more compact conformation (Jiang et al., 2011), and this permits ATP to bind 
RIG-I (Luo et al., 2011). Effective RIG-I binding of short RNA ligands is 
dependent on the presence of triphosphate, and the ATPase activity requires 
the presence of a blunt-end formation at the triphosphate end (Schlee et al., 
2009). An ATP-dependent conformational change occurs, inducing a packed 
complex formation of the helicase domain: CTD with dsRNA (Kowalinski et al., 
2011). This conformational change disrupts the CARD:Hel2i interaction, as the 
CARDs and dsRNA bind partially to the same helicase region (Anchisi et al., 
2015). The CARDs, released from auto-repression, are available for interaction 
with MAVS (Kowalinski et al., 2011). Although RIG-I binding to RNA is 
independent of ATPase activity, ATP hydrolysis is essential for RIG-I signalling 
(Anchisi et al., 2015). 
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Fig. 1.4. Schematic of RIG-I activation. (A) RIG-I leaves the auto-repressed conformation (B) 
upon capture of 5'ppp dsRNA by the CTD. (C) Cooperative ATP and dsRNA binding to the 
helicase drives a conformational switch that leads to a closed form with high affinity for 
dsRNA, where CARDs (C1 and C2) are released. ATP hydrolysis could allow cycling between 
(C) and (D) pending CARD ubiquitination. (D) K63-linked polyubiquitination of the CARDs 
allows downstream signalling via MAVS. (E) ATP hydrolysis leads to helicase re-opening and 
recycling of RIG-I as long as the CARDs no longer bind polyubiquitin. Dotted lines represent 
flexible linkers. Adapted from Kowalinski et al., 2011. 
The helicase domain and CTD of Mda5 surrounds dsRNA in the same manner 
as RIG-I. Contrary to RIG-I, Mda5 CTD interacts with the dsRNA stem allowing 
both ends of dsRNA to be free from interaction (Wu et al., 2013). Mda5 CTD 
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brings the dsRNA closer as compared to the RIG-I structure, allowing contact of 
CTD with Hel1 and forming a closed ring around the dsRNA. This promotes 
cooperative filament formation along the dsRNA that is initiated from internal 
sites in the dsRNA, as opposed to RIG-I where filament formation begins from 
one of the ends (Peisley et al., 2011). Filament formation along dsRNA is 
essential for the activation of RIG-I and Mda5, and is dependent on ATP 
hydrolysis (Patel et al., 2013). Mda5 specificity for long dsRNA is determined 
by filament assembly and disassembly dynamics (Reikine et al., 2014), and 
LGP2 could play a role in RNA recognition by Mda5 and filament formation 
(Bruns et al., 2014). Mda5 ATP-dependent filaments are longer and more stable 
than RIG-I filaments (Peisley et al., 2013). 
RIG-I/Mda5 oligomerization is essential for signalling and is driven by CARD-
CARD interactions (Patel et al., 2013; Saito et al., 2007). Large oligomers on 
RNA possibly induce more robust aggregation of MAVS, thereby leading to a 
strong activation of IFN (Patel et al., 2013). The minimal signalling unit for 
Mda5 contains no less than 11 Mda5 molecules, much larger than that required 
for RIG-I (Peisley et al., 2013). Increased levels of RIG-I during the IFN response 
may further promote its self-association and potentiate signalling to drive an 
IFN amplification loop (Saito et al., 2007). 
Ubiquitination is a versatile post-translational modification involved in various 
cellular functions. RIG-I, but not Mda5, requires E3 ubiquitin ligase tripartite 
motif containing (TRIM) 25-dependent ubiquitination to interact with MAVS 
(Gack et al., 2007). K63-polyubiquitination of RIG-I by TRIM25 also promotes 
oligomerization (Gack et al., 2007), facilitating the assembly of RIG-I into a 
tetrameric 'lock-washer' stabilized by CARD-CARD interactions (Reikine et al., 
2014). This provides stabilization of the oligomer, facilitating interaction with 
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MAVS and thereby increasing IFN signalling capacity, as shown in Fig. 1.4.D. 
The requirement for ubiquitination by RIG-I seems not to be completely strict, 
as ubiquitin-independent signal activation of RIG-I has also been reported 
(Peisley et al., 2013). 
1.3.3.2. MAVS activation and the IFNβ  induction pathway 
The RLR-dependent IFNβ induction pathway is illustrated in Fig. 1.5. Active 
RIG-I/Mda5 oligomers promote the polymerization and activation of 
mitochondrial antiviral signalling protein (MAVS) (Hou et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.5. The RLR-dependent IFNβ  induction pathway. RIG-I/Mda5 activation leads to 
activation of MAVS by initiating two different signalling pathways to activate the 
transcriptional activators NFκB and IRF3. NFκB and IRF3, together with ATF-2/c-Jun, form the 
enhanceosome complex that upregulates the IFNβ gene. Adapted from Randall and 
Goodbourn, 2008. 
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The RIG-I/Mda5-dependent signalling adaptor MAVS was identified by four 
different groups. MAVS (Seth et al., 2005), also called IFNβ promoter stimulator 
signalling protein 1 (IPS-1) (Kawai et al., 2005), virus-induced signalling 
adaptor (VISA) (Xu et al., 2005) and CARD adaptor inducing IFNβ (Cardif) 
(Meylan et al., 2005), contains a CARD domain that shares homology with RIG-
I/Mda5 CARDs (Johnson and Gale, 2006). It is composed of an N-terminal 
single CARD, a central proline-rich region and a transmembrane domain that 
specifically restricts mitochondrial localization of MAVS (Yoneyama et al., 
2015). MAVS CARD interacts with the 2 CARDs of RIG-I/Mda5 (Xu et al., 2005), 
nucleating the formation of MAVS polymers and drawing soluble MAVS 
monomers into the polymer. Polymeric MAVS activates downstream RLR 
signalling (Hou et al., 2011). 
MAVS oligomerization leads to the independent activation of the 
transcriptional activators NFκB and IRF3 (Kotwal et al., 2012). As it can be 
observed in Fig. 1.5, in the nuclear factor κB (NFκB) pathway the C-terminal 
effector domain in MAVS recruits the kinase receptor interacting protein 1 
(RIP1) and tumour necrosis factor (TNF) receptor-associated factor 6 (TRAF6) 
(Hiscott et al., 2006). TRAF6 recruitment and oligomerization activate its K63-
linked ubiquitin E3 ligase activity, leading to polyubiquitination of itself and 
RIP1 (Chen, 2005). Polyubiquitinated RIP1 is recognized and stabilized by 
NFκB essential modulator (NEMO), also known as the γ subunit of the IκB 
kinase (IKK) complex (Li et al., 2006; Wu et al., 2006). The polyubiquitin chains 
are recognized by transforming growth factor β (TGFβ)-activated kinase 1 
(TAK1)-binding proteins 2 and 3 (TAB2 and TAB3) (Kanayama et al., 2004), 
leading to the recruitment and activation of the inhibitor of κB (IκB) kinase 
kinase (IKKK) TAK1 to the complex (Wang et al., 2001). IKKα and IKKβ are two 
kinases that phosphorylate the inhibitors of NFκB, known as IκBs (Hayden and 
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Ghosh, 2004). They interact with NEMO and, together with NEMO, they form 
the IKK complex (Hayden and Ghosh, 2004). 
NFκB proteins are a family of transcriptional activators that regulate the 
expression of different proteins involved in the immune response (Hayden and 
Ghosh, 2004). They contain a conserved N-terminal Rel homology domain that 
is responsible for dimerization, interaction with IκBs and binding to DNA 
(Huang et al., 2000b). The five members of the mammalian NFκB family, p65 
(RelA), RelB, c-Rel, p50/p105 (NFκB1), and p52/p100 (NFκB2) exist as homo- or 
heterodimers. The p50/p65 heterodimer is the most abundant and it is found in 
almost all cell types (Huang et al., 2000b). In unstimulated cells, all NFκB 
proteins are bound to IκB proteins. There are seven IκB family members. IκBα 
binds to p65/p50 and masks the nuclear localization signal (NLS) of p65, 
whereas the NLS of p50 remains accessible. This accessible NLS coupled with 
the nuclear export signal (NES) present on IκBα and p65 results in constant 
shuttling of IκB:NFκB complexes between the nucleus and the cytoplasm, 
although they are mainly located in the cytosol (Huang et al., 2000b). 
Prior to induction, NFκB is held in the cytoplasm associated with IκB. Activated 
TAK1 phosphorylates the IKKβ subunit of the IKK complex, leading to the 
downstream phosphorylation of IκB, that is subsequently ubiquitinated and 
degradated (Randall and Goodbourn, 2008). Free from inhibition, the NLS of 
the p65 subunit becomes accessible and, as the NES contribution of IκB is 
removed, NFκB can translocate to the nucleus (Silverman and Maniatis, 2001). 
In the IFN regulatory factor 3 (IRF3) pathway (Fig. 1.5), MAVS recruits TRAF3. 
TRAF family member-associated NFκB activator (TANK) binds to the 
conserved TRAF domain of TRAF3 (Li et al., 2002). TANK also associates with 
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TANK-binding kinase 1 (TBK1) (Pomerantz and Baltimore, 1999), promoting 
stimulation of TBK1 and the related IKKε (also known as IKKi). TBK1 and IKKε 
are kinases that directly phosphorylate IRF3 (Fitzgerald et al., 2003). IRF3 has 
two compact domains: the N-terminal DNA-binding domain and the C-
terminal transactivation domain, essential for dimerization of the protein 
following virus-induced phosphorylation (Dragan et al., 2007). These domains 
are connected by a 70-residue proline-rich linker where a NES sequence resides 
(Lin et al., 1999). In unstimulated cells, IRF3 is held in the cytoplasm by the NES 
and the CTD blocks DNA binding to the NTD (Yoneyama et al., 1998). 
Activated IKKε/TBK1 phosphorylate several serine and threonine residues 
within the C-terminal transactivation domain of IRF3, relieving its association 
with the NTD (Tang et al., 2007). Phosphorylated IRF3 dimerizes and 
translocates to the nucleus (McWhirter et al., 2004). 
1.3.3.3. Formation of the enhanceosome complex and IFNβ  gene induction 
NFκB and phosphorylated IRF3 translocation to the nucleus is essential for 
IFNβ gene activation. NFκB, IRF3 and ATF-2/c-Jun heterodimers assemble 
cooperatively on the promoter to form the enhanceosome complex. The high-
mobility group (HMG) chromatin-associated protein HMGI(Y) (also known as 
HMGA) facilitates formation of the complex. The assembled enhanceosome 
components allow the recruitment of cAMP response element binding protein 
(CREB)-binding protein (CBP)/p300, as it possesses strong affinity for 
phosphorylated IRF3 (Randall and Goodbourn, 2008; Yoneyama et al., 1998). 
CBP/p300 has histone acetylase activity and may have a role in converting the 
chromatin from an inert to an activated conformation, which would aid 
recruitment of different transcription factors to optimize gene activation 
(Yoneyama et al., 1998). It also promotes the assembly of the basal 
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transcriptional machinery and the holoenzyme RNA polymerase II (PolII) (Yie 
et al., 1999). This aids binding of each of the transcription factors to the IFNβ 
promoter with limited affinity, although cooperativity between factors in the 
enhanceosome complex leads to optimal induction of the IFNβ promoter 
(Merika and Thanos, 2001), as can be seen in Fig. 1.6. 
 
 
 
 
 
 
Fig. 1.6. The enhanceosome complex. The enhanceosome complex is made from different 
transcriptional activators and proteins that cooperatively help in DNA distortion and 
modification to enhance transcription by the RNA PolII. Adapted from Elias-Arnanz et al., 2010. 
The IFNβ gene is normally silent. The IFNβ promoter is composed of several 
overlapping positive and negative regulatory elements. In unstimulated cells, 
the transcription of the IFNβ gene is off due to negative factors occupying the 
regulatory elements. They are replaced by positive factors in virus-infected 
cells, causing activation of IFNβ mRNA transcription (Sen, 2001). The IFNβ 
gene contains an enhancer upstream of the transcription start site that involves 
three overlapping positive regulatory domains (PRDs): PRD I-III, II and IV, 
recognized by members of the IRF family, NFκB and ATF-2/c-Jun, respectively 
(Merika and Thanos, 2001). Dimeric IRF3 binds preferentially to specific 
binding sites in PRDI-PRDIII (Dragan et al., 2007). Conformation of IRF3 DNA-
binding domain may be altered by association with CBP/p300, resulting in 
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binding to specific DNA sites in PRDI-III (Yoneyama et al., 1998). 
HMGI(Y) binds to the minor groove of the DNA in PRDII and changes its 
structure, facilitating NFκB to be properly positioned for enhanceosome 
formation (Berkowitz et al., 2002). HMGI(Y) unbends the DNA and this lowers 
the free energy required for transcriptional activator binding (Merika and 
Thanos, 2001). NFκB recognizes κB sites with a specific consensus sequence in 
promoter and enhancer regions (Hayden and Ghosh, 2004). NFκB contains 
different flex points and this allows the protein to bind many different DNA 
sequences and conformations. Due to its flexible DNA-contacting sites, NFκB 
binds DNA bases specifically and the DNA backbone non-specifically 
(Berkowitz et al., 2002). NFκB acts by 'nucleating' enhanceosome assembly 
(Apostolou and Thanos, 2008). Once the enhanceosome complex is formed and 
the RNA PolII is brought to the complex, efficient transcription of IFNβ mRNA 
occurs. Acetylation of HMGI(Y) by CBP results in detachment of the protein 
from the DNA leading to enhanceosome disruption and subsequent 
termination of IFNβ transcription. Thus, HMGI(Y) functions as the sensitive 
molecular switch required for both enhanceosome assembly and disassembly 
(Merika and Thanos, 2001). 
IFNα/β genes include immediate-early genes, whose activation following virus 
infection is protein synthesis-independent (IFNβ and murine IFNα4, which is 
equivalent to human IFNα1), and delayed genes (which include the other IFNα 
subtypes), whose expression is de novo protein synthesis-dependent (Marie et 
al., 1998). Secreted IFN produced from immediate-early genes acts in an 
autocrine and paracrine manner on cells, activating the transcriptional 
upregulation of IRF7 and other proteins. Virus infection induces 
phosphorylation, and therefore activation, of IRF7 in a manner analogous to the 
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way IRF3 is activated i.e. following activation of PRRs including RIG-I and 
Mda5. Phosphorylated IRF3 and IRF7 promote the transcriptional upregulation 
of immediate-early and delayed IFN genes (Marie et al., 1998). IRF7 interacts 
preferentially to the PRDI domain in the IFNβ promoter and binds to a related 
sequence as the consensus sequence in IRF3, but with greater flexibility (Lin et 
al., 2000). This, together with the different affinities of the IRF3 and IRF7 CTDs 
for CBP, can explain that IRF7 also induces transcription of other IFNα genes 
that cannot be induced by IRF3 (Marie et al., 1998). IRF3 is a specific inducer of 
immediate-early IFN genes due to its restricted binding site specificity (Lin et 
al., 2000). 
RLRs signalling must be tightly controlled given the abundance of cellular 
RNAs and the potential risk of inappropriate induction of IFN that can lead to 
an autoimmune response. RLRs only need to respond to non-self RNA and are 
kept in an unstimulated state when not confronted by viral RNA (Anchisi et al., 
2015). Downregulation of the IFN induction pathway includes attenuation of 
RIG-I signalling by phosphorylation at the 2CARD and CTD of RIG-I by protein 
kinase C (PKC) α/β and casein kinase II (CKii), respectively. For Mda5, 
phosphorylation at the Ser88 residue in 2CARD attenuates Mda5 signalling and 
it is dephosphorylated by protein phosphatase 1 (PP1) (Wies et al., 2013). 
1.3.4. IFN signalling pathway 
1.3.4.1. The JAK/STAT signalling pathway 
There are two types of pathways activated by cytokine receptors: the JAK-STAT 
pathway and other pathways generally activating the MAP kinase cascade 
(Murray, 2007). IFNα/β is secreted and acts in an autocrine and paracrine 
Chapter 1: 
Introduction 
 
 
23 
manner by binding to the IFNAR receptor located on the plasma membrane of 
cells to activate the JAK-STAT pathway. The JAK-STAT pathway is illustrated 
in Fig. 1.7. The IFNAR receptors are composed of heterodimers of the products 
of the IFNAR1 and IFNAR2 genes (Stark et al., 1998), and they bind janus 
kinases (JAKs) through JAK-binding sites within the cytoplasmic domains. 
Their close location to the membrane facilitates the stimulation of the JAK 
kinase activity following cytokine binding (Murray, 2007). 
 
 
 
 
 
 
 
 
 
Fig. 1.7. The IFNβ  signalling pathway. IFNAR receptor activation by cytokine binding leads to 
the activation of a cascade of kinases that ends with the formation of the ISGF3 complex. ISGF3 
translocates to the nucleus and upregulates the induction of ISGs. Adapted from Randall and 
Goodbourn, 2008. 
The mammalian signal transducer and activator of transcription (STAT) family 
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includes seven members: STAT1, 2, 3, 4, 5A, 5B and 6 (Reich and Liu, 2006). 
They have an NTD that plays a role in STAT dimerization, a coiled coil domain 
that is often involved in interactions with other proteins, a central DNA-
binding domain, a Src homology 2 (SH2) domain, a conserved single tyrosine 
residue that is phosphorylated following activation, and a CTD that facilitates 
transcriptional activation (Reich and Liu, 2006). STATs are the only known 
transcription factors that need to be tyrosine phosphorylated to be activated, 
and this modification is required for the dimer formation through reciprocal 
tyrosine phosphorylation and SH2-domain interactions (Banninger and Reich, 
2004; Reich and Liu, 2006). They form homo- or heterodimers in an inactivated 
state, but it is the specific conformation of tyrosine-phosphorylated dimers that 
permits STATs binding to consensus sequences in target genes (Reich and Liu, 
2006). 
In an inactive state, the cytoplasmic tail of IFNAR1 is associated with tyrosine 
kinase 2 (Tyk2) and IFNAR2 is associated with the tyrosine kinase JAK1. STAT2 
is also associated with IFNAR2 and weakly with STAT1 (Precious et al., 2005). 
Ligand-induced dimerization of the receptor drives a conformational change, 
such that Tyk2 phosphorylates tyrosine 466 on IFNAR1, generating a strong 
binding site for the SH2 domains of STAT2 (Murray, 2007). Tyk2 then 
phosphorylates STAT2 on tyrosine 690, and JAK1 phosphorylates STAT1 on 
tyrosine 701. STAT1 phosphorylation allows heterodimerization with STAT2 
through SH2-domain interactions (Reich and Liu, 2006). In an inactive state, the 
NES activity in STAT2 keeps the molecule predominantly cytoplasmic (Frahm 
et al., 2006). Such NES activity comes from a hydrophobic leucine-rich NES in 
the C-terminus that is recognized by the exportin chromosomal maintenance 1 
(CRM1, also known as exportin 1) (Banninger and Reich, 2004). 
Heterodimerization with STAT1 generates a novel NLS and, simultaneously, 
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phosphorylation of STAT2 inactivates the NES of STAT2, allowing the dimers 
to be transported into the nucleus and be kept there until their 
dephosphorylation (Reich and Liu, 2006). 
CBP is recruited to IFNAR2 and catalyses IFNAR2 acetylation, which allows 
binding of IRF9 (Tang et al., 2007). Association of the STAT1:STAT2 complex 
with a monomer of IRF9 creates the IFN-stimulated gene factor 3 (ISGF3) 
complex. Both IRF9 and STAT2 of an active ISGF3 complex are highly 
acetylated. Acetylation in STAT2 facilitates a more flexible interaction with 
STAT1 and aids STAT1 to interact with IRF9 and also DNA (Tang et al., 2007). 
STAT1 phosphorylation on serine 727 is also required for transcriptional 
activation, facilitating the interaction of STAT1 with the basal transcriptional 
machinery and with other adaptor proteins. In response to IFN, STAT2 also 
binds CBP/p300, facilitating interaction with the basal transcriptional 
machinery, although it is not serine-phosphorylated (Randall and Goodbourn, 
2008). NLS in STAT1:STAT2 dimers in the ISGF3 complex are recognized by 
importin α5 (Banninger and Reich, 2004). ISGF3 enters the nucleus and binds to 
the IFN-stimulated response element (ISRE), present in the promoters of most 
IFN-stimulated genes (ISGs) (Reich and Liu, 2006). 
STAT1 is also tyrosine phosphorylated in response to IFNγ and forms a 
homodimer called IFNγ activated factor (GAF). This homodimer masks the NES 
of STAT1 and generates a NLS (Banninger and Reich, 2004). GAF enters the 
nucleus and binds to a distinct DNA in the promoter of target genes known as 
the IFNγ-activated site (GAS) (Reich and Liu, 2006). 
To maintain the antiviral state in cells, the JAK-STAT pathway needs to be 
continuously activated. Once the virus has been cleared, this pathway needs to 
be downregulated to avoid unintentional damage to the cell. There are several 
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ways to downregulate the JAK-STAT pathway, including receptor 
downregulation, the action of suppressors of cytokine signalling (SOCS) 
proteins on the JAK tyrosine kinases, and the dephosphorylation and 
degradation of STATs (Endo et al., 1997). 
1.3.5. Genes induced by IFN 
Induction of high levels of type I IFNs is the major initial response against a 
viral infection (Biron and Sen, 2001). A second wave of cytokines elicited to 
combat infection also includes cytokines with antiviral properties. Many 
cytokines are present in cells at low levels, but their gene expression is 
enhanced by IFN (Schneider et al., 2014). Activation of ISGs leads to the 
expression of hundreds of genes that act simultaneously to specify the antiviral 
state and, apart from type I IFNs, they also stimulate the production of other 
cytokines (Kotwal et al., 2012). Genes regulated by type I IFNs can be similarly 
or differentially regulated by IFNα or IFNβ (Der et al., 1998). Among those 
induced by both IFNα/β are ISG 6-16 whereas other ISGs, e.g. ISG54, ISG56, 
ISG58, IFI16 and STAT1, are preferentially induced by IFNβ (Der et al., 1998). 
The IFN-inducible transmembrane (IFITM) family of proteins plays an 
important role in host antiviral defence. It includes four members in humans: 
IFITM1, IFITM2, IFITM3 and IFITM5. They are mainly found in late endosomes 
and lysosomes and therefore affect viruses requiring transit to these 
compartments for entry (Huang et al., 2011). Although the exact mechanism is 
unclear, they likely affect virus entry by inhibiting steps prior to fusion with the 
endosomal membrane (Li et al., 2013). 
TRIM5α is one of the best-known members of the large family of tripartite motif 
(TRIM) proteins and has been identified as a potent inhibitor of early stages of 
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HIV-1 infection (Stremlau et al., 2004). The activities of the TRIM proteins are 
diverse and range from protein ubiquitination to SUMOylation and ISGylation 
(Ozato et al., 2008; Chu and Yang, 2011; Zou and Zhang, 2006).  
Viral egress is mainly inhibited by the action of two proteins known as viperin 
and tetherin. Viperin can be induced via the JAK/STAT pathway or directly by 
IRF1/3 (Stirnweiss et al., 2010; DeFilippis et al., 2006) and plays a role in the 
inhibition of many enveloped viruses. It has also been described to affect early 
steps in the virus life cycle, such as viral replication (Helbig et al., 2013). 
Tetherin also inhibits budding of many enveloped viruses. Many viruses 
contain diverse viral evasion strategies against tetherin, reflecting the 
importance of this protein for the host defence against viral infection (Swiecki et 
al., 2013). 
Other genes also induced by type I IFN include 2'-5'-oligoadenylate synthetases 
(2-5[A]), a family of enzymes that activate the latent ribonuclease (RNase L) by 
inducing its dimerization upon binding of trimeric or longer 2-5(A) to the 
protein (Kumar et al., 2000). ISG56, which encodes P56, is the most strongly 
induced gene among all ISGs. It interacts with the P48 subunit of the translation 
initiation factor (eIF)-3 (Guo and Sen, 2000), and has been shown to specifically 
inhibit virus transcription and protein synthesis (Andrejeva et al., 2013). Serine-
threonine protein kinase R (PKR) is inactive as such and needs to be activated 
by autophosphorylation. dsRNA is a strong activator of PKR. Activated PKR 
can phosphorylate selected cellular proteins, the best known of which is eIF-2α, 
whose phosphorylation causes an inhibition of protein synthesis (Clemens and 
Elia, 1997). Myxovirus resistance (Mx) are a family of genes also induced by 
IFNs. They encode dynamin-like GTPases that have been shown to have 
antiviral activity against a broad range of RNA viruses (Randall and 
Goodbourn, 2008). They act by inhibiting virus entry (Schneider et al., 2014). 
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Other genes important to combat infection include IL-6, IL-8 and TNFα. IL-6 is 
a multifunctional pro-inflammatory cytokine that is a key factor in the immune 
response (Ishihara and Hirano, 2002). IL-8 is a potent chemotactic factor for 
neutrophils and T lymphocytes (Papoff et al., 1995). TNFα is a pro-
inflammatory cytokine generated by a diverse range of immune cells (Cantaert 
et al., 2010). 
1.4. Paramyxoviruses 
1.4.1. Introduction to paramyxoviruses 
The Paramyxoviridae family consists of enveloped, non-segmented negative-
strand RNA viruses of the order mononegavirales (MNV) and includes the 
Paramyxovirinae and the Pneumovirinae subfamilies (Harrison et al., 2010; 
Lamb and Parks, 2006). All paramyxoviruses share common structural, 
biochemical and genetic elements, including the ssRNA genome that encodes a 
small number of proteins (Ramachandran and Horvat, 2009). According to 
antigenic cross-reactivity and neuraminidase activity, the Paramyxovirinae 
subfamily is classified into seven genera: Rubulavirus, Morbillivirus, 
Avulavirus, Respirovirus, Henipavirus, Ferlavirus and Aquaparamyxovirus 
(Audsley and Moseley, 2013), and virus examples of each genera are shown in 
Table 1.1. 
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Table 1.1. Examples of viruses included in each genus of the Paramyxovirinae subfamily. 
Hendra and Nipah viruses are highly pathogenic in humans, although humans are not the main 
host. Host range in Hendra and Nipah viruses is unknown, but they were isolated in 
chiropteran hosts. Modified from Audsley and Moseley, 2013. 
The Paramyxoviridae family includes viruses that cause some of the most 
infectious and prevalent diseases worldwide (Lamb and Parks, 2006). Human 
RSV and human parainfluenza virus (hPIV) types 1-3 are some of the main 
causes of respiratory infections in young children and elderly people (Harrison 
et al., 2010). hRSV is the cause of 33.8 million new episodes of acute lower 
respiratory infection (ALRI) worldwide in children younger than 5 years of age, 
with a global mortality of 253,500 deaths in 2010, most occurring in developing 
countries (WHO, 2014). Measles virus (MeV), together with mumps virus 
(MuV), still remains a health issue in developing countries, with recent 
important outbreaks in the United States, Canada and the United Kingdom 
(Peltola et al., 2007). Infection of Nipah and Hendra viruses in humans results 
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in severe and widespread vasculitis and encephalitis that lead to a mortality 
rate of about 40% (Bishop et al., 2008). In respect to agriculture, Newcastle 
disease virus (NDV) is the cause of an extremely contagious respiratory and 
neurological disease in several avian species, and cattle is severely affected by 
rinderpest virus (Harrison et al., 2010). 
Paramyxoviruses are highly diverse in terms of tissue tropism, and they infect a 
large number of species in a manner that seems to be independent of genus 
classification. Additionally, they use different mechanisms to counteract the 
IFN response (e.g. proteosomal degradation, inhibition of phosphorylation) that 
frequently vary significantly between disctint species of different or the same 
genera (Audsley and Moseley, 2013). 
1.4.2. Structure of paramyxoviruses 
DNA viruses generally contain large genomes. RNA viruses, in contrast, have 
restricted genome sizes to minimize errors when the RNA-dependent RNA 
polymerase (RdRp) reads the viral genome because RdRps lack proof-reading 
activity. Therefore, in contrast to genes in viral DNA genomes that often encode 
one protein, viral RNA genomes often contain genes that encode two or more 
proteins. For example, IFN antagonist proteins in RNA viruses are normally 
generated as 'accessory' protein isoforms that are encoded within one or more 
conserved genes (Audsley and Moseley, 2013). Paramyxovirus genome includes 
six principal genes, specifically matrix (M), attachment (G/HN/H), fusion (F), 
polymerase (L, large), nucleocapsid (N/NP) and phosphoprotein (P) (Audsley 
and Moseley, 2013). The P gene encodes different 'accessory' proteins in 
different viruses, such as V, C and P proteins, and also a protein termed W, D 
or I (Audsley and Moseley, 2013; Ramachandran and Horvat, 2009). 
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A paramyxovirus structure is illustrated in Fig. 1.8. Paramyxoviruses encode 
two glycoproteins: F and G (glyco)/HN (hemagglutinin-neuraminidase)/H 
(hemagglutinin). These proteins pack very densely into the viral envelopes, 
forming spike layers (Lamb and Parks, 2006). Virus particles obtain the 
envelopes, or membranes, from the infected host cells in the process of budding 
from cellular membranes when virus particles are released (Choppin and 
Compans, 1975). Within the viral membranes are the ribonucleoproteins 
(RNPs), formed by viral RNA genomes bound with N/NP proteins forming 
helical structures (Harrison et al., 2010). Underlying the viral membranes are 
the M proteins that nucleate viral assembly, bridging the cytoplasmic tails of 
viral glycoproteins and the RNPs (Harrison et al., 2010). Paramyxoviruses 
normally form spherical particles, although sometimes they form filamentous 
forms, with enormous variation in size and shape. Viral particles normally 
range from 150 to 300nm in diameter, reaching more than 1µm in some cases 
(Lamb and Parks, 2006). 
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Fig. 1.8. Schematic illustration of a paramyxovirus particle. The virion is enveloped by a lipid 
bilayer membrane in which the G/HN/H proteins are inserted. Beneath the envelope, the M 
protein binds to the cytoplasmic tails of the G/HN/H and F proteins as well as to the RNP 
complex. The RNP, made of viral RNA and also of the NP/N, P and L proteins, is shown below 
the viral particle. The encapsidated RNA is shown as a green dotted line embedded in the 
middle of N. The L protein is tethered onto the nucleocapsid by its cofactor, the P protein. 
Adapted from Habchi and Longhi, 2012. 
1.4.3. Paramyxovirus infection and life cycle 
The paramyxovirus life cycle is illustrated in Fig. 1.9. Paramyxovirus infections 
start upon binding of virus particles to receptor molecules on surfaces of target 
cells. Some paramyxoviruses, such as Sendai virus (SeV), MuV and PIV5, attach 
to sialic acid (SA) receptors through their HN proteins. These HN proteins also 
possess sialidase activity, which will act later to allow the separation of virions 
from infected cells and also to prevent virion aggregation (Lamb and Parks, 
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2006). Other paramyxoviruses attach different receptors through H (e.g. MeV) 
or G proteins (e.g. Henipaviruses) (Lamb and Parks, 2006). Binding of target cell 
receptors by the attachment protein globular heads leads to F protein 
destabilization, refolding of F from initial metastable states into more stable 
hairpin structures, and fusion of virion and target cell membranes (Poor et al., 
2015; Russell and Luque, 2006). This allows entry of RNPs, together with other 
virion contents, into the cytoplasm of target cells, where viral transcription is 
initiated. Encapsidated genomic RNA within RNPs, not free RNA, serves as the 
template for the production of mRNAs by viral RdRps (Harrison et al., 2010). 
Later in infection, the viral RdRp switches to a replication mode in which viral 
genomes act as genomic templates for the production of positive-sense 
antigenomes. Subsequently, these antigenomes serve as templates for the 
generation of negative-sense genomes. RNPs and newly synthesized viral 
proteins meet at the host plasma membranes, where they assemble together in 
virion particles that are then released from the cells via budding (Harrison et 
al., 2010). Viral proteins and RNPs can only assemble together at specific sites 
on infected cell plasma membranes, generally in cholesterol- and sphingolipid-
rich raft microdomains (Brown and London, 2000). 
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Fig. 1.9. Paramyxovirus life cycle. After attachment and fusion of viral membrane with host cell 
membrane, viral RNP is released into the host cell cytoplasm. Viral transcription and genome 
replication occur in the cytoplasm. Newly synthesised RNPs and structural viral proteins 
assemble together near the infected host cell plasma membrane to form viral particles that are 
released via budding. Adapted from Harrison et al., 2010. 
1.4.4. Replication and transcription of viral genomes 
Primary transcription from viral RNPs occurs early in virus infection before 
viral proteins accumulate to high levels. Viral RNPs also serve as templates to 
produce (+) sense antigenomes, which are in turn used as templates to produce 
new (-) genomes. Progeny genomes produced then serve as additional 
templates to produce much higher levels of viral mRNA transcripts (secondary 
transcription) (Lamb and Parks, 2006). 
Transcription and replication of paramyxoviruses are illustrated in Fig. 1.10. 
Transcription by the viral RdRp leads to production of Leader (Le) RNA and 
mRNAs. Once the N/NP gene is transcribed, RdRp responds to cis-acting 
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sequences at the end of each gene to produce capped and polyadenylated viral 
mRNAs. RdRp then reinitiates mRNA synthesis at the start of the next 
downstream gene or disassembles from the template (Lamb and Parks, 2006). 
This 'stop-start' mechanism continues across the viral genome in a 3' to 5' 
direction and results in a transcription gradient in which the genes near the 3' 
end of the genome are more abundantly transcribed than the genes near the 5' 
end (Lamb and Parks, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.10. Transcription and replication in paramyxoviruses. In the transcription process, there 
is a gradient of abundance of mRNA in which the genes near the 3' end are more frequently 
transcribed than those near the 5' end. In the replication process, the viral RdRp generates a 
complementary copy of the genomic RNA called antigenomic RNA that serves as the template 
to generate more genomic RNA. 
RNA editing, or pseudotemplated addition of nucleotides, is a mechanism to 
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obtain more coding potential from a gene, and it was first identified in 
parainfluenza virus 5 (PIV5, formerly known as simian virus 5 [SV5]) (Thomas 
et al., 1988). Most paramyxovirus P genes contain a functional editing site 
within the P gene-coding region. RNA editing occurs when the viral RdRp 
localizes a determined purine rich region into P gene mRNA transcripts and 
facilitates the insertion of additional non-coded guanosine (G) nucleotides, 
causing a +1 or +2 frameshift in the downstream open reading frame (ORF) that 
results in the generation of two or three different proteins (P, V and W/D/I), 
which have common N-terminal sequences but unique C-termini (Audsley and 
Moseley, 2013; Barr and Fearns, 2010). The P protein plays a key role as a 
polymerase cofactor in genome transcription and replication, and is normally 
generated from an unedited ORF that encodes the principal P gene product. 
The +1 frameshift commonly encodes V and the +2 frameshift W/D/I. Members 
of the rubulavirus genus encode the V protein in the unedited transcript, and 
the P protein translation requires editing (Paterson et al., 1989). Members of the 
henipavirus, morbillivirus and respirovirus genus use a start codon in an 
alternate ORF within the P gene to produce a C protein, and the SeV (a 
respirovirus) P gene generates four C proteins encoded by overlapping 
sequences in the +1 reading frame (Fig. 1.11) (Vidal et al., 1990). 
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Fig. 1.11. P gene coding strategies in paramyxovirus. A) Genome organization of the 
Paramyxovirinae subfamily. B) Editing strategies from several Paramyxovirinae genera. 
Proteins from unedited (+0), or edited (+1 or +2 frameshift) mRNA are indicated. Several 
members from the henipavirus, morbillivirus or respirovirus genera generate one or more C 
proteins from internal start codon(s) in alternate ORF(s). Modified from Audsley and Moseley, 
2013.  
Chapter 1: 
Introduction 
 
 
38 
Studies in SeV showed that the intracellular level of unassembled NP protein 
seems to play a key role in the switch of viral RdRp from transcription to 
replication (Vidal and Kolakofsky, 1989). In the replication process, concurrent 
assembly of the nascent RNA by NP must occur for efficient encapsidation. Not 
enough NP leads to Le RNA and mRNA production, and RdRp tends to 
dissociate when reading gene junctions. If enough NP binds the nascent strand, 
the polymerase 'ignores' the junctions (and editing sites) and replication occurs 
(Lamb and Parks, 2006; Vidal and Kolakofsky, 1989). 
In the replication process, nascent genomic and antigenomic viral RNA is 
encapsidated coupled with RNA synthesis (whereas mRNA is not 
encapsidated). The promoter sequences (Le and Trailer [Tr]) function as 
nucleation sites, binding N/NP proteins to form helical RNP complexes in 
which the RNA is so tightly packaged that is resistant to exogenous RNases. 
RNA is wrapped around a ring of N/NP protein, and RdRp recognizes its 
template in this structure even without disassembly of the RNP (Lamb and 
Parks, 2006). It has been observed that most, if not all, members of the 
Paramyxovirinae subfamily have a genome length that is divisible by six 
(Alayyoubi et al., 2015; Kolakofsky et al., 1998). This is in accordance with the 
'rule of six' that establishes that efficient replication occurs when the total 
genome nucleotide length is a number divisible by six (Calain and Roux, 1993). 
The viral NP protein encapsidates the replicative genomic (or antigenomic) 
RNA in a 5'-->3' direction as the RNA is being synthesized and remains 
associated with it. The 'rule of six' reflects the stoichiometry of the RNA 
nucleotides to the NP protein, as each NP binds six nucleotides (Barr and 
Fearns, 2010). 
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1.4.5. Paramyxoviruses and the IFN response 
In a normal acute infection, the IFN response constitutes a constant selective 
pressure that keeps paramyxoviruses maximally fit in terms of replication 
speed, competence and maintenance of mechanisms to counteract the IFN 
response. The efficiency by which a virus overcomes the IFN response critically 
determines its pathogenesis and host range (Young et al., 2003). A competition 
is established between the speed by which a virus can block the IFN response 
and the capacity of cells to generate and respond to IFN. Many factors influence 
the outcome of this competition, and they differ between cells and also between 
species (Hagmaier et al., 2007). The IFN response considerably limits cross-
species infection by paramyxoviruses (Hagmaier et al., 2007), and they respond 
by generating proteins that target multiple steps in the IFN system (Randall and 
Goodbourn, 2008). 
1.4.5.1. Inhibition of the RIG-I/Mda5-dependent IFN induction pathway 
Paramyxoviruses inhibit the IFN induction cascade in several ways. The viral 
RNP complex prevents viral genome from being free in the cytoplasm, thus 
avoiding recognition by cytoplasmic PRRs (Lamb and Parks, 2006). 
Paramyxoviruses also generate proteins that interact with key proteins involved 
in the IFN induction pathway, as summarized in Fig. 1.12. 
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Fig. 1.12. Inhibition of type I IFN induction by paramyxoviruses. Type I IFN induction is 
inhibited by paramyxovirus IFN antagonist proteins at multiple stages. Adapted from Audsley 
and Moseley, 2013. 
The viral V proteins are the main paramyxovirus IFN-induction antagonists. V 
proteins are highly conserved in the C-terminal region, where a zinc finger 
domain is formed by seven absolutely conserved cysteine residues and a 
histidine (Huang et al., 2000a; Paterson et al., 1995). In the PIV5 V proteins, two 
zinc atoms are coordinated by two loops (Paterson et al., 1995). The V proteins 
of many paramyxoviruses (e.g. PIV5, hPIV2, MuV, NiV, HeV, MeV and SeV) 
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interact with Mda5 via their cysteine-rich CTDs (Andrejeva et al., 2004; Childs 
et al., 2009; Takaki et al., 2011). They bind to a specific region of the Mda5 
helicase domain (Audsley and Moseley, 2013), preventing dsRNA binding to 
Mda5, and thereby inhibiting the activation of transcription of the IFNβ gene 
(Childs et al., 2009). Although this interaction reduces significantly the 
production of IFN by infected cells, it does not completely prevent cells from 
secreting IFN, suggesting that even when V changes dsRNA-binding properties 
of Mda5, it may still allow non-cooperative dsRNA binding, rather than 
inhibiting dsRNA binding completely (Audsley and Moseley, 2013; Carlos et 
al., 2005). 
In contrast to what occurs for Mda5, RIG-I is not directly recognized by V 
proteins (Childs et al., 2007). V proteins can inhibit RIG-I by interaction with 
LGP2, as LGP2 contains a region homologous to the V protein-binding region 
in Mda5 (Childs et al., 2012). V proteins have been shown to be able to inhibit 
RIG-I signalling only in cells co-expressing LGP2, and RIG-I:LGP2 interaction 
has been detected only in cells expressing V protein, suggesting that this 
interaction is mediated by V to shut down RIG-I activation (Childs et al., 2012). 
V protein in rubulaviruses represents the default ORF transcribed at the P/V 
locus. Therefore, rubulaviruses contain a much higher level of V as compared 
with other paramyxoviruses and is present during the initial stages of infection 
(Lu et al., 2008). Moreover, rubulaviruses, including hPIV2, MuV and PIV5, use 
V as a decoy substrate for TBK1 and IKKε, both inhibiting IRF3 
phosphorylation and facilitating TBK1/IKKε polyubiquitination and 
degradation to prevent further signalling (Lu et al., 2008). This function seems 
to be accomplished by W proteins in henipaviruses. It appears that W proteins 
bind and sequester IRF3 in the nucleus, where the W proteins are, thus 
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preventing interaction with cytoplasmic TBK1/IKKε (Shaw et al., 2005). 
1.4.5.2. Inhibition of the IFN signalling pathway 
The IFN signalling pathway is targeted by paramyxovirus IFN-antagonist 
proteins at different stages, as summarized in Fig. 1.13. 
 
 
 
 
 
 
 
 
 
 
Fig. 1.13. Inhibition of the IFN signalling pathway by paramyxoviruses. The IFN signalling 
pathway is targeted by paramyxovirus IFN-antagonist proteins through different mechanisms. 
Adapted from Audsley and Moseley, 2013. 
Almost all rubulavirus V proteins target STAT1 or STAT2 for degradation using 
the host-cell proteosomal complex via the assembly of a V-degradation complex 
that includes V protein, STAT1, STAT2, and several components of an E3 
ubiquitin ligase complex (Andrejeva et al., 2002a; Andrejeva et al., 2002b; 
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Kubota et al., 2005; Nishio et al., 2002). The ubiquitin system plays a key role for 
the correct functioning of the cell (Hershko and Ciechanover, 1998). DNA 
damage-binding protein 1 (DDB1) assembles with Cul4A:ROC1 complex 
forming a cullin-RING ubiquitin ligase scaffold with E3 ligase function that 
mediates substrate recruitment (Angers et al., 2006). In order to divert this E3 
ligase function of the DDB1:Cul4A:ROC1 complex for its own use, V protein 
binds to DDB1, altering its substrate recognition properties by presenting a 
STAT-binding site (Li et al., 2006; Precious et al., 2007). 
In PIV5, the V protein C-terminal cysteine-rich domain mediates STAT1 
degradation, thus blocking STAT1 signalling (Poole et al., 2002), as a 
recombinant PIV5 virus missing the V protein CTD is unable to mediate STAT1 
degradation (He et al., 2002). PIV5 V protein does not bind directly to STAT1. In 
contrast, it binds directly to unphosphorylated STAT2 (Audsley and Moseley, 
2013), thereby recruiting STAT1:STAT2 complex to the E3 ligase complex. The 
weak binding affinity of PIV5 V protein to STAT2 is enhanced by the generation 
of the DDB1:V:STAT2:STAT1 complex (Precious et al., 2005). Following 
polyubiquitination of STAT1 by the ubiquitin E3 complex, it dissociates from 
STAT2 and becomes degraded by the proteasome. Loss of STAT1 from the 
degradation complex destabilises the interaction of V with STAT2, leading to 
either STAT2 dissociating from the complex or being displaced by 
STAT1:STAT2 complexes, which allows recycling of the components of the 
degradation complex and the catalytic degradation of STAT1 (Precious et al., 
2005; Precious et al., 2007). 
As with some rubulaviruses such as PIV5, the avulavirus NDV targets STAT1 
for degradation, but not STAT2 (Audsley and Moseley, 2013). In contrast, V 
protein of hPIV2 does not target STAT1, but STAT2 for degradation (Poole et 
Chapter 1: 
Introduction 
 
 
44 
al., 2002). In contrast to V proteins of other rubulaviruses, Mapuera virus 
(MPRV) V protein binds to STAT1 and STAT2, thereby blocking their nuclear 
translocation without inducing degradation (Hagmaier et al., 2007). Like the V 
protein of MPRV, the V protein of MeV prevents STAT nuclear translocation by 
sequestration in the cytoplasm regardless of its phosphorylation state 
(Hagmaier et al., 2007). STAT1-independent targeting of STAT2 is important to 
MeV, as MeV V protein N-terminal and C-terminal regions associate with 
STAT1 and STAT2, respectively, through different sites (Caignard et al., 2009). 
MeV also affects ISGF3 formation by interacting with IRF9. MeV N protein also 
plays a role in inhibiting STAT1:STAT2 signalling (Caignard et al., 2009). STAT 
targeting by respiroviruses differs considerably from other paramyxoviruses as 
respiroviruses express additional proteins from the P gene. The C' protein of 
hPIV1 associates with STAT1 and maintains it in perinuclear aggregates 
(Schomacker et al., 2012). Moreover, all SeV C proteins (C', C, Y1 and Y2) bind 
to STAT1 thereby preventing signalling (Schomacker et al., 2012), but only the 
larger forms induce STAT1 ubiquitination and degradation (Garcin et al., 2002), 
whilst the SeV V protein blocks IFN induction (Poole et al., 2002). 
1.5. Influenza A virus 
Stocks of recombinant influenza A virus were used in experiments in Chapter 4. 
Therefore, a brief description of influenza A virus is introduced here. 
1.5.1. Introduction to influenza A virus 
Influenza viruses (family Orthomyxoviridae) are important human and animal 
pathogens generally causing respiratory tract infections in yearly epidemics 
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and sporadic pandemics (Fodor, 2013). They are divided into influenza A, B 
and C viruses, being A and B the most common in humans. Influenza A and B 
are also the cause of seasonal epidemics, being responsible for 3-5 million 
clinical infections and more than 250,000 fatal cases yearly (Glezen et al., 2014; 
Kuiken et al., 2012). Influenza C is less common and produces milder disease. 
The viral pathogenesis ranges from subclinical upper respiratory tract (URT) 
disease to conjunctivitis, pneumonia, encephalitis, and even lethal infection of 
the lower respiratory tract (LRT) (Kuiken et al., 2012). 
Influenza A virus subtypes are classified according to their two surface 
glycoproteins: hemagglutinin (HA) and neuraminidase (NA) (Glezen et al., 
2014). For example, the 1918, 1957 and 1968 pandemics were caused by the 
influenza A virus H1N1, H2N2 and H3N2 subtypes, respectively, and the more 
recent 2009 pandemic was caused by a H1N1 subtype of swine origin (Kuiken 
et al., 2012). The most common influenza A subtypes found in people are H1N1 
and H3N2, and the seasonal influenza vaccines include two influenza A 
subtypes and one influenza B lineage (influenza B is not divided into subtypes, 
although two antigenically and genetically distinct lineages have circulated 
worldwide since 1983) (Glezen et al., 2014). 
1.5.2. Structure of influenza A virus 
The structure of influenza A virus is illustrated in Fig. 1.14. The pleiomorphic 
influenza virion forms spherical particles that are ~100nm in diameter. It also 
forms filamentous particles that are ~100nm in diameter but can reach over 
20µm in length (Rossman and Lamb, 2011). The virion contains eight segments 
of viral negative sense ssRNA (vRNA) that encode at least 16 polypeptides 
(Fodor, 2013; Rossman and Lamb, 2011). The surface spike glycoproteins HA 
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and NA are the two main antigenic determinants of the virus and are located in 
the viral envelope, a lipid membrane of cellular origin, as is incorporated to the 
new virion particles in the budding process (Rossman and Lamb, 2011). There 
are 17 HA and 10 NA identified to date (Schrauwen et al., 2014). HA mediates 
viral entry into cells by binding to the receptor and driving membrane fusion, 
whereas NA functions by enzymatically cleaving the viral receptor, thus 
permitting the release of progeny virions in the late stages of infection. M2, 
another integral membrane protein with a multifunctional proton-selective ion 
channel, also plays a role in virus entry, and also in the assembly and budding 
of the virions. The matrix protein (M1) is located inside the viral envelope and 
organizes the structure of the virion as it bridges the membrane and the RNP 
complex (Rossman and Lamb, 2011). 
 
 
 
 
 
 
 
Fig. 1.14. Schematic illustration of an influenza A virus particle. HA and NA are located in the 
lipid bilayer. M2 is also located in the lipid bilayer and acts as a proton-selective ion channel. 
M1 bridges the lipid bilayer with the RNP complexes. Each influenza A virus particle contains 
eight RNPs. Each RNP consists in a segment of the viral genome encapsidated into viral NP 
proteins, plus the polymerase complex consisting in the PB1, PB2 and PA viral proteins. NEP 
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facilitates export of newly generated viral RNPs from the cell nucleus during the replication 
process. Adapted from Ge et al., 2010. 
The RNP complex includes the polymerase basic protein 1 (PB1), polymerase 
basic protein 2 (PB2) and polymerase acidic protein (PA), and the nucleocapsid 
protein (NP) that plays a key role in the viral genome binding and packaging 
(Fig. 1.15) (Rossman and Lamb, 2011). 
 
 
 
 
Fig. 1.15. The influenza A RNP complex. The RNP complex is 
composed of the viral proteins PB1, PB2 and PA, and NP protein that 
mediates binding and packaging of the viral genome. Adapted from 
Shi et al., 2014. 
Additional proteins are encoded by the influenza A virus genome. Non-
structural protein 1 (NS1) is a multifunctional protein with a key role in evasion 
of the host immune response. In human cells, NS1 prevents RIG-I activation by 
binding to TRIM25 (Gack et al., 2009). NS2 (also known as nuclear export 
protein [NEP]) mediates the export of newly generated viral RNPs from the cell 
nucleus during the replication process. Moreover, many strains of influenza 
virus express the PB1-F2 protein that acts by facilitating induction of the host-
cell apoptosis (Rossman and Lamb, 2011). PB1-F2 also localizes to the 
mitochondria and inhibits IFN induction by interacting with MAVS (Cauldwell 
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et al., 2014). N40 has been more recently discovered (Wise et al., 2009), as well 
as the PA-X protein, which plays a role in the suppression of the host antiviral 
response (Hayashi et al., 2015). M42, also discovered recently, encodes a novel 
M2 ion channel-like protein (Wise et al., 2012). 
1.5.3. Influenza A virus infection and life cycle 
The influenza A virus life cycle is illustrated in Fig. 1.16. The HA glycoprotein is 
composed of two subunits, HA1 and HA2. In virus infection, HA recognize 
specific SA receptors on the surface of target cells. Receptor binding specificity 
of human and avian influenza viruses is dependent on specific amino acid 
residues in the HA protein, that vary between virus subtypes. Human influenza 
viruses preferentially recognize α2,6-linked SA receptors which are 
predominantly on epithelial cells in the URT, whilst avian influenza viruses 
recognize α2,3-linked SA receptors which are mainly located on epithelial cells 
in the intestine of birds and in the LRT of humans (Schrauwen et al., 2014). 
Following receptor binding, virus particles enter the cell through receptor-
mediated endocytosis and, subsequently, a low pH-triggered conformational 
change of HA mediates fusion of the viral membrane with the endosomal 
membrane. The viral RNPs (vRNPs) are then released into the cytoplasm and 
transported to the nucleus. Once there, transcription and replication by the viral 
RdRp complex take place (Schrauwen et al., 2014). In the nucleus, the viral 
RdRp transcribes the vRNA segments into 5' capped and 3' polyadenylated 
mRNAs that are exported to the cytoplasm for translation by cellular 
mechanisms. The viral RdRp also performs replication of vRNA by copying it 
into complementary RNA (cRNA) which in turn serves as a template for the 
production of more vRNA. cRNA and vRNA are assembled with newly 
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expressed viral polymerase and NP to form cRNPs and vRNPs, respectively 
(Fodor, 2013). Subsequent direct interaction of NEP with Crm1 mediates the 
nuclear export of vRNPs to the cytoplasm (Paterson and Fodor, 2012). Virus 
proteins and RNPs translocate to lipid rafts at the plasma membrane, where 
new virus particles are assembled and released via budding (Rossman and 
Lamb, 2011; Schrauwen et al., 2014). The 5' and 3' termini of each segment 
contain signals required for the specific packaging of each of the eight genome 
segments into virions (Fodor, 2013). The NA glycoprotein cleaves SA residues 
from the host cell surface, thus allowing detachment from the cell of the new 
virus particles (Schrauwen et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.16. Influenza A virus life cycle. After attachment of HA to SA in the host cell membrane, 
viral particles enter the cell through endocytosis. The viral membrane is then fused with the 
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endosomal membrane, where vRNP is retained until it is released into the cytoplasm and 
translocated to the nucleus, where viral transcription and replication take place. Newly 
synthesised vRNPs are transported to the cytoplasm, and vRNPs and proteins assemble 
together in lipid rafts in the host cell membrane to form viral particles that are released. 
Modified from Shi et al., 2014. 
Infection of influenza A virus results in protective immunity against the viral 
proteins HA and NA. However, the virus can escape the host defence due to 
accumulated point mutations in HA and, to a lesser extent, NA. This is known 
as 'antigenic drift' and is the cause of seasonal influenza epidemics. As a result, 
the vaccine composition needs to be updated annually (Schrauwen et al., 2014). 
'Antigenic shift' occurs when a new influenza A virus subtype is introduced in 
humans by direct introduction of a new virus from an animal reservoir, or also 
by re-assortment, i.e. when genes from two (or more) viruses, between animal 
and human influenza A viruses, are mixed (Schrauwen et al., 2014). 
1.5.4. Influenza A virus replication and transcription 
The vRNA genome segments are in the form of vRNPs, that is, the 5' and 3' 
termini of vRNA interact through base-pairing to form a partially double-
stranded structure which is bound by the RdRp complex (Fodor et al., 1994). 
The rest of the vRNA associates with multiple copies of oligomeric NP with one 
NP for approximately every 24 nucleotides (Fodor, 2013). The trimeric viral 
RdRp, consisting of PB1, PB2 and PA subunits, is responsible for the 
transcription and replication of the viral RNA genome segments (Fodor et al., 
2013). The RNA polymerase complex forms a compact globular structure where 
interaction between PA and PB1, and also between PB1 and PB2, occurs 
(Arranz et al., 2012; Sugiyama et al., 2009). 
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Transcription of influenza A virus genome is illustrated in Fig. 1.17. First, the 
cis-acting viral RdRp recognizes the promoter in the vRNA initiating the 
synthesis of viral mRNA. This promoter recognition and binding is aided by PA 
and PB2 (Fodor et al., 1994). PA and PB2 also play critical roles in initiation of 
transcription, as they bind and cleave capped host pre-mRNAs, respectively, 
that will be used for capping of viral mRNA (Yuan et al., 2009). Besides, NP 
binds RNA with high affinity, being an essential structural component of 
vRNPs and cRNPs. For this, NP is essential for transcription and replication of 
the viral genome (Yamanaka et al., 1990). PB1 catalyses the sequential addition 
of nucleotides during RNA chain elongation (Fodor, 2013). Synthesis of new 
viral 5' capped mRNA is dependent on host RNA PolII activity (Fodor, 2013), as 
the viral RdRp associates with Pol II, facilitating the access of RdRp to the 5' cap 
of host nascent pre-mRNA (Engelhardt et al., 2005). End of transcription 
elongation is reached when RdRp reaches a sequence of 5-7 uridine residues, 
usually located 16 nucleotides from the 5' end of the vRNA template. This 
sequence of U residues also acts as a signal for polyadenylation (Robertson et 
al., 1981). Viral mRNA synthesis peaks early, at about 2-6 hours post-infection, 
after which it declines sharply, in contrast to genome replication, which 
continues late in infection (Shapiro et al., 1987). 
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Fig. 1.17. Transcription of the influenza A virus genome. (A) Binding of PB1 to 
the 5' end of vRNA activates PB2 cap binding activity and PA endonuclease 
activity, which cleaves host pre-mRNA to produce a capped RNA primer. (B) A 
guanosine residue is added to the capped RNA primer, initiating viral trancription. 
(C) vRNA is read in 3'-->5' direction, but the 5' end remains bound to PB1. RdRp 
begins to stutter-read upon encountering the U stretch, thus producing the poly(A) 
tail. Adapted from Zhang and Toyoda, 2011. 
vRNPs serve as templates for both mRNA and cRNA synthesis. First, genomic 
vRNA is replicated into cRNA. cRNA, devoid of a 5' cap structure and a 3' 
poly(A) tail, is then copied into vRNA (Fodor, 2013). 
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1.6. Defective interfering (DI) viruses 
1.6.1. Introduction to defective interfering viruses 
The interference phenomenon was first reported by Preben von Magnus when 
he was studying the growth characteristics of influenza viruses during 
sequential passages in embryonated chicken's eggs at high multiplicity of 
infection (MOI). He observed an increase in the amount of virus particles with 
respect to infectivity of the preparation, which reflected a loss in the number of 
infectious virus. He referred to the non-infectious particles generated as 
'incomplete' virus (Von Magnus, 1947; Von Magnus, 1954). 
Defective interfering (DI) viruses are generated by nearly all viruses. They are 
virus particles that contain a deleted version of the infectious genome, as they 
lack one or more genes, and can interfere with the normal replication of the 
infectious virus from which those DI particles were generated, diminishing the 
production of new infectious virus (Huang, 1973). A DI virus is non-infectious 
due to its deleted gene(s), and is defective for replication unless the product(s) 
of the deleted gene is present (Marriott and Dimmock, 2010). All DI genomes 
contain the molecular signals to replicate and package into new DI particles, 
although they only replicate in cells co-infected by infectious 'helper', non-
defective virus (ND; normally the virus from which the DI genome derived) 
that provides the function(s) missing by the DI genome. Hence, the progeny DI 
and ND virus are antigenically identical (Dimmock and Easton, 2014). 
DI genomes are generated by the viral RdRp in the replication process. Due to 
the notoriously error-prone characteristics of RdRps, DI genomes may be by-
products of an inefficient replication that have evolved together with normal 
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ND genomes (Dimmock and Easton, 2014; Yount et al., 2006). Alternatively, 
they may have evolved to stimulate the innate immunity, which could favour 
survival of the host species, facilitating the perpetuation of the virus population 
(Marriott and Dimmock, 2010). 
DI genomes can be classified into four main types, as illustrated in Fig. 1.18. The 
'simplest' form of DI RNA is of an internal deletion type, and is generated when 
RdRp detaches from the RNA template and reattaches at another point of the 
template nearer the 5' end as shown in Fig.1.18.b. This results in some internal 
genes being deleted (sometimes over 90%) while retaining the original termini 
that are required for replication and/or packaging. Multiple deletions are also 
possible. A second form comprises a 5' terminus and an inverted repeat of the 
same terminus at the other end, while between the termini is a genome 
constituted as shown in Fig. 1.18.c. A third form, known as copyback DI RNA 
or 'hairpin' DI RNA, contains a variable length of the genome and a 5' terminus 
followed immediately by an inverted repeat of some of that sequence and the 5' 
end. This is the likeliest mechanism for the generation of DI genomes and 
occurs when RdRp 'jumps' from the template to the newly synthesized nascent 
strand and resumes elongation on it (often referred as 'copy-choice' mechanism) 
(Fig. 1.18.d) (Marriott and Dimmock, 2010). A fourth form consists of a 
snapback DI RNA comprising a single terminus but with an inverted repeat of 
almost all the sequence (Fig. 1.18.e). The last two DI RNA types potentially 
form double stranded structures when they are not complexed with 
nucleoproteins that could prevent base pairing (Dimmock and Easton, 2014). 
The type of DI generated does not depend on the virus family, but on the 
individual virus. For example, paramyxoviruses frequently generate copyback 
DI RNAs (Finke and Conzelmann, 1999). Among the Rhabdoviridae most VSV 
DI RNAs are copyback RNAs, whereas rabies virus DI RNAs are more prone to 
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form internal deletion DIs (Marriott and Dimmock, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.18. Types of DI genomes. Schematic of the different forms of DI RNA (not to scale). a) 
represents a normal virus genome with terminal sequences containing the replication signals 
labelled at the 5' end (a) and at the 3' end (g). The remainder of the genome is divided into 
arbitrary sections to indicate the possible origin of some of the DI RNA sequences. See the text 
for explanations of sections b) to e). Adapted from Dimmock and Easton, 2014. 
Errors of the viral polymerase can occur when reading the viral genome or 
antigenome. For example, a leader copyback DI (DI[LeCB]) RNA is generated 
when the viral RdRp is reading the viral genome. A trailer copyback DI 
(DI[TrCB]) RNA is generated when the viral RdRp is reading the viral 
antigenome (Fig. 1.19). 
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Fig. 1.19. Generation of DI(LeCB) and DI(TrCB) RNAs. Generation of DI(LeCB) or DI(TrCB) 
RNAs from the genomic or antigenomic strand of PIV5, respectively. 
DI RNAs differ from other interfering RNAs (e.g. siRNA, miRNA) in which 
they originate from viral genomes and compete with them for replication 
and/or packaging (Dimmock and Easton, 2014). The DI genome must retain the 
critical signals required for viral morphogenesis, packaging and replication in 
order to be propagated, but all other sections of the DI genome can potentially 
be deleted (Marriott and Dimmock, 2010). The DI virus 'interferes' by 
competitively inhibiting the helper virus replication, as the DI genome 
sequesters some essential proteins, such as viral polymerase components (e.g. 
viral L and P proteins, components of the viral RdRp), thus inhibiting the 
replication of the helper virus. Moreover, as a DI genome is normally much 
smaller than the helper genome, the viral polymerase can generate more copies 
of the DI genome than the helper genome (Fuller and Marcus, 1980). In the case 
of a DI(TrCB) RNA, the strong antigenomic replication promoter is present at 
both ends of the DI genome. The stronger antigenomic replication promoter in 
comparison to the genomic replication promoter reflects the requirement of the 
virus to produce greater numbers of genomes than antigenomes (Killip et al., 
2013). DI(TrCB) genomes are thus preferentially amplified over the ND helper 
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virus genome, since both strands possess the antigenomic replication promoter 
(Finke and Conzelmann, 1999). Copyback DI genomes are stronger activators of 
IFNβ than internal deletion DI genomes because they have a stronger potential 
to form dsRNA, as both termini in copyback DI genomes can self-anneal 
intramolecularly (Killip et al., 2013; Strahle et al., 2006). In general, DI viruses 
will only interfere with the virus from which they were derived (Marriott and 
Dimmock, 2010). 
The DI genome must also be packaged efficiently into virions, and multiple 
copies of RNA are often packaged in a DI particle (Fuller and Marcus, 1980). 
This indicates that there is frequently a low limit to the nucleic acid content into 
virus particles, and so the optimal length for the DI genome is a balance 
between rapid replication and efficient packaging (Marriott and Dimmock, 
2010). The length of the DI RNA is also dependent on the need to retain 
essential cis-acting sequences for an efficient replication and packaging 
(Marriott and Dimmock, 2010). 
A high MOI favours that more cells can be simultaneously infected with DI and 
infectious viruses, thus facilitating the propagation of DI viruses. This is called 
the 'Von Magnus effect' and leads to an increase in the DI:helper genome ratio 
(Marcus et al., 2009; Von Magnus, 1951). Nevertheless, a residual amount of the 
helper virus is necessary in order for the successful propagation of the DI virus. 
Thereby, the continued propagation of DI viruses requires a compromise ratio 
of DI:helper virus (Marriott and Dimmock, 2010). 
There has been extensive research on the use of DI particles as potential 
vaccines. Soon after DI viruses were first observed, attenuation of illness in 
animals by DI viruses was detected. Intracerebral inoculation of VSV DI virus 
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in laboratory animals was able to prevent or, at least, delay death in a dose- and 
also DI amount-dependent manner (Barret and Dimmock, 1986). Intranasally 
administered Semliki Forest virus in adult mice leads to a lethal encephalitis, 
but this can be completely prevented by treatment with intranasal DI SFV virus 
(Barret and Dimmock, 1986). Influenza virus DI genomes have been extensively 
studied. The earliest indications that DI influenza virus could protect animals 
were from 1950s, as it was observed that preparations containing large amounts 
of defective virus were attenuated relative to standard virus. Most stocks of 
influenza virus contain multiple defective species, generated during their 
generation in cell culture or in embryonated eggs. If amplified by high MOI, 
these mixed DI preparations can strongly interfere with helper influenza virus 
(Dimmock, 1996). 
1.6.2. IFNβ  induction by paramyxovirus DI viruses 
Virtually every virus species generate DI genomes that are encapsidated into 
virus particles. RNA viruses generate a high number of DI genomes as a 
consequence of the high rate of errors made by the viral RdRp in the replication 
process. Among all types of DI genome structures, paramyxoviruses mainly 
generate two types: internal deletion or copyback DI RNAs (Finke and 
Conzelmann, 1999; Strahle et al., 2006). Copyback DIs possess a stem-loop 
structure with blunt ends. Thus, the stem component is formed by a blunt-
ended dsRNA that, as previously mentioned, makes it a potential target for 
recognition by cytoplasmic PRRs (Kato et al., 2008; Weber, 2015; Wilkins and 
Gale, 2014). 
The IFN-inducing capacity of the DI genomes present in stocks of 
paramyxoviruses has been extensively studied. For example, studies on MeV 
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have shown that DI RNAs play a major role in the induction of IFN by MeV-
infected monocyte-derived dendritic cells (moDC). Despite low-MOI passage, 
DI RNA could still be detected that had no effect in MeV ability to infect moDC 
but affected MeV replication (Shivakoti et al., 2013). Moreover, Shingai and 
colleagues showed how certain laboratory-adapted and vaccine strains of MeV 
induced IFNβ mRNA in infected cells. These virus strains were found to 
contain high levels of DI particles (Shingai et al., 2007). Another study showed 
that a SeV stock that is highly contaminated with copyback DI genomes is a 
potent inducer of IFN. This could be possibly due to the reduced expression of 
viral products that block the host response to infection, as 'interference' of the 
DI genome would lead to less proteins being generated from the ND genome 
(Strahle et al., 2006). Interestingly, it has been observed that DI-rich 
preparations of several paramyxoviruses, including PIV5, MuV and SeV, 
induce IFN even in the absence of protein synthesis, that is, in the absence of 
genome replication. In DI-poor preparations, though, the generation of DI 
genomes requires replication of the ND virus to activate the IFN induction 
cascade (Killip et al., 2012), as negative strand RNA virus replication requires 
protein synthesis for encapsidation of newly synthesised RNA. 
Studies on PIV5 DIs have shed light into the IFN response against viral 
infection. PIV5-VΔC is a virus mutant that contains two translational stop 
codons in the V/P gene so that transcription of the P gene is not affected, but 
transcription of the V gene generates a truncated V protein that fails in binding 
to DDB1 and, therefore, targeting STAT1 for degradation (He et al., 2002). A DI-
rich preparation of PIV5-VΔC can be obtained by two high-multiplicity 
passages in Vero cells (that do not produce IFN and can therefore be used to 
propagate the virus), and it can be referred to as PIV5-VΔC vM2. Interestingly, a 
PIV5-VΔC vM0 virus stock, a DI-low preparation generated by low-multiplicity 
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passage so as to limit DIs propagation, did not lead to induction of the IFN 
response regardless of whether the parental virus encoded a truncated IFN 
antagonist (Killip et al., 2011). On the contrary, PIV5-VΔC vM2 was very 
efficient at inducing the IFN response, showing a correlation between the IFN-
inducing capacity of a PIV5 virus stock and the presence of DIs (Killip et al., 
2013). A deep sequencing analysis of a PIV5-VΔC vM2 stock showed that 
DI(TrCB) genomes were the most prevalent DI genomes in the stock. 
Interestingly, a deep sequencing analysis of a stock of PIV5 wt that had been 
obtained by 12 high-multiplicity passages in Vero cells showed that DI(TrCB) 
genomes were also the most prevalent DI genomes in the stock. Internal 
deletion type DI genomes and other DI(TrCB) genomes of different lengths 
were also found in each stock, showing that there was no particular part of the 
Trailer in which a template switching error was more likely to occur (Killip et 
al., 2013). 
The viral V protein is the main IFN antagonist of PIV5. In a cellular infection 
with a DI-containing stock of PIV5, the IFN induction cascade will normally be 
activated only if a ND virus cannot produce sufficient V protein quickly enough 
to prevent activation of the IFN induction pathway by co-infecting DI(TrCB)s, 
although cells can also be infected with DI(TrCB)s in the absence of a co-
infecting ND virus (Killip et al., 2013). The properties of the DIs generated in a 
host cell can also be affected by the V protein, since it was observed that the 
major DI(TrCB) genomes identified in DI-containing PIV5-VΔC preparations 
failed to obey the 'rule of six' whereas the major DI(TrCB) present in a DI-
containing PIV5 wt preparation obeyed this rule (Killip et al., 2013). 
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1.7. The need to purify RNA:protein complexes from cells 
Macromolecule complexes are the centre of many biochemical processes within 
cells. And not only this, as cells rely on the generation of such complexes for 
their correct functioning. In addition, viral proteins often work as part of 
complexes with cellular factors. Interactions between RNAs and proteins play 
important roles for cell maintaining and survival, for example gene regulation 
(Varani and Nagai, 1998) or recognition of viral RNA by cytoplasmic PRRs. 
Given the importance of RNA:protein complexes, there is a need to develop 
appropriate techniques for purifying such complexes for biochemical, structural 
and functional studies.	
In the past, it was generally assumed that RNA could function alone, but 
nowadays it is well known that RNA acts almost invariably associated with 
RNA-binding proteins (Cusack, 1999). RNA is structurally more versatile than 
DNA and has more diverse biological roles. RNA-binding proteins act by 
stabilizing, protecting, packaging or transporting RNA, and mediating 
interactions with other macromolecules or acting catalytically on RNA (Cusack, 
1999). Whereas, until relatively recently, it was assumed that RNA-binding 
proteins tend to possess β-sheet RNA binding surfaces to interact with RNA, 
now more binding motifs different from β-sheet structures are being 
discovered. Several of these are all helical, for example the influenza virus NS1 
protein (Chien et al., 1997). To make it more complicated, proteins recognize 
RNA by a wide range of structures (Cusack, 1999). These binding motifs lead to 
the generation of stable or transient associations of RNA with RNA-binding 
proteins to accomplish a wide variety of functions (Mehta and Trinkle-
Mulcahy, 2013). Therefore, studies of RNA-binding proteins and their RNA 
complexes are critical to understand the complexity of the processes occurring 
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within a cell, and is one of the main goals of biology (Cusack, 1999; Mehta and 
Trinkle-Mulcahy, 2013). 
1.7.1. PP7-based RNA:protein complexes 
Purification of native complexes is often technically difficult and time-
consuming. The study of RNA:protein interactions in vivo includes numerous 
methods such as electrophoretic mobility shift assay (EMSA), systematic 
evolution of ligands by exponential enrichment (SELEX), RNA footprinting, 
UV-induced crosslinking immunoprecipitation (CLIP) and RNA pull-down 
assays (Popova et al., 2015). Each of these methods has advantages and 
drawbacks and therefore there is always a demand for new methods to 
improve the isolation and purification of RNA:protein complexes with the 
objective to study their components. 
The diverse methods to study RNA:protein complexes are based on the specific 
interactions between RNA and proteins. In this sense, the specific interaction 
between the PP7 protein and its target RNA has been the basis for the 
successful development of an RNA-based affinity purification method to 
specifically isolate influenza A virus cRNPs from infected cells (York et al., 
2013). PP7 is a Pseudomonas aeruginosa bacteriophage coat protein that binds its 
translational operator RNA with high affinity (Kd =~1 nM) (Chao et al., 2008; 
Lim and Peabody, 2002). Coat proteins of ssRNA bacteriophages regulate 
translation of the phage replicase by binding with high affinity to an RNA 
hairpin containing the initiation site (Chao et al., 2008). In the case of PP7, the 
RNA hairpin, or PP7 recognition sequence (PRS), is a short RNA made up of a 
specific 25-nucleotide stem-loop RNA structure with a bulged adenine that is 
critical for the specific recognition by an extended β-sheet contained in the PP7 
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structure. In fact, small changes in the PRS sequence lead to significant loss of 
RNA:protein affinity (Chao et al., 2008; Lim and Peabody, 2002). 
With the aim to facilitate the study of RNA:protein complexes, a system was 
devised that took advantage of the specific interaction between PP7 and its 
translational operator. This PP7-based system was designed for the study of the 
complexes that are formed within cells when RIG-I/Mda5 recognize viral 
copyback DI genomes and initiate the IFN response. 
1.8. Thesis objectives 
The aim of this research was to develop a simple PP7-based purification 
protocol for isolating proteins that interact with specific RNAs by applying the 
methodology to study RNA:protein complexes that occur within the cell when 
RLRs detect viral RNA. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1. Materials 
2.1.1 Cells, viruses and antibodies 
2.1.1.1. Mammalian cell-lines 
293T: Human embryonic kidney cell-line (provided by Professor Richard 
Iggo, University of Bordeaux). 
A549: Human carcinomic alveolar basal epithelial cell-line (European 
Collection of Authenticated Cell Cultures [ECACC]). 
HSF: Human skin fibroblast cell-line (Hambleton et al., 2013). 
Vero: African Green Monkey kidney cell-line (ECACC). 
In addition to the basic cell-lines listed above, the following cell-line derivatives 
were also used in this study: 
HSF/STAT2-/-: HSF cell-line that is STAT2-deficient (Hambleton et al., 2013). 
BSR-T7: Baby Hamster Kidney (BHK)-21 cell-line clone stably expressing T7 
RNA polymerase (Buchholz et al., 1999). 
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293T.pr(IFNβ).GFP: 293T cell-line expressing the green fluorescent protein 
(GFP) gene under the control of the IFNβ promoter. Additionally, this cell-line 
contains inducible resistance to puromycin as expression of puromycin N-
acetyl-transferase (PAC) is also under the control of the IFNβ promoter (see 
section 2.8 for the generation of this cell-line). 
A549/V: A549 cell-line stably expressing the V protein from Parainfluenza virus 
5 (Young et al., 2003). 
A549/Npro: A549 cell-line stably expressing the N-terminal protease (Npro) of 
Bovine Viral Diarrhoea virus (BVDV) (Chen et al., 2010). 
293T.PP7-V5: 293T cell-line stably expressing the PP7 protein with a C-terminal 
V5 tag, as well as encoding for PAC (see section 2.8 for the generation of this 
cell-line). 
A549.PP7-V5: A549 cell-line stably expressing the PP7 protein with a C-terminal 
V5 tag, as well as encoding for PAC (see section 2.8 for the generation of this 
cell-line). 
293T.PP7-V5.8x: 293T cell-line stably expressing the PP7 protein with a C-
terminal V5 tag, as well as encoding for PAC. Cells were transduced 8 times 
with the lentiviral vector (see section 2.8 for the generation of this cell-line). 
A549.PP7-V5.8x: A549 cell-line stably expressing the PP7 protein with a C-
terminal V5 tag, as well as encoding for PAC. Cells were transduced 8 times 
with the lentiviral vector (see section 2.8 for the generation of this cell-line). 
293T.V5-TEV-PP7.puro: 293T cell-line stably expressing the V5-TEV-PP7 
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construct with an N-terminal V5 tag, as well as encoding for PAC (see section 
2.8 for the generation of this cell-line). 
293T.V5-TEV-PP7.bla: 293T cell-line stably expressing the V5-TEV-PP7 
construct with an N-terminal V5 tag. This cell-line also encodes for blasticidin-S 
deaminase, which confers resistance to blasticidin (see section 2.8 for the 
generation of this cell-line). 
A549.V5-TEV-PP7.puro: A549 cell-line stably expressing the V5-TEV-PP7 
construct with an N-terminal V5 tag, as well as encoding for PAC (see section 
2.8 for the generation of this cell-line). 
A549.V5-TEV-PP7.bla: A549 cell-line stably expressing the V5-TEV-PP7 
construct with an N-terminal V5 tag, as well as containing the blasticidin 
resistance gene (see section 2.8 for the generation of this cell-line). 
2.1.1.2. Viruses 
PIV5 wt: Human Parainfluenza virus 5 W3A strain (Choppin, 1964). 
PIV5 wt (vM9): A stock of PIV5 wt that contains defective-interfering (DI) 
viruses and was generated by Mr Dan Young. 
PIV5-VΔC (vM2): A strain of PIV5 with the C-terminus of the V protein 
deleted; therefore, this virus cannot counteract the IFN response (He et al., 
2002). The PIV5-VΔC (vM2) stock is a DI rich preparation of the PIV5-VΔC 
strain and was generated by Mr Dan Young (Chen et al., 2010). 
Influenza A wt: Influenza A virus strain WSN (York et al., 2013). Provided by 
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Professor Ervin Fodor. 
Influenza A vRNA: Influenza A virus strain WSN containing the PP7-
recognition sequence (PRS) in the Neuraminidase (NA) gene in the orientation 
to capture vRNP (see Chapter 6) (York et al., 2013). Provided by Professor Ervin 
Fodor. 
Influenza A cRNA: Influenza A virus strain WSN containing the PRS sequence 
in the NA gene in the orientation to capture cRNP (see Chapter 6) (York et al., 
2013). Provided by Professor Ervin Fodor. 
2.1.1.3. Antibodies 
All the primary and secondary antibodies (Ab) used in this study are listed on 
Table 2.1. 
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Table 2.1. List of antibodies used for Western Blot (WB) and/or 
Immunostaining (IF). 
2.1.2. Plasmids 
Plasmids used in this study were generated by Mr Francisco Dominguez unless 
specified.  
pGEM-Teasy.DI plasmid: Encodes for DI(TrCB) RNA under the control of the 
Antibody Company 
Ab dilution 
for W/B 
Time 
WB/IF 
Ab dilution 
for IF 
Primary Antibodies 
mouse anti-V5 (336/SV5-Pk1) 
(monoclonal) 
AbD Serotec® 1:5000 
1h to 
O/N/1h 
1:400 
rabbit anti-V5 (polyclonal) Abcam 1:2000 O/N/1h 1:200 
mouse anti-PIV5 NP (monoclonal) RER1 - -/1h 1:200 
mouse anti-PIV5 P (monoclonal) RER1 - -/1h 1:200 
mouse anti-influenza A NP 
(monoclonal) 
Abcam 1:2000 O/N/1h 1:200 
mouse anti-β-actin (monoclonal) Sigma-Aldrich 1:10000 O/N/- - 
Secondary Antibodies 
rabbit anti-mouse (HRP2)-
conjugated 
Sigma-Aldrich 1:2000 1h/- - 
donkey anti-goat (HRP2)-
conjugated 
Santa Cruz 
Biotechnology 
1:2000 1h/- - 
donkey anti-rabbit (TR3)-
conjugated 
Abcam - -/1h 1:200 
goat anti-mouse (FITC4)-
conjugated 
Southern 
Biotech 
- -/1h 1:200 
IRDye®680RD goat anti-mouse Li-COR 1:10000 2h/- - 
1 Randall et al., 1987 
2 Horseradish peroxidase (HRP) 
3 Texas Red (TR) 
4 Fluorescein isothiocyanate (FITC) 
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standard T7 promoter (Dr Marian Killip). 
φ2.5.DI plasmid: Encodes for DI(TrCB) RNA under the control of the T7 φ2.5 
promoter (Professor Stephen Goodbourn). 
φ2.5.DI-PRS plasmid: Encodes for DI(TrCB) RNA containing a PRS sequence 
under the control of the T7 φ2.5 promoter (see section 2.6 for the generation of 
this plasmid). 
pCAGGS plasmid: Empty plasmid (Dr Lena Andrejeva). 
pCAGGS-L: Encodes for PIV5 L protein (Dr Lena Andrejeva). 
pCAGGS-NP plasmid: Encodes for PIV5 NP protein (Dr Lena Andrejeva). 
 pEF-P plasmid: Encodes for PIV5 P protein (Dr Lena Andrejeva). 
pIFNβ .luc plasmid: Encodes for luciferase under the control of the IFNβ 
promoter (Dr Marian Killip). 
pCMV.GFP plasmid: Encodes for the GFP protein in mammalian cells (Dr Matt 
Smith). 
pTM1.GFP plasmid: Encodes for the GFP protein under the control of the 
standard T7 promoter (Dr Lee Sherry). 
pEMiB plasmid: Encodes for mCherry Fluorescent Protein followed by a 2A 
ribosomal-skipping sequence that is followed by the T7 polymerase sequence 
(Professor Martin Ryan). 
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pdl'IFNβ .GFP plasmid: Contains the GFP gene under the control of the IFNβ 
promoter (Dr Zoe Gage). 
pdl'PP7-V5.puro plasmid: Contains the PP7-V5 tagged sequence coupled to the 
PAC gene (Dr Marian Killip). 
pdl'V5-TEV-PP7.puro plasmid: Contains the V5-TEV-PP7 construct sequence 
coupled to the PAC gene (see section 2.8 for the generation of this plasmid). 
pdl'V5-TEV-PP7.bla plasmid: Contains the V5-TEV-PP7 construct sequence 
coupled to the blasticidin resistance gene (see section 2.8 for the generation of 
this plasmid). 
2.1.3. Primers 
Primers used in this study are listed in Table 2.2. 
Table 2.2. Forward and Reverse primers used for PCR or qRT-PCR. 
 
Name Use Sequence (5'-->3') 
φ2.5.DI 1st 
PstI+PRS Fwd 
Plasmid 
construction 
AAATTTCTGCAGTAAGGAGTTTATATGGAAACC
CTTAGCTACATTAGGAAATTGATTGAGGGG 
φ2.5.DI 2nd PstI 
Rev 
Plasmid 
construction 
AAATTTCTGCAGATTCCGGGTCACTGTGAGTGG 
BamHI V5-TEV 
Fwd 
Lentiv. vector 
construction 
AAATTTGGATCCATGGGCAAACCGATTCCGAAC
CCGC 
TEV compl PP7 
Rev 
Lentiv. vector 
construction 
ATGGTTTTGGCCATGCCCTGAAAATACAG 
PP7 compl TEV 
Fwd 
Lentiv. vector 
construction 
CTGTATTTTCAGGGCATGGCCAAAACCAT 
PP7 NdeI Rev 
Lentiv. vector 
construction 
AAATTTCATATGTTAACGGCCCAGCGGCACAAG
GTT 
A DI loop binding 
Fwd 
RT-PCR CATATGAATGACAGCTTGTGTAG 
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A PRSseq Rev RT-PCR TAAGGGTTTCCATATAAACTCCTTA 
DI loop binding 
Rev 
RT-PCR 
AAATTTGTTAGATCGATATTGCAATCCCCCTCAA
TC 
NA Flu WSN Fwd RT-PCR GGG TCA ATC TGT ATG GTA GTC GG 
NA Flu WSN Rev RT-PCR GTC AAT GGT GAA CGG CAA CTG AG 
β-actin Fwd RT-PCR ACCAACTGGGACGACATGGAG 
β-actin Rev RT-PCR TAGCACAGCCTGGATAGCAAC 
hIFNβ Fwd qRT-PCR CTT TGC TCT GGC ACA ACA GG 
hIFNβ Rev qRT-PCR GTG GAG AAG CAC AAC AGG AGA 
hIL6 Fwd qRT-PCR TAGTGAGGAACAAGCCAGAGC 
hIL6 Rev qRT-PCR TTGGGTCAGGGGTGGTTATTG 
hIL8 Fwd qRT-PCR CTT GGC AGC CTT CCT GAT TTC 
hIL8 Rev qRT-PCR TTT GGG GTG GAA AGG TTT GG 
hTNFα Fwd qRT-PCR CTTTGGAGTGATCGGCCCC 
hTNFα Rev qRT-PCR GTTATCTCTCAGCTCCACGCC 
hGAPDH Fwd qRT-PCR GAG AAG GCT GGG GCT CAT TT 
hGAPDH Rev qRT-PCR AGT GAT GGC ATG GAC TGT GG 
2.2. Cell culture 
2.2.1. Cell maintenance 
Cell monolayers were cultured in 25cm2, 75cm2 (Greiner Bio-One) or 300cm2 
(Helena Biosciences) tissue culture flasks and maintained in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% (v/v) foetal bovine 
serum (FBS; Thermo Fisher Scientific) and 1% (v/v) penicillin and streptomycin 
(pen/strep) (10% DMEM). Cells were incubated at 37°C/5% CO2 and routinely 
passaged when approximately 90% confluent using 
Trypsin/ethylenediaminetetraacetic acid (EDTA). 
2.2.2. Cryopreservation and resuscitation of cells 
Cells generated during this study were prepared for cryopreservation in liquid 
nitrogen by trypsinisation of the cell monolayer, followed by re-suspension in 
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10% DMEM and pelleting at 1200rpm for 5min at room temperature (RT). Cells 
were then re-suspended in freezing medium (10% [v/v] DMSO, FBS), aliquoted 
into cryovials and frozen at -80°C before storage in liquid nitrogen. To 
resuscitate cells, cryovials were thawed rapidly at 37°C, centrifuged at 1200rpm 
for 5min at RT and re-suspended and maintained in 10% DMEM at 37°C/5% 
CO2. If necessary, the appropriate antibiotic selection (puromycin at 2µg/ml or 
blasticidin at 10µg/ml) was added following the first passage. 
2.3. Infection of mammalian cells 
To infect cells, the medium was removed from cell monolayers and replaced 
with virus suspended in a low volume of serum-free and antibiotic-free DMEM 
(SF DMEM) at an appropriate MOI. After an initial adsorption period of 1-2h on 
a rocking platform at 37°C/5% CO2, an equal volume of 2% (v/v) FBS pen/strep 
DMEM (2% DMEM) was added to each monolayer and the cells were incubated 
at 37°C/5% CO2 until harvested. 
2.4. Restriction enzyme digestion 
Restriction enzyme digestions were performed with the kits provided by 
Promega according to the manufacturer's instructions. Two microliters of the 
appropriate 10X restriction enzyme buffer were added to a volume of DNA at 
an appropriate concentration. Zero point two microliters of acetylated bovine 
serum albumin (BSA) and 0.5µl of the appropriate restriction enzyme were also 
added to the reaction mixture. Finally, H2O was added to a volume of 20µl. The 
components were mixed by pipetting and centrifuged for several seconds 
before incubating for 2h at 37°C. 
Chapter 2: 
Materials and methods 
 73 
When performing restriction digests using two restriction enzymes with 
incompatible buffers, the DNA was firstly cut with one restriction enzyme 
followed by incubation with the second restriction enzyme. The volumes of the 
reagents were scaled up accordingly. 
Following incubation, the enzyme was inactivated by heating at 65°C for 15min. 
After inactivation of the enzyme, the mixture was run on an agarose gel to test 
that the DNA was successfully cut (see section 2.5). 
2.5. Nucleic acid analyses 
2.5.1. Measurement of RNA and DNA concentrations 
RNA and plasmid DNA concentrations were quantified using a NanoDrop ND-
1000 spectrophotometer (Thermo Scientific). RNA or DNA purity was 
estimated by calculating the Abs260/Abs280 ratio and considered acceptable 
within the range 1.8-2. 
2.5.2. TRIzol extraction of RNA 
RNA was extracted from cells and samples using TRIzol reagent (Invitrogen) 
according to the manufacturer's instructions. Briefly, cells or samples were re-
suspended in an appropriate volume of TRIzol reagent and incubated for 5min 
at RT. Chloroform was added at one fifth of the volume of TRIzol reagent, 
followed by vigorous shaking for 15s and incubation for 3min at RT. Following 
incubation, centrifugation was performed at 12000g for 15min at 4°C. The clear 
upper liquid layer was then transferred to a clean microcentrifuge tube and 
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isopropanol added at a volume equal to half of the TRIzol reagent used in the 
previous step. Additionally, 1µl of Glycoblue® (Ambion) was added as a co-
precipitant of nucleic acids. The samples were left for 10min at RT before 
centrifugation at 12000g for 10min at 4°C. The RNA pellet was washed in 75% 
ethanol followed by centrifugation at 7500g for 5min at 4°C. The RNA pellet 
was partially air dried and dissolved in an appropriate volume of 
diethilpyrocarbonate (DEPC) H2O. Finally, the concentration was measured and 
the RNA was stored at -80°C. 
2.5.3. RT-PCR and PCR 
When necessary, an RNA reverse transcription was performed prior to a PCR. 
The complementary DNA (cDNA) was generated in a two-step reaction. 
Briefly, aliquots from samples were taken to contain 1µg where possible. The 
aliquots were added to the reverse primer at a final concentration of 1.5µM with 
DEPC H2O added to a final volume of 10µl. The samples were incubated for 
10min at 72°C. Following incubation, samples were added 4µl 5X RT buffer, 1µl 
M-MLV RT RNase (H-) Pt mutant 200u/µl (Promega), 1µl RNasin ribonuclease 
inhibitor 40u/µl (Promega), dNTP mix (Promega, final concentration 1mM), and 
dithiothreitol (DTT) (final concentration  10mM). Samples were incubated for 
1h at 42°C. 
PCR reactions were performed with GoTaq2 DNA polymerase (Promega) or 
KOD Hot Start DNA polymerase (Novagen) according to the conditions 
described in Table 2.3: 
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Table 2.3. Reaction set-up and conditions for a PCR using GoTaq2 or KOD 
Hot Start polymerases. 
2.5.4. Gel electrophoresis of nucleic acids 
A gel was made containing 1% (w/v) agarose in TBE buffer (89mM Tris, 89mM 
Reaction set-up 
GoTaq KOD Hot Start 
Reagents Volume Reagents Volume 
5X Green reaction 
buffer 
10µl 
10X buffer for KOD 
Hot Start pol. 
5µl 
dNTP mix (10mM 
each) 
1µl MgSO4 (25mM) 3µl 
Fwd primer (10µM) 1µl 
dNTP mix (2mM 
each) 
5µl 
Rev primer (10µM) 1µl Fwd primer (10µM) 1.5µl 
GoTaq2 polymerase 0.25µl Rev primer (10µM) 1.5µl 
Template DNA x KOD Hot Start pol. 1µl 
PCR grade H2O y Template DNA x 
Final volume 50µl PCR grade H2O y 
  Final volume 50µl 
Conditions 
Initial denaturation 94°C 2min Initial denaturation 95°C 2min 
Denaturation 94°C 1min Denaturation 95°C 20s 
Annealing Tm°C1 1min Annealing Tm°C1 10s 
Extension 72°C 1min/Kb Extension 70°C 20s/Kb 
No cycles 15-35 No cycles 25-35 
Final extension 72°C 5min Final extension 70°C 5min 
Soak infinite Soak infinite 
1 The lowest Tm of the primers 
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borate, 2mM EDTA). Ethidium bromide (EtBr) was added to a final 
concentration of 0.5µg/ml. The gel was solidified in a horizontal gel 
electrophoresis unit (Biophoretics). DNA samples were mixed with the 
appropriate volume of 6x loading dye (Promega) prior to gel loading. The gel 
was run at 95V for 35min before analysing with UV-light. 
2.5.5. Real-Time Quantitative PCR 
Total cellular RNA was extracted using TRIzol reagent and cDNA generated as 
described in sections 2.5.2 and 2.5.3. The cDNA generated was subsequently 
used in a Real Time Quantitative PCR reaction (qRT-PCR) using SYBR Green-
based master mix (MESA blue qPCR MasterMix Plus for SYBR Assay; 
Eurogentec). Reactions were set-up in 96-well qRT-PCR plates (Eurogentec) as 
follows: 
SYBR Green Mix: 10µl 
Fwd primer (5mM): 0.4µl 
Rev primer (5mM): 0.4µl 
20X low dye: 0.2µl 
Template cDNA: 1-2µl 
PCR grade H2O: up to 20µl 
Reactions were set-up in triplicate. The plate was sealed with a plastic seal 
followed by centrifugation at 2000g for 2min. After centrifugation, the reaction 
was performed in a MxPro Mx3005P qPCR System with the conditions: 
Initial denaturation: 95°C 3min 
Denaturation: 95°C 10s 
Annealing/extension: 60°C 20s 
 repeat denaturation-annealing/extension 40 cycles 
Melt curve/dissociation curve: 95°C 1min 
 58°C 30s 
Chapter 2: 
Materials and methods 
 77 
 95°C 30s 
Data was processed to obtain Tm curves for each gene and graphics were 
obtained with GraphPad Prism. 
2.6. φ2.5.DI-PRS plasmid construction 
2.6.1. Generation of the φ .2.5.DI-PRS plasmid 
A schematic of the procedure is shown in Figure 2.1. This is a brief description 
and a full description of the procedure is in section 4.2. Appendix 1 shows the 
sequence of the φ2.5.DI plasmid highlighting the PstI sites. The φ2.5.DI plasmid, 
which does not contain the PRS sequence, was cut with the PstI restriction 
enzyme (Promega) to generate a linear vector containing PstI sites at both 3' and 
5' ends. To prevent self re-ligation, the vector was treated with CIAP (calf 
intestinal alkaline phosphatase, Promega) for 60min at 37°C. The φ2.5.DI 
plasmid was also used as a template for a PCR using φ2.5.DI 1st PstI+PRS Fwd, 
which contains the PRS sequence, and φ2.5.DI 2nd PstI Rev primers. This 
generated an insert containing the PRS sequence in the loop component of the 
DI RNA with PstI sites at both 3' and 5' ends. This insert was then ligated into 
the destination vector using the Rapid DNA Ligation Kit (Thermo Scientific) 
with T4 DNA ligase (Promega), according to manufacturer's instructions. 
Briefly, the appropriate volumes for a 1:3 ratio vector:insert were mixed and 
added to 5X Rapid Ligation Buffer (4µl), T4 DNA Ligase (1µl, 5 U/µl) and 
nuclease-free H2O to a final volume of 20µl. After vortexing and centrifuging 
briefly, the reaction was incubated at 22°C for 5min. 
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Fig. 2.1. Generation of the φ2.5.DI-PRS plasmid. The φ2.5.DI plasmid was cut with PstI to 
generate a linear vector containing PstI sites at both ends. The φ2.5.DI plasmid was also used as 
a template to generate an insert containing the PRS sequence in the loop component of the DI 
RNA with PstI sites at both ends. The insert was ligated with the vector to generate the φ2.5.DI-
PRS plasmid expressing the DI-PRS sequence in the loop component. 
2.6.2. Transformation into competent E. coli 
The ligation product was used to transform DH5α E.coli competent cells 
(Invitrogen) using a heat shock procedure. Briefly, 50µl cells were incubated 
with 5µl ligation product on ice for 1h. Cells were then subjected to 2min heat 
shock at 42°C followed by 2min on ice. One millilitre Lysogeny Broth (LB) 
medium was added and cells were incubated for 1h at 37°C. After incubation, 
200µl of transformed cell dilution was seeded onto an agar plate with ampicillin 
(Amp) and incubated overnight (O/N) at 37°C. The following day, a number of 
colonies were picked and grown in LB medium (+Amp) O/N at 37°C. 
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2.6.3. Plasmid preparation and sequencing 
Minipreps were prepared from grown bacterial colonies using the QIAprep 
Spin Miniprep Kit (QIAGEN) according to manufacturer's instructions, with the 
plasmids obtained cut with PstI. Digestion products were run in an agarose gel 
and positive clones (in terms of containing the plasmid) were subjected to PCR 
using 'A DI loop binding Fwd' and 'A PRSseq Rev' primers. Positive clones (in 
terms of having the DI-PRS sequence in the correct orientation) were sent to the 
MRC Protein Phosphorylation Unit DNA Sequencing and Services (University 
of Dundee) to be sequenced. 
The sequences were analysed with 4Peaks and Serial Cloner software to 
confirm the successful generation of a plasmid containing the PRS sequence in 
the loop component of the DI RNA. The plasmid was termed φ2.5.DI-PRS and 
the sequence is shown in Appendix 2. 
2.7. Transfection of cells 
Cells were seeded in 25cm2, 75cm2 flasks (Greiner Bio-One), or in 24-well plates 
(Thermo Scientific). Once they were 50-70% confluent, they were transfected 
using Fugene® 6 Transfection Reagent (Promega) following manufacturer's 
instructions with a 1:3 ratio DNA(µg):reagent(µl). Briefly, the appropriate 
volume of Fugene® Transfection Reagent was added to an adequate volume of 
SF DMEM and the mixture was incubated for 5min at RT. The appropriate 
volume of DNA was added to the Fugene® Transfection Reagent/medium, 
incubated for 15min at RT before mixing. Meanwhile, old medium was 
removed from cells and replaced with fresh 10% DMEM. The mixture was then 
added to the fresh medium and cells were incubated for 24-48h at 37°C. When 
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selection was required, cells were left incubating for 48h before adding the 
appropriate antibiotic to the medium. 
2.8. Lentiviruses 
For the generation of cell-lines that stably express a particular protein or 
construct, a second-generation lentivirus system was used consisting of three 
lentiviral plasmids. The transfer vectors supply the minimum cis-acting genetic 
sequences (e.g. LTRs, packaging (ψ) site, the rev response element (RRE), the 
central polypurine tract (cPPT) and the spleen focus-forming virus [SFFV] 
promoter) necessary for the vector to transduce the target cell and deliver the 
gene of interest. In order to create an infectious lentivirus two packaging 
plasmids are required: firstly, the CMV-R plasmid encoding the gag structural 
proteins and pol, and secondly, the VSV-G plasmid encoding the envelope 
glycoprotein of vesicular stomatitis virus (VSV). This allows for the generation 
of pseudotyped virus particles that can be transduced to a broad range of cell 
types. 
2.8.1. Generation of a V5-TEV-PP7 insert by PCR overlap 
extension and insertion into lentivirus vectors 
To generate an insert for the lentiviral transfer vectors used in the generation of 
the V5-TEV-PP7 lentiviruses, two PCRs were made using a plasmid containing 
the V5-TEV sequence (shown in Appendix 3; provided by PhD Reyes Sanles-
Falagan), and also a plasmid containing the PP7 sequence (pdl'PP7-V5.puro 
plasmid), as templates. The first PCR fragment was made using the V5-TEV 
plasmid as a template, and using BamHI V5-TEV Fwd and TEV compl PP7 Rev 
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primers that covered V5, TEV and partially PP7. The second PCR fragment was 
made using the pdl'PP7-V5.puro plasmid as a template, and using PP7 compl 
TEV Fwd and PP7 NdeI Rev primers that covered PP7. Both PCR fragments 
generated were partially complementary to one another in the PP7 sequence. 
The fragments were purified using the QIAquick PCR Purification Kit 
(QIAGEN) following manufacturer's instructions. For an 'overlap' PCR, KOD 
Hot Start DNA polymerase was added to a mix of equimolecular amounts of 
purified fragments and a PCR was performed for 15 rounds using an annealing 
temperature of 60°C. Next, end primers (BamHI V5-TEV Fwd and PP7 NdeI 
Rev) were added and the PCR was continued for another 20 rounds using an 
annealing temperature of 72°C, generating a V5-TEV-PP7 construct. The 
fragment was loaded in an agarose gel and the band was cut and purified using 
the QIAquick Gel Extraction Kit (QIAGEN) following manufacturer's 
instructions. This generated an insert that contained BamHI and NdeI 
restriction sites at the 5' and 3' ends, respectively. 
Two lentiviral transfer vectors were used for the generation of the 293T and 
A549 cell-line derivatives encoding for the V5-TEV-PP7 construct. These were 
the pdl'SV5V'IB vector, which encodes the blasticidin resistance gene, and the 
pdl'SUR.pK.IP vector, which encodes for PAC and hence confers resistance to 
puromycin. Both transfer vectors contain compatible restriction sites (BamHI 
and NdeI) with the insert generated; therefore, both transfer vectors and the 
insert were cut with these restriction enzymes (Promega). Products were then 
purified using the QIAquick PCR Purification Kit (QIAGEN) following 
manufacturer's instructions and run in an agarose gel. The appropriate bands 
were cut and purified using the QIAquick Gel Extraction Kit (QIAGEN) 
according to manufacturer's instructions. Insert and vectors were then ligated 
using the Rapid DNA Ligation Kit (Thermo Scientific) according to 
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manufacturer's instructions. Five microliters of each mixture was used to 
transform competent E. coli cells. Minipreps were made from grown bacterial 
colonies using the QIAprep Spin Miniprep Kit (QIAGEN) according to 
manufacturer's instructions, and an aliquot of the plasmids was cut with 
BamHI and NdeI before loading into an agarose gel to confirm the successful 
generation of the pdl'V5-TEV-PP7.puro and pdl'V5-TEV-PP7.bla transfer 
vectors. 
2.8.2. Generation of lentivirus stocks 
All the transfer vectors provided or generated (i.e. pdl'IFNβ.GFP, pdl'PP7-
V5.puro, pdl'V5-TEV-PP7.puro and pdl'V5-TEV-PP7.bla plasmids) were used 
for the generation of the corresponding lentivirus stocks. For this, Fugene® 
Transfection Reagent was used to transfect T75 flasks of 60-70% confluent 293T 
cells. Thirty three microliters of Fugene® Transfection Reagent was added to 
1ml SF DMEM and the mixture incubated for 5min at RT. Three microliters of 
VSV-G and 3µl of CMV-R packaging plasmids, together with 5µl of transfer 
vector, were added to the mixture and incubated for a further 15min at RT. 
Meanwhile, the old medium was removed from cells and replaced by 10ml 
fresh 10% DMEM. The mixture was added to the new medium and the flasks 
were incubated at 37°C. At 48h post-transfection the supernatant was collected 
and then clarified by centrifugation (3500 rpm, 15min) and filtration (45 µm 
filters). Lentivirus stocks were stored in 1ml aliquots at -80°C. 
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2.8.3. Infection with lentiviruses and generation of stable cell-
lines 
The lentivirus stocks were used to generate cell-lines expressing the gene of 
interest. Therefore, 25cm2 flasks of 50% confluent cells (293T or A549) were 
transduced with 1 ml of lentivirus, 1ml SF DMEM and polybrene (to a final 
concentration of 8 µg/ml). The flasks were centrifuged in a plate rotor at 2600 
rpm for 30min to favour adsorption. Cells were then incubated on a rocking 
platform at 37°C/5% CO2 for 1h prior to the addition of 2ml of 10% DMEM and 
incubated at 37°C/5% CO2 for 48h. Selection with the appropriate antibiotic 
followed; selection with puromycin (2 µg/ml) for 2 days and selection with 
blasticidin (10 µg/ml) for 4-6 days. The generated cell-line derivatives were 
maintained under antibiotic selection until used for further experiments. 
2.8.4. Sequential infections for the generation of 293T.PP7-V5.8x 
and A549.PP7-V5.8x cell-lines 
When multiple transductions (i.e. 8x) of lentiviral vectors were required, cells 
were subjected to cycles consisting of transduction with 1ml of lentivirus, 1ml 
SF DMEM and polybrene (to a final concentration of 8 µg/ml), followed by 
centrifugation (2600 rpm, 30min) and incubation for 1h at 37°C/5% CO2. The 
final cycle was followed by the addition of 2ml 2% DMEM and incubation for 
48h at 37°C/5% CO2. 
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2.9. Generation of DI-PRS RNA-containing stocks of viruses by 
sequential passages in Vero cells 
50% confluent 25cm2 flasks of BSR-T7 cells were transfected with the φ2.5.DI-
PRS plasmid and the empty pCAGGS plasmid using Fugene® Transfection 
Reagent, according to manufacturer's instructions, or, also co-transfected with 
plasmids encoding for viral L, P and NP proteins. 
Fugene® Transfection Reagent was added to SF DMEM and the mixtures 
incubated for 5min at RT. These mixtures were then added to the 
corresponding plasmids and incubated for 15min at RT. Meanwhile, old 
medium was removed from cells and replaced by fresh 10% DMEM. After 
incubation, the mixtures were added to the fresh medium and flasks were 
incubated for 48h at 37°C/5% CO2. Following incubation, medium was removed 
from cells and they were infected at a  MOI of 10 with an appropriate dilution 
of PIV5 W3A in SF DMEM to a final volume of 1ml. Flasks were incubated on a 
rocking platform at 37°C/5% CO2 for 1h before adding 1ml 2% DMEM and 
incubating at 37°C/5% CO2 for 30h. 
Following incubation, supernatant was collected and RNA from cells was 
extracted for further analysis using TRIzol reagent. Supernatant was clarified 
by centrifugation (3500 rpm, 15min) and filtration (45 µm filters), and was 
termed vM1'. One milliliter of supernatant from each flask was stored at -80°C, 
with the other 1ml mixed with 4ml 2% DMEM and used to infect a 90% 
confluent 75cm2 flask of Vero cells. Cells were incubated on a rocking platform 
at 37°C/5% CO2 for 48h. Following incubation, supernatant was collected and 
clarified by centrifugation (2500 rpm, 5min). The stock was termed vM1 (1 
passage in Vero cells) and half of this was stored in 1ml aliquots at -80°C. The 
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remaining half (2.5ml) was mixed with 2.5ml 2% DMEM and was used to infect 
a 90% confluent 75cm2 flask of Vero cells. Supernatants and infected cells were 
collected and sequential infections in Vero cells performed and named vM2, 
vM3, etc. according to the number of passages in cells. 
2.10. Protein analysis 
2.10.1. SDS-polyacrylamide gel electrophoresis 
Cells were lysed in disruption buffer (250µl for a 25cm2 flask) (10M urea, 20% 
(w/v) sodium dodecyl sulphate [SDS], β-mercaptoethanol, bromophenol blue). 
Cell lysates were sonicated for 20s to reduce viscosity and then heated to 99°C 
for 2min to ensure denaturation of proteins. Subsequently, samples were 
loaded on 4-12% precast Mini-Protean polyacrylamide gels (Bio-Rad) or 4-12% 
NuPAGE polyacrylamide gradient gels (Invitrogen). Mini-Protean gels were 
run with 1X TGS running buffer (25mM Tris, 192mM glycine, 0.1% SDS pH 8.3) 
at 200V for 35min in Bio-Rad electrophoresis tanks. NuPAGE gradient gels 
were run with 1X MOPS buffer (50mM MOPS [3-(N-morpholino) 
propanesulfonic acid], 50mM Tris [Tris(hydroxymethyl) aminomethane], 
3.5mM SDS, 1mM EDTA) at 180V for 60min in Invitrogen electrophoresis tanks. 
2.10.2. Western Blotting 
Following SDS-PAGE electrophoresis, proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes which were previously activated 
in methanol. The transfer was performed using the Bio-Rad Trans-Blot Turbo 
Transfer System with 1x TG transfer buffer (25mM Tris, 192mM glycine, 10% 
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methanol) following manufacturer's instructions. Following transfer, the 
membranes were placed in blocking buffer (PBS [phosphate-buffered saline] 
containing 5% [w/v] skimmed milk powder and 0.1% Tween-20) for 1h at RT. 
The membranes were subsequently incubated with the corresponding primary 
antibody at the appropriate dilution in blocking buffer from 1h (at RT) to O/N 
(at 4°C). Following incubation, the membranes were washed 3 times by quick 
rinse in PBS followed by a wash in blocking buffer for 10min to remove any 
unbound primary antibody. 
To detect proteins by chemiluminescence, the membranes were subsequently 
incubated with secondary antibodies conjugated to horseradish peroxidase 
(HRP) with the appropriate dilution in blocking buffer for 1-2h at RT. Following 
incubation, the membranes were washed 3 times by quick rinse in PBS followed 
by a wash in blocking buffer for 10min. After this second round of washes the 
membranes were added to enhanced chemiluminescent (ECL) substrate 
(Thermo Scientific) for HRP, followed by exposure to X-ray film and 
development using the KODAK X-OMAT 1000 processor. 
When Odyssey CLx was used as an alternative to chemiluminiscence, HRP 
conjugated secondary antibodies were replaced with the IRDye®680RD goat 
anti-mouse Li-COR secondary antibody diluted 1:10000 in blocking buffer. The 
Odyssey CLx Imaging Suite program was used to image membranes and 
quantify bands. 
2.10.3. Coomassie staining of proteins 
When Coomassie staining of gels was required, gels were left in Coomassie 
buffer (Coomassie Brilliant Blue R [Sigma-Aldrich], 20% glacial acetic acid, 20% 
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methanol) for 30min following electrophoresis. Gels were then washed in de-
staining buffer (20% methanol, 10% glacial acetic acid) for 20min and washes 
repeated until bands were clearly observed. 
2.11. Luminescence luciferase assay 
A luciferase assay was performed with a Luciferase Assay System (Promega) 
according to manufacturer's instructions. Briefly, 100µl of Reporter Lysis Buffer 
(RLB, Promega) was added to each well from a 24-well plate and left to freeze 
at -80°C for 15min. Cells were then thawed and scraped before transferring to a 
clean microcentrifuge tube. They were vortexed for 15s and centrifuged at 
12000g for 15s at RT. Twenty microliters of each supernatant were added to a 
Luminometer tube containing 50µl of Luciferase Assay Reagent (Promega), the 
tube was vortexed briefly, and luminescence was measured in a Sirius Tube 
Luminometer (Berthold Detection Systems). 
2.12. RNA in vitro transcription 
2.12.1. RNA linearization and purification 
RNA was generated in vitro using RiboMAX® Large Scale RNA T7 Production 
Systems (Promega) according to the manufacturer's instructions. For this, the 
DNA template was first linearized with an appropriate restriction endonuclease 
followed by purification using the QIAquick PCR Purification Kit (QIAGEN), 
following manufacturer's instructions. 
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2.12.2. RNA in vitro transcription and purification 
Once purified, the RNA in vitro transcription reaction was set up using the 
following reagents according to manufacturer's instructions (RiboMAX Large 
Scale T7, Promega): 
T7 Transcription 5X Buffer:  20µl 
 rNTPs (25mM each): 30µl 
linear DNA template (5-10µg total): x 
Nuclease-free H2O: y 
Enzyme Mix (T7 RNA pol): 10µl 
Total volume: 100µl 
The reaction was mixed by pipetting and incubated for 4h at 37°C. Following 
incubation, RQ1 RNase-free DNase was added to a concentration of 1U/µg of 
template DNA and the mixture was incubated for 15min at 37°C. RNA was 
then purified by TRIzol extraction. 
2.12.3 32P radiolabelling of RNA 
When 32P radiolabelled RNA was required, an RNA in vitro transcription was 
performed using the MEGAscript® Kit (Ambion). For this, a linearized and 
purified DNA template was obtained, and a reaction set up with the following 
reagents: 
10X Reaction Buffer:  2µl 
ATP solution: 2µl 
CTP solution: 2µl 
GTP solution: 2µl 
UTP solution: 2µl 
(α-32P)UTP 1µl 
linear DNA template (0.1-1µg total): x 
Nuclease-free H2O: y 
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Enzyme Mix: 2µl 
Total volume: 20µl 
The reaction was mixed by pipetting and incubated for 4h at 37°C. Following 
incubation, 1µl TURBO DNase was added and the mixture was incubated for 
15min at 37°C. 
2.13. In vitro immunoprecipitation of 32P DI or DI-PRS RNA 
captured by PP7 on Dynabeads 
This method is described fully in section 4.4 and here is a brief description. 
1microliter of φ2.5.DI and φ.2.5.DI-PRS plasmids were linearized with XbaI. 
Linearized plasmids were used as templates to generate in vitro transcribed 32P 
DI and DI-PRS RNAs according to manufacturer's instructions (MEGAscript 
Kit, Life Technologies): 
10X Reaction Buffer:  2µl 
 rNTPs (75mM each): 8µl 
linear DNA template (5-10µg total): 1µl 
Nuclease-free H2O: 6µl 
(α-32P)UTP 1µl 
Enzyme Mix: 2µl 
Total volume: 20µl 
The reaction was mixed by pipetting and incubated for 4h at 37°C. 
Apart, 1.5mg PP7-Dynabeads were generated (see section 4.4), washed twice 
with 0.2M salt buffer and split in two. Each half of PP7-Dynabeads was 
incubated with each of the in vitro generated 32P DI, or DI-PRS, RNA in the 
presence of RNase inhibitors for 30min at 4°C, washed three times with a high 
salt (1M NaCl) buffer and the amount of 32P captured by the Dynabeads 
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measured. 
2.14. In vitro immunoprecipitation of a PP7-based system using 35S 
radiolabelled proteins from IFN-induced cells 
This method is described in section 4.5 and here is a brief description. A549 cells 
in an 80% confluent 75cm2 flask were treated with 103 U/ml of purified IFNα 
(Roferon, NHS) in 10% DMEM for 16h at 37°C /5% CO2. For metabolic-labelling, 
following incubation medium was replaced with 4ml SF DMEM (no cysteine, 
methionine or glutamate; Sigma-Aldrich), 40µl glutamate 200mM, 80µl FBS 
(Thermo Fisher Scientific) and 7.5µl 35S methionine (10µCi/µl) and left 
incubating for 1h at 37°C /5% CO2. Cells were subjected to a cytoplasmic-nucleic 
fractionation (see section 4.3).  
300µg DI-PRS-containing PP7-Dynabeads were generated as described in 
section 4.4 and incubated by rotation for 1h at 4°C with cytoplasmic extracts of 
A549 cells that had, or had not, been treated with IFN for 16h prior to 
metabolic-labelling with 35S methionine. Dynabeads were then washed 5x with 
Tris Lysis buffer. 
2.15. Mass Spectrometry 
Samples excised from a gel band were placed in a microcentrifuge tube and 
sent to the Mass Spectrometry Facility located within the BMS Building 
(University of St Andrews). The samples were digested with trypsin and the 
resultant peptides were analysed by nLC-ESI MSMS. The resulting data file was 
searched against the human proteins in the NCBI database using the Mascot 
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search algorithm. 
2.16. Immunofluorescence Microscopy 
Cells were seeded in 24-well plates containing circular coverslips (1mm thick). 
When 293T cells were used, poly-L-lysine was added to coverslips prior to 
addition of 293T cells to enhance attachment. Briefly, 0.1% poly-L-lysine was 
added to wells containing coverslips for 1h at RT before washing 3 times with 
sterile H2O. After incubation, cells were fixed in fixation buffer (10% 
formaldehyde in PBS) for 10min. Cells were then permeabilized using 
permeabilization buffer (0.5% Triton X-100, 0.5% IGEPAL, 10% sucrose, 0.1% 
azide in PBS) for 10min. Cells were added to blocking buffer (10% foetal calf 
serum [FCS] in PBS) for 1h at RT to block unspecific binding sites. Following 
blocking, coverslips were incubated with 50µl of the corresponding primary 
antibody with the appropriate dilution in blocking buffer for 1h at RT. After 
incubation, coverslips were washed with blocking buffer to remove unbound 
antibody and then incubated with 50µl of secondary antibody with the 
appropriate dilution and DAPI dye (1/200) in blocking buffer for 1h at RT. 
Coverslips were subsequently washed with blocking buffer, inverted, and 
placed on glass slides containing citifluor (Citifluor Ltd) for proper attachment. 
Fluorescence was observed with a Nikon Microphot-FXA immunofluorescence 
microscope. 
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CHAPTER 3: INDUCTION OF CYTOKINES BY PIV5 DIs 
IN CELLS 
3.1. Introduction 
It is well established that DIs of PIV5 induce IFNβ. Other cytokines previously 
mentioned, i.e. IL-6, IL-8 and TNFα are known to be induced in response to 
viral infection. In this chapter, we aimed to determine whether DIs of PIV5 
could lead to induction of IL-6, IL-8 or TNFα in cells. For this, two different cell-
lines (i.e. A549 cells and primary human skin fibroblasts [HSF]) were infected 
with DI-containing stocks of PIV5. Cells deficient in different steps of the IFN 
response (i.e. A549/V, A549/Npro and HSF-STAT2-/-) were also used to 
determine whether IL-6, IL-8 or TNFα could be induced by DIs in them. A549/V 
cells express the PIV5 V protein that targets STAT1 for degradation and 
therefore blocks IFN signalling (Didcock et al., 1999). A549/Npro cells express 
the bovine viral diarrhoea virus (BVDV) Npro protein that targets IRF3 for 
proteasomal degradation and leaves cells unable to mount IRF3-dependent 
antiviral responses, such as the production of IFNβ or ISG56 (Hilton et al., 
2006). HSF-STAT2-/- cells are deficient in STAT2 (Hambleton et al., 2013). 
Different stocks of viruses containing DI particles were used to infect cells. PIV5 
wt vM0 is a DI-poor stock of viruses. PIV5 wt vM9 is a stock of viruses that has 
been generated after sequentially infecting Vero cells 9 times with PIV5 wt at 
high MOI, thereby generating a DI rich-stock of PIV5. PIV5-VΔC vM2 is a DI-
rich stock of PIV5-VΔC, a virus that does not encode a functional IFN 
antagonist (Killip et al., 2011). 
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Experiments in this chapter were performed in Queen's University Belfast as a 
result of collaboration with Professor Jose Bengoechea. 
3.2. Cytokine expression induced by PIV5 DIs in cells 
To determine the induction of IFNβ, IL-6, IL-8 and TNFα in cells by DI 
genomes, A549, A549/V, A549/Npro, HSF and HSF-STAT2-/- cells were mock 
infected or infected with PIV5 wt vM0, PIV5 wt vM9 or PIV5-VΔC vM2 stocks 
of viruses at a MOI of 10. Infected cells were further incubated for 6h, 14h or 
24h. RNA from infected cells was TRIzol extracted and a qRT-PCR was 
performed for each RNA using primers specific to the IFNβ, IL-6, IL-8 or TNFα 
genes. Results are shown in Fig. 3.1. 
As can be observed in Fig. 3.1, infection with PIV5 wt vM0, a DI-poor stock of 
viruses, led to little, or no, cytokine induction in the cell-lines tested. When 
A549 cells were infected with PIV5 wt vM9, induction of IFNβ could be first 
observed at 14h after infection and this level increased at 24h, strongly 
suggesting that DIs had been detected and the cells were responding by 
inducing IFNβ. This was also the case for A549/V cells infected with PIV5 wt 
vM9. Interestingly, the levels of IFNβ at 14h and 24h in A549/V cells were 
higher than those found in A549 cells. As it was expected, no induction of IFNβ 
was observed when A549/Npro cells were infected with PIV5 wt vM9, as 
induction of IFNβ is dependent on IRF3. Induction of the cytokine could also be 
seen in HSF and HSF-STAT2-/- cells infected with PIV5 wt vM9. In both cell-
lines, induction of IFNβ was first observed at 14h post-infection and this level 
decreased at 24h. Higher level of IFNβ induction was observed in HSF-STAT2-/- 
cells than in HSFs. 
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Cells infected with PIV5-VΔC vM2 showed the highest levels of induction of 
IFNβ, with levels peaking as early as 6h post-infection in A549 and A549/V 
cells. Interestingly, and similar to what occurred in cells infected with PIV5 wt 
vM9, induction of IFNβ was significantly higher in A549/V cells than in A549 
cells. The induction of IFN seen in HSFs at 6h post-infection was also lower 
than the induction observed in HSF-STAT2-/- cells at the same time. This, 
together with the data observed for cells infected with PIV5 wt vM9, indicates 
that induction of IFNβ by DI-containing stocks of viruses (i.e. PIV5 wt vM9 and 
PIV5-VΔC vM2) was higher in cells deficient in the IFN signalling pathway than 
in cells that can respond to IFN. A possible explanation could be that the lack of 
an IFN response could affect viral genome replication thus facilitating DI 
replication and greater stimulation of the IFN response. 
Induction of IL-6 in A549 and A549/V cells was observed at 6h post-infection 
when cells were infected with either PIV5 wt vM9 or PIV5-VΔC vM2 but, in 
contrast to what was observed for IFNβ, the level of IL-6 induction gradually 
increased throughout the time of infection. Interestingly, induction of IL-6 
could be seen in A549/Npro cells when they were infected with PIV5-VΔC vM2 
(although this level was considerably much lower than that seen for either A549 
or A549/V cells), suggesting that possibly not all of the induction of IL-6 is IRF3-
dependent. IL-6 was induced in HSF cells and also in HSF-STAT2-/- cells after 
they were infected with either DI-containing virus stocks. Induction of the 
cytokine when HSF and HSF-STAT2-/- cells were infected with PIV5 wt vM9 
was observed at 14h and 24h post-infection, whilst the level of induction of IL-6 
when HSF and HSF-STAT2-/- cells were infected with PIV5-VΔC vM2 was 
relatively constant at all the times of infection tested. The levels of induction of 
IL-6 were higher in HSF-STAT2-/- cells than in HSFs when the cell-lines were 
infected with any DI-containing virus stock. 
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High levels of IL-8 were induced as early as 6h post-infection in A549 and 
A549/V cells infected with PIV5-VΔC vM2, and this level decreased to a great 
extent at 14h and 24h. Strikingly, in contrast to IFNβ and IL-6, highest levels of 
IL-8 induction were observed at 6h post-infection in A549/Npro cells (although 
this level also decreased at 14h and 24h), suggesting that the promoter of the IL-
8 gene was not dependent upon IRF3. Surprisingly, infection of HSFs with a 
PIV5-VΔC vM2 did not lead to an obvious induction of IL-8, although IL-8 was 
induced in HSF-STAT2-/- cells. No induction of IL-8 was observed at 6h post-
infection when HSF-STAT2-/- cells were infected with PIV5 wt vM9, but 
induction of the cytokine could be seen at 14h of infection. 
Infection of A549 and A549/V cells with PIV5-VΔC vM2 led to induction of 
TNFα at 6h post-infection. The level of the cytokine decreased at 14h, and 
increased slightly at 24h in both cell-lines. Poor induction of TNFα was seen in 
A549/Npro cells when they were infected with PIV5-VΔC vM2, suggesting that 
induction of TNFα was dependent on IRF3. For HSF and HSF-STAT2-/- cells, the 
peak of induction was at 6h post-infection and it decreased at later times. 
Interestingly, the maximum cytokine expression when HSFs were infected with 
PIV5 wt vM9 was at 6h post-infection, whilst the peak of expression in HSF-
STAT2-/- cells was at 14h. 
 
 
 
 
Chapter 3: 
Induction of cytokines by DIs in cells 
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1. Cytokine expression in cells induced by PIV5 DIs. A549, A549/V, A549/Npro, HSF 
and HSF-STAT2-/- cells were infected with PIV5 wt vM0 (DI-poor), PIV5 wt vM9 (DI-containing) 
or PIV5-VΔC vM2 (DI-containing) stocks of viruses. At 6, 14 and 24h post-infection, RNA was 
TRIzol extracted and qTR-PCR performed using primers specific for the IFNβ, IL6, IL8, TNFα 
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and GAPDH genes. Data for each cytokine is expressed as the fold expression level relative to 
GAPDH. Results are the mean of 2 independent experiments. 
Results in Fig. 3.1 show that, upon cellular detection of DIs, cells respond by 
activating multiple signalling pathways, including RIG-I/Mda5, and this ends 
with the production of a range of molecules with antiviral and/or pro-
inflammatory properties e.g. IFNβ, IL-6, IL-8 and TNFα. To get a better 
understanding of the events occurring upon cellular detection of viral genome, 
we wanted to further investigate the RNA:protein complexes formed within 
cells in which the IFN-induction cascade has been activated by PIV5 DIs, and 
this is discussed in Chapter 4. 
3.3. Discussion 
The blunt-ended dsRNA structure of copyback DI genomes make them easily 
recognizable by cytosolic receptors RIG-I/Mda5. Thus, DI genomes are very 
efficient at inducing the IFN response. In this series of experiments, we were 
interested in determining whether DIs induced other cytokines that play a role 
in the host antiviral response. We observed that IL-6, IL-8 and TNFα are 
induced, together with IFNβ, within cells when DI particles are recognized. 
These are preliminary results and further investigations are required to 
establish a more complete spectrum of cytokines that are induced by DIs. 
However, results presented here suggest that DIs activate different cellular 
signalling pathways, discussed below, that end with the activation of NFκB, 
IRF3 and other transcription factors that culminate with the activation of 
distinct cytokines with antiviral effects that may act in combination to establish 
an effective antiviral response. 
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3.3.1. Distinct induction profiles for IFNβ , IL-6, IL-8 and TNFα  in 
cells infected with DIs 
Infection with DI-containing virus stocks (PIV5 wt vM9 and PIV5-VΔC vM2) 
resulted in induction of IFNβ, IL-6, IL-8 and TNFα, and was dependent on the 
cell-line infected. In general, for the cytokines tested, induction was higher in 
cells infected with PIV5-VΔC vM2 than in those infected with PIV5 wt vM9, and 
occurred at earlier times. This can be explained by the fact that PIV5-VΔC vM2 
encodes a non-functional V protein that is unable to counteract the host 
immune response. This could lead to the generation of high cytokine levels 
from the beginning of infection. In contrast, PIV5 wt vM9 has a functional V 
protein that could help to limit cytokine induction, at least at the first stages of 
infection. In a previous work, Killip and colleagues observed very low IFN 
induction in cells infected with PIV5-VΔC vM0, a DI-poor stock of PIV5-VΔC, 
whereas they observed high IFN induction following infection with PIV5-VΔC 
vM2. Therefore, they suggested that PAMPs may not be produced during the 
replication of normal, ND, viral genomes regardless of the ability of the viruses 
to counteract the IFN response, and it is the presence of DI genomes that 
triggers activation of IFN (Killip et al., 2011). This is in accordance with our 
results, in which infection with a DI-poor stock of PIV5 did not lead to an 
obvious induction of IFNβ, IL-6, IL-8 or TNFα in any of the cell-lines tested. DI 
genomes activate important transcription factors for the host immune response, 
and some transcription factors, such as NFκB, are present in the promoters of 
genes that encode for many proteins with antiviral roles, such as IL-6, IL-8 and 
TNFα. This could explain that these cytokines were not induced upon infection 
of cells with a DI-poor stock of viruses. 
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Infection with PIV5-VΔC vM2 led to the induction of IFNβ, IL-6, IL-8 and TNFα 
in most cell-lines tested, although the level of induction differed considerably 
between cell-lines. Induction of cytokines indicated that DIs were being 
recognized by cellular receptors, and cells were responding by generating 
antiviral cytokines. In most cases, induction of the cytokines was higher in cells 
deficient in the IFN signalling pathway (i.e. A549/V and HSF-STAT2-/-). 
Although the reasons for this are unclear, as has already been suggested, it 
could be that lack of IFN signalling enhanced DI replication (as no antiviral 
state would be induced by the IFN produced) leading to greater stimulation of 
the antiviral response. Interestingly, in general the level of induction of the 
cytokines in HSF-STAT2-/- cells with respect to HSFs was higher than the level 
of induction in A549/V cells with respect to A549s. This could be explained 
because in the IFN signalling pathway, the complex formed by STAT1, STAT2 
and IRF9 acts as a transcriptional factor to upregulate the production of 
proteins with antiviral effect. Nevertheless, STAT2:IRF9 complexes have been 
observed that act in a STAT1-independent manner that also upregulate antiviral 
proteins (Au-Yeung et al., 2013; Blaszczyk et al., 2016). This could explain, at 
least in part, that the immune response was less impeded in A549/V cells than 
in HSF-STAT2-/- cells, that led to a reduction in viral replication and, 
subsequently, cytokine activation. 
Induction of IFNβ was not observed in A549/Npro cells, that lack IRF3, 
following infection with PIV5-VΔC vM2. This is because the IFNβ promoter is 
highly dependent on IRF3 activation (Honda et al., 2005). IL-6 was weakly 
induced in A549/Npro cells infected with PIV5-VΔC vM2. An explanation could 
be that the IL-6 gene is regulated by the coordination of different transcription 
factors, such as AP1, C/EBP and NFκB (Xiao et al., 2004a; Xiao et al., 2004b). 
Nevertheless, contribution of IRF3 to IL-6 upregulation has been suggested to 
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be important but not essential (Cheng et al., 2006), leaving the possibility that 
some induction of the cytokine is independent of IRF3. 
The levels of IL-8 in A549/Npro cells were higher than those in A549 or A549/V 
cells following infection with PIV5-VΔC vM2, strongly suggesting that the IL-8 
promoter is IRF3-independent. Also, infection of A549/Npro cells with PIV5-
VΔC vM2 did not induce TNFα. Induction of TNFα involves the coordination 
of different proteins such as NFκB, C/EBP and c-Jun (Barthel et al., 2003; Liu et 
al., 2000; Tsai et al., 1996), and IRF3 plays an essential role in the induction of 
TNFα (Wang et al., 2008). The IL-8 promoter is composed of binding sites for 
several transcription factors, including AP1, CBP/p300 and NFκB (Jundi and 
Greene, 2015; Mukaida et al., 1990), but lacks specific binding sites for members 
of the IRF family, thus explaining its regulation even in the absence of IRF3. 
Additionally, it has been observed that expression of IFNβ could adversely 
affect IL-8 expression in certain cells (Nyhlen et al., 2000). This could explain 
that the levels of IL-8 were higher in A549/Npro cells than in A549 cells, where 
induction of IFNβ is not inhibited. 
3.3.2. Induction of cytokines in vivo by DIs 
Generation of DIs in vitro has long been established and were considered by 
some investigators as artifacts of viral replication in vitro. Not much attention to 
the generation of DIs in vivo was paid until fairly recently, when some studies 
demonstrated that DIs are naturally generated during in vivo infections. DI 
viruses have been detected in sera from patients infected with distinct viruses 
including hepatitis B virus, influenza virus and dengue virus (Dimmock and 
Easton, 2014). RSV DIs have been detected in respiratory secretions of 
hospitalized patients (Sun et al., 2015). They have also been detected in 
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nasopharyngeal swabs from patients infected with influenza virus, what raises 
the question whether DIs are generated following infection or they can 
effectively be transmitted from person to person (Saira et al., 2013). 
The biological significance for the generation of DIs in vivo is not fully 
understood, although it is clear that DIs play a critical role in the virus:host 
interactions during natural infections (Sun and Lopez, 2017). Given that DIs are 
such powerful activators of cytokines, if generated in vivo not only may they be 
the primary inducers of protective cytokines, but if produced in large amounts, 
they could also act as agents of 'cytokine storms'. A consequence of 'cytokine 
storms' may result in damage or death of the host. On the other hand, as DIs 
also interfere with the transcription and replication of ND viruses, it has been 
suggested that they may directly limit virus spread, disease severity and 
influence the establishment of persistent infections. Examples of how infection 
with DIs in animals induce a protective response resulting in a diminished 
infection are diverse. For example, Lopez and colleagues observed that 
infection of mice with SeV strains with low propensity to generate DIs persisted 
longer in the lungs than the infection caused by strains prone to generate DIs 
(Lopez et al., 2006). They suggested that this is probably because RSV strains 
with high propensity to produce DIs induce greater amounts of type I and III 
IFN, and also other cytokines such as IL-6, than RSV strains that do not readily 
produce DIs (Sun et al., 2015; Tapia et al., 2013). Other studies performed with 
influenza virus DIs have also shown protective immunity against infection. For 
example, inoculation of mice with a solution composed of a limited amount of 
influenza DI particles previous to infection with influenza virus resulted in 
delayed clinical symptoms, and a considerable reduction in mortality (Morgan 
et al., 1993). Inoculation of ferrets, being the best animal models to study human 
influenza infections, with a protective dose of DIs previous to infection with 
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influenza virus, resulted in an almost complete supression of clinical disease 
and a solid protective immunity against re-infection (Dimmock and Easton, 
2014; Mann et al., 2006). 
Further investigation is required concerning PIV5 DIs, as some questions still 
need to be addressed. Preliminary studies in mice showed the generation of 
high levels of IFNβ in the spleen and liver following intravenous infection with 
PIV5-VΔC vM2 (professor R.E. Randall personal communication), but which 
other cytokines are induced by PIV5 DIs in animal models still need to be 
elucidated. This and other concerns, such as whether infection with a DI-rich 
stock of virus would diminish clinical symptoms in animals or, on the contrary, 
would enhance them, are important to address in terms of a potential 
therapeutical use of PIV5 DIs. 
3.3.3. Therapeutic use of DIs 
As DIs are unable to replicate by themselves, if they were purified from 
infectious virus, they could be used safely for a number of purposes in vivo. A 
controlled generation and functions of DIs in vivo would provide valuable 
advances in their use as therapeutical agents (Sun et al., 2015), such as the 
control in the spread of drug-resistant strains (Tanner et al., 2016). Indeed, the 
use of DIs as potential vaccine adjuvants is currently being investigated and it 
has already been shown that addition of DI particles to live virus vaccines 
enhances their immunogenic potential (Yount et al., 2006). Furthermore, as DIs 
retain virus antigens they could also be potentially used to induce adaptive 
immune responses, e.g. as has been proposed for influenza viruses (Dimmock 
and Easton, 2015; Scott et al., 2011). 
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The use of DI particles as potential detectors of chronic infection is currently 
under investigation. Elimination of acute infection with MeV, Ebola virus and 
other viruses often results in the establishment of persistent infections in which 
the amount of DI particles is gradually increased. Therefore, DI particles could 
be used as signs to predict persistent infection and the subsequent risk of a 
relapse (Calain et al., 2016). A possible concern here is the possibility that 
persistent infection in humans could potentially enable those with mild disease 
to widely disseminate the virus (Li et al., 2011). 
Anti-cancer treatment could benefit from DIs in a near future. Studies on SeV 
DIs have shown that strains that are high in DI particles are more efficient in 
activating pro-apoptotic genes in human prostate cells than strains that are low 
in DI particles (Liu et al., 2016). SeV DIs have also been shown to be very 
effective at activating IL-6, IFNβ and TNFα in mouse dendritic cells from a 
colon carcinoma, and they efficiently upregulated antitumour immunity 
induced by T cells (Shi et al., 2014). These and other studies are founding the 
basis for a future therapeutical treatment of cancer based on nucleic acids. 
Active research is being done on the use of DIs in the treatment of distinct 
diseases. There still remain some questions such as how long would protection 
last, or whether DI sequences can be manipulated in order to enhance their 
immunogenicity. In this respect, efforts need to be addressed in understanding 
the characteristics that make some DI sequences better than others (Marriott 
and Dimmock, 2010). In the near future, we could witness the development of 
DI RNAs as the basis for a novel type of potential therapeutical treatments that 
can target a broad range of human and animal diseases. 
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CHAPTER 4: GENERATION OF A PP7-BASED SYSTEM 
TO CAPTURE IFN-INDUCED PROTEINS THAT BIND 
VIRAL dsRNA 
4.1. Introduction 
This chapter is concerned with attempts to develop a simple purification 
protocol for the study of proteins that are part of RNA:protein complexes. The 
aim was to identify RNA:protein complexes formed when RIG-I/Mda5 are 
activated by paramyxovirus DIs during the induction of IFN. The protocol 
involved the generation of a PP7-based system within cells as is illustrated in 
Fig. 4.1. Taking advantage of the specific interaction of PP7 and its recognition 
sequence PRS, (1) a copyback DI genome that expresses the PRS sequence in the 
loop would be introduced in cells that (2) express the V5 epitope-tagged PP7 
protein. (3) The PRS sequence in the loop component of the copyback DI 
genome would be recognized by PP7-V5 with high affinity, (4) and the stem 
component of the copyback DI genome would be recognized by RIG-I/Mda5 
and any other proteins involved in recognition of the copyback DI genome. (5) 
The complex thus formed would be immunoprecipitated and its components 
identified by mass spectrometry. 
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Fig. 4.1. Isolation of RNA:protein complexes within cells using a PP7-based system. (1) A 
copyback DI-PRS genome would be introduced in (2) a PP7-V5-expressing cell. (3) PP7 would 
recognize the PRS sequence expressed in the loop of the DI-PRS genome structure with high 
affinity. In turn, PP7-V5 would be detected through anti-V5 Ab binding. (4) RIG-I/Mda5 and 
any other proteins involved in recognition would bind to the stem of the DI-PRS genome. (5) 
The complex would be immunoprecipitated and its components studied by mass 
spectrometry. 
To identify proteins that interact with DI-PRS it was first necessary to establish 
that PP7 could be used to immunoprecipitate DI-PRS RNA:protein complexes. 
Initially the ability of PP7 to specifically capture DI-PRS RNA was tested in 
vitro. Subsequently, attempts were made to further develop the protocol to 
isolate DI-PRS:protein complexes from cells. 
To implement the PP7-based capture of DI-PRS:protein complexes in vitro, the 
following steps were undertaken: 
Step A. Cloning PRS into the DI genome structure to generate DI-PRS genomes 
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Step B. Generating cell-lines expressing V5-tagged PP7 
Step C. Capturing DI-PRS onto PP7-V5-containing Dynabeads 
Step D. Isolating DI-PRS:protein complexes 
4.2. Step A. Cloning PRS into the DI genome structure to generate 
DI-PRS genomes 
The proposed purification method requires PRS to be inserted into copyback DI 
RNA to facilitate its capture using PP7. Previous to this project, a plasmid 
(φ2.5.DI plasmid) was generated that expresses the cloned copyback DI RNA 
sequence from the most prominent DI(TrCB) species found in a PIV5-VΔC vM2 
preparation (Killip et al., 2013). The sequence of this plasmid is given in 
Appendix 1, and its structure is depicted in Fig. 4.2. The φ2.5 promoter, used to 
drive the expression of the DI RNA, is a variant of the T7 promoter. T7 
promoters are recognized by the T7 polymerase (T7pol). A requisite of the 
standard T7 promoter is that the sequence starts with a guanine. However, to 
begin replication or transcription, PIV5 RdRp first recognizes an adenine at the 
3’ end of the viral genome. PIV5 genomes therefore start with an adenine, as do 
PIV5 DI genomes. As the φ2.5 promoter uses an adenine to begin transcription 
(Huang et al., 2008), it was selected to generate the plasmid instead of the 
standard T7 promoter. The sequence of the DI(TrCB) contains two 
complementary regions of 223 nt each that form the stem component of the DI 
genome. It also contains a loop component of 982 nt. The DI sequence is 
followed by a hepatitis D virus (HDV) ribozyme sequence that cleaves at the 
end of the DI sequence. This allows the generation of a DI genome structure 
with a double-stranded stem component that is blunt-ended. The ribozyme 
sequence is followed by a T7 termination sequence that stops T7pol 
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transcription. 
 
 
 
 
 
Fig. 4.2. Structure of the φ2.5.DI plasmid. The DI(TrCB) sequence is under the control of the 
φ2.5 promoter. The DI(TrCB) sequence contains two complementary stem strands and one loop. 
A HDV ribozyme sequence generates a ribozyme that cuts the DI genome after the last nt (a 
thymine) in the second stem so that the sequence generates a stem-loop structure that is blunt-
ended. The ribozyme sequence is followed by a T7 termination sequence that stops T7pol 
transcription. 
The φ2.5.DI plasmid was used as a template to generate a plasmid (φ2.5.DI-PRS 
plasmid) that encodes a DI(TrCB) genome that contains the PRS sequence in the 
loop. The procedure is illustrated in Fig. 4.3. First, the φ2.5.DI plasmid was cut 
with PstI to generate a linear vector flanked by PstI sites at both ends. The 
φ2.5.DI plasmid was also used as a template to generate an insert using primers 
complementary to regions next to the PstI sites in the φ2.5.DI plasmid. These 
primers contained the PRS sequence and PstI sites in such a way that the insert 
contained the PRS sequence so that it would be expressed in the loop 
component of the DI RNA. The uncut φ2.5.DI plasmid, or cut with PstI, and the 
PCR generated insert, were electrophoresed through an agarose gel to 
determine whether vector and insert were successfully generated (Fig. 4.3). The 
correctly cut vector and insert were ligated and a number of plasmids rescued 
were sent for sequencing. As the insert may have been ligated in either 
orientation, a plasmid that contained the insert in the orientation to generate a 
DI-PRS RNA was selected for further experiments, and it was called φ2.5.DI-
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PRS plasmid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3. Generation of the φ2.5.DI-PRS plasmid that expresses PRS in the loop of a DI RNA. 
The φ2.5.DI plasmid was cut with PstI to generate a linear vector with PstI sites at both ends. 
The φ2.5.DI plasmid was also used as a template to generate an insert using primers 
complementary to regions adjacent to the PstI sites in the φ2.5.DI plasmid. These primers 
contained the PRS sequence and PstI sites in such a way that the insert generated  contained the 
PRS sequence expressed in the loop of the DI RNA. The uncut φ2.5.DI plasmid, or cut with PstI, 
and the insert were electrophoresed through an agarose gel to determine whether vector and 
insert had successfully been generated. The correctly cut vector and insert were then ligated 
and putative clones were sent for sequencing. A plasmid that contained the insert in the 
orientation to generate a DI-PRS RNA was selected and termed φ2.5.DI-PRS plasmid. 
The sequence of the φ2.5.DI-PRS plasmid is in Appendix 2. The predicted 
structure of the DI-PRS, and also the DI RNA, were generated with CLC Main 
Workbench (QIAGEN) and can be seen in Fig. 4.4: 
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Fig. 4.4. Structure of the DI(TrCB) and the PRS-containing DI(TrCB) RNAs. A. Predicted 
stem-loop structure for the most abundant DI RNA found in a DI-rich preparation of PIV5-
VΔC vM2. B. Predicted stem-loop structure for the most abundant DI RNA found in a DI-rich 
preparation of PIV5-VΔC vM2 with an additional PRS RNA sequence (in red circle) that is 
bound by PP7 protein. Predicted structures were generated with CLC Main Workbench 
(QIAGEN). 
4.3. Step B. Generating cell-lines expressing V5-tagged PP7 
A source of PP7 was also required to isolate DI-PRS RNA:protein complexes 
using the PP7-based system. As the long term aim of the project required the 
capture of RNA:protein complexes from cells, it was decided to generate 
mammalian cell-lines that express PP7 rather than use bacterial expression 
systems as a source of PP7. Also, to purify PP7, and hence the molecules that 
form part of the complexes, PP7 also needed to be tagged. A common 
procedure to purify proteins is to tag them with a peptide motif that consists of 
six histidine (His) residues. However, a problem of this procedure is the non-
specific binding of untagged proteins. Some cellular proteins can contain two or 
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more adjacent His residues and therefore may co-elute with the recombinant 
protein, resulting in the contamination of the final product (Bornhorst and 
Falke, 2010). To reduce the amount of non-specific binding, it was decided to 
capture PP7 with an Ab bound to beads. However, due to the lack of an Ab 
against PP7, the protein first needed to be epitope tagged. The V5 epitope tag is 
derived from a small epitope (Pk) present on the P and V proteins of PIV5, and 
represents 14 amino acids (GKPIPNPLLGLDST) (Southern et al., 1991). 
Monoclonal antibodies against V5 bind the epitope with high affinity and 
specificity. Previous to this project, a lentiviral transfer vector, termed pdl’PP7-
V5.puro, was generated that encodes PP7 protein V5-epitope tagged at its C-
terminus. The lentiviral vector also encodes the puromycin resistance gene 
(PAC) to permit selection of transduced cells. 
PP7-V5 was expressed in 293T and A549 cells. 293T cells have high transfection 
efficiency and, for this reason, have been widely used in research on viral and 
cellular functions. However, they are modified cells and their use as 'normal' 
cells in research is still debatable (Stepanenko and Dmitrenko, 2015). 
Nevertheless, although the TLR-dependent IFN response is not completely 
functional in 293T cells, the RLR-dependent IFN response is functional 
(Reynolds et al., 2006). Also, 293T cells are difficult to manipulate in some 
techniques such as immunofluorescence. A549 cells are human alveolar basal 
epithelial adenocarcinoma cells. They have lower transfection efficiency than 
293Ts but they are less 'abnormal' than 293T cells and are therefore extensively 
used to study the IFN response to virus infections. 
To generate cell-lines stably expressing PP7-V5, 293T and A549 cells were 
transduced with pdl’PP7-V5.puro. Lentiviral vectors are randomly inserted into 
the cell genome, leading to variable levels of expression dependent upon the 
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site of integration. However, multiple insertions of a lentivirus can occur in the 
same cell. To determine whether multiple insertions of the lentiviral vector in 
the cell genome leads to higher PP7-V5 expression, cells were either transduced 
1 or 8 times and the relative levels of expression estimated by Western Blot 
analysis (Fig. 4.5). It can be observed that, for 293T cells, multiple transductions 
(293T.PP7-V5.puro.8x) led to similar levels of PP7-V5 protein expression as in 
cells transduced only once (293T.PP7-V5.puro.1x). In contrast, multiple 
transductions in A549 cells (A549.PP7-V5.puro.8x) led to higher levels of PP7-
V5 protein expression than in cells transduced only once (A549.PP7-
V5.puro.1x). Also, as might be expected, both 293T and A549 cells transduced 8 
times with pdl’PP7-V5.puro were resistant to higher levels of puromycin 
compared to those transduced only once (Fig. 4.5). 
 
 
 
 
 
 
 
 
 
Fig. 4.5. Detecting PP7-V5 expression in 293T and A549 cells transduced with pdl'PP7-
V5.puro by Western Blot analysis. 293T and A549 cells were transduced 1 or 8 times with 
pdl'PP7-V5.puro and the relative levels of PP7-V5 expression were estimated by Western Blot 
analysis using anti-V5 Ab. As a negative control, cells were mock transduced. As a positive 
control, cells were infected with PIV5 W3 wt, as anti-V5 Ab binds to the viral V protein. 
Additionally, a puromycin resistance assay was performed for each cell-line generated to 
determine the highest concentration of antibiotic at which no cell death was observed. 
To determine whether multiple insertions of pdl'PP7-V5.puro in the cell 
genome led to a quantitatively higher PP7-V5 expression, a ratio of the level of 
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PP7-V5 expressed in cells 1 time vs. 8 times transduced was roughly calculated 
using Odissey CLx Imaging System (data not shown). 293T cells transduced 8 
times with pdl’PP7-V5.puro expressed approximately five times higher levels of 
PP7-V5 than cells transduced only once. In contrast, A549 cells transduced 8 
times with pdl’PP7-V5.puro only showed two times higher PP7-V5 expression 
than cells transduced only once. Although multiple insertions of pdl'PP7-
V5.puro in the cell genome led to a higher PP7-V5 expression, this data is 
contradictory to the data presented in Fig. 4.5 and more investigation should be 
undertaken. 
Expression of PP7-V5 in the newly generated cell-lines was also tested by 
immunofluorescence (Fig. 4.6). Higher fluorescence intensity was observed in 
cells 8 times transduced compared to those transduced only once, also 
indicating higher protein expression. The immunofluorescence also showed 
that PP7-V5 is primarily, if not exclusively, expressed in the cell cytoplasm. 
 
 
 
 
 
 
 
Chapter 4: 
Generation of a PP7-based system to capture IFN-induced proteins that bind viral dsRNA 
 113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6. Detecting PP7-V5 expression in 293T and A549 cells transduced with pdl'PP7-
V5.puro by immunofluorescence. Expression of PP7-V5 in 293T and A549 cells transduced 1 
or 8 times with pdl'PP7-V5.puro was determined by immunofluorescence using anti-V5 Ab. As 
a negative control, cells were mock transduced. As a positive control, cells were infected with 
PIV5 W3 wt. 
4.3.1. Obtaining a cytoplasmic fraction of PP7-V5-expressing cells 
Fig. 4.6 showed that PP7-V5 is primarily located in the cytoplasm of PP7-V5-
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expressing 293T and A549 cells. Therefore, cytoplasmic fractions of PP7-V5-
expressing cells would potentially provide the same levels of PP7-V5 as total 
cell lysates. It was therefore decided to use cytoplasmic extracts as a source of 
PP7-V5 as this would improve the processing of dynabeads, as total cell lysates 
tend to be viscous due to the presence of DNA, and potentially reduce 
background binding nuclear proteins to dynabeads. 
To obtain a cytoplasmic fraction of PP7-V5-expressing cells a cytoplasmic-
nucleic fractionation was performed on 293T.PP7-V5.puro.8x cells. Cells in a 
confluent monolayer in a 75cm2 flask were trypsinized and resuspended in PBS 
and pelleted by centrifugation at 2000rpm for 10min at 4°C. The cell-pellet was 
resuspended in 400µl ice-cold buffer containing 0.15M NaCl, 0.05M Tris-HCl 
pH 7.5, 0.5% Igepal-CA-630 (Sigma) and complete EDTA-free protease inhibitor 
cocktail (Roche) and incubated on ice for 5min, vortexed for 30s and the nuclei 
pelleted by centrifugation at 4700rpm for 5min at 4°C. The supernatant was 
collected and re-centrifuged at 4700rpm for 5min at 4°C. The efficiency of the 
cytoplasm-nucleus separation was then monitored by Western Blot. Fig. 4.7 
shows that, after the fractionation of the cell lysate, the nuclear fraction 
contained most of the coilin, a protein that is expressed in the nucleus and is 
one of the main components of the Cajal bodies, and the cytoplasmic fraction 
contained most of the β-actin. The fractionation was not 100% efficient as low 
levels of coilin could still be observed in the cytoplasmic fraction. 
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Fig. 4.7. Testing the efficiency of cytoplasmic-nucleic fractionation from a cell 
lysate of PP7-expressing cells by Western Blot. A confluent monolayer of 293T-
PP7-V5.puro.8x cells in a 75cm2 flask was trypsinized for 20s and resuspended in 
PBS. Cells were pelleted by centrifugation at 2000rpm for 10min at 4°C. The cell-
pellet was resuspended in 400µl ice-cold buffer containing 0.15M NaCl, 0.05M 
Tris-HCl pH 7.5, 0.5% Igepal-CA-630 (Sigma) and complete EDTA-free protease 
inhibitor cocktail (Roche) prior to incubation on ice for 5min. Following 
incubation cells were vortexed for 30s and the nuclei pelleted by centrifugation at 
4700rpm for 5min at 4°C. The supernatant was collected and re-centrifuged at 
4700rpm for 5min at 4°C. Cell lysate before fractionation, cytoplasmic, and nuclear 
fractions were analyzed by Western Blot using anti β-actin (cytoplasmic fraction) 
and coilin (nuclear fraction) Abs. 
4.4. Step C. Capturing DI-PRS onto PP7-V5-containing Dynabeads 
4.4.1. Binding anti-V5 Ab to Dynabeads 
The immunoprecitipation of DI-PRS RNA:protein complexes requires the use of 
beads as a solid substrate to bind anti-V5 antibody that would subsequently be 
used to capture PP7 bound to DI-PRS RNA. Therefore, first an appropriate solid 
substrate was selected. Dynabeads (Invitrogen) are magnetic beads that have 
protein G attached that bind IgG with high affinity and were considered a 
better option compared to agarose beads, as centrifugation is not an absolute 
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requirement when using Dynabeads thus minimizing the likelihood of losing 
RNA:protein complexes. In addition, Dynabeads have reduced non-specific 
protein binding compared to agarose beads, and they are easier to handle with 
small volumes. 
To determine the amount of anti-V5 Ab necessary to saturate Dynabeads, 
aliquots containing equal amounts of Dynabeads (300µg) were incubated with 
different amounts of Ab. The theoretical binding capacity of Dynabeads is 8µg 
human IgG/mg Dynabeads. Therefore, 300µg Dynabeads would theoretically 
bind 2.4µg Ab. Aliquots of Dynabeads were incubated by rotation with 2.4µg, 
4.8µg, 24µg or 48µg Ab for 10min at 22°C, washed and the amount of Ab bound 
estimated by PAGE. As observed in Fig. 4.8, the intensity of the Coomassie 
stained bands corresponding to the heavy and light chains of the Ab captured 
by Dynabeads was similar in all cases. There may have been a slight increase in 
the amount of Ab bound when the Dynabeads were incubated with 4.8µg Ab 
compared to 2.4µg Ab but not with higher concentrations of Ab. 
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Fig. 4.8. Saturation of Dynabeads with anti-V5 Ab. Aliquots containing equal 
amounts of Dynabeads (300µg) were incubated with different amounts of anti-
V5 Ab: 2.4µg, 4.8µg, 12µg or 24µg Ab by rotation for 10min at 22°C. Dynabeads 
were then washed and the amount of Ab bound was estimated by PAGE. The 
figure represents the Coomassie stained gel. 
Saturation of anti-V5 Ab-containing Dynabeads with PP7-V5 was further 
investigated. Saturation of 300µg Dynabeads, which were saturated with anti-
V5 Ab, was achieved by incubating them with 36µl cytoplasmic extract of 
293T.PP7-V5.puro.8x cells by rotation for 10min at 22°C (data not shown, also 
see later). Therefore, in further experiments, Dynabeads, saturated with anti-V5 
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Ab, were saturated with PP7-V5 by incubating the equivalent of 300µg 
Dynabeads with 36µl cytoplasmic extract of 293T.PP7-V5.puro.8x cells and were 
termed PP7-Dynabeads. 
4.4.2. Testing the specificity of the DI-PRS:PP7 interactions 
A critical step for the successful purification and isolation of RNA:protein 
complexes is the specific binding of PP7 with the PRS sequence expressed in the 
copyback DI genome. This interaction depends on the affinity of PP7 for the 
particular stem-loop structure of PRS (Lim and Peabody, 2002). 
The experiment in this section was performed with the kind help of Dr. Bernie 
Precious, who was licensed to manipulate 32P radiolabelled materials. 
To test the specificity of the interaction between PP7 and PRS, 1µg 32P labelled 
DI and DI-PRS RNAs were generated by in vitro transcription. The relative 
amounts of the RNAs generated were estimated by measuring the amount of 
32P incorporated into the DI and DI-PRS RNAs generated. Also, RIPA buffer 
(50mM Tris-HCl pH 7.5, 1mM EDTA, 150mM NaCl, 1% Igepal CA-630 [Sigma], 
0.5% sodium deoxycholate [DOC], 0.05% sodium dodecyl sulphate [SDS], 
complete EDTA-free protease inhibitor cocktail [Roche]) was used to generate a 
cytoplasmic extract of 293T.PP7-V5.8x cells. 1.5mg PP7-Dynabeads were 
generated as described above, washed twice with 0.2M salt buffer and split in 
two. Each half of PP7-Dynabeads was incubated with each of the in vitro 
generated 32P DI, or DI-PRS, RNA in the presence of RNase inhibitors for 30min 
at 4°C, washed three times with a high salt (1M NaCl) buffer and the amount of 
32P captured by the Dynabeads measured. A schematic diagram of the 
procedure is shown in Fig. 4.9.A. As can be observed in Fig. 4.9.B, four times 
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more radioactivity was found in the PP7-Dynabeads incubated with DI-PRS 
RNA compared to those incubated with DI RNA, strongly suggesting that PP7 
specifically bound the PRS sequence contained in DI RNA. The DI-PRS RNA 
captured was 4.7% of the total DI-PRS RNA incubated with PP7-Dynabeads, 
whilst this proportion was only 1% for DI RNA (Fig. 4.9.B), supporting the fact 
that PP7 specifically bound DI-PRS. However, as 32P was detected in the PP7-
Dynabeads incubated with DI RNA that did not contain the PRS sequence, 
some non-specific binding of RNA to the complex must have occurred. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.9. PP7 specifically bound to the PRS sequence contained in a DI RNA. A) 1µg 32P 
radiolabelled DI, or DI-PRS, RNA was generated by in vitro transcription, dissolved in 250µl 
DEPC H2O and the relative amounts of the RNAs generated were estimated by measuring the 
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amount of 32P incorporated. In addition, 1.5mg PP7-Dynabeads were washed twice with 0.2M 
salt buffer and split in two. Each half of PP7-Dynabeads was incubated with each of the in vitro 
generated DI or DI-PRS 32P RNA in the presence of RNase inhibitors for 30min at 4°C and 
further washed 3 times with a high salt (1M NaCl) buffer. B) Dynabeads were resuspended in 
250µl 1M salt buffer, radioactivity captured by the beads measured and the proportion of RNA 
captured with respect to the total RNA incubated with dynabeads calculated in each case. 
As only a small proportion (4.7%) of the total DI-PRS incubated with PP7-
Dynabeads was specifically captured, attempts to improve affinity of the DI-
PRS:PP7 interactions were further investigated in next sections. 
4.4.3. Testing the effect of the binding buffer in the affinity of the 
DI-PRS:PP7 interactions 
As I was not licensed to manipulate 32P radioactive material at the time when 
these experiments were performed, and as Dr. Bernie Precious retired, the 
capture of DI-PRS RNA by PP7-Dynabeads was subsequently monitored by 
PCR. Using this method, the effect that different buffers had on the efficiency of 
capture of DI-PRS RNA by PP7-Dynabeads was investigated. The buffers, that 
contained either ionic or non-ionic detergents, were:  
- RIPA buffer (50mM Tris-HCl pH 7.5, 1mM EDTA, 150mM NaCl, 1% Igepal 
CA-630 [Sigma], 0.5% DOC, 0.05% SDS, complete EDTA-free protease 
inhibitor cocktail [Roche]) 
 
- Tris Lysis buffer (50mM Tris-HCl pH 7.5, 200mM NaCl, 0.5% Igepal CA-630 
[Sigma], 33% glycerol, 20mM imidazole, 1mM DTT, complete EDTA-free 
protease inhibitor cocktail [Roche]) 
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- IPB buffer (20mM Tris-HCl pH 7.8, 1mM EDTA, 650mM NaCl, 0.1% Igepal 
CA-630 [Sigma], complete EDTA-free protease inhibitor cocktail [Roche]) 
Dynabeads onto which PP7-V5 had, or had not (control beads) been captured 
(as described in section 4.4.1), were washed five times with the above buffers 
and incubated with DI-PRS RNA, generated by in vitro transcription, in the 
appropriate buffers by rotation for 10min at 4°C. After incubation, the 
Dynabeads were washed five times with the same buffers that were used 
during the capture of the RNA onto the beads. RNase inhibitors were also used 
in all steps where DI-PRS RNA was present. The RNA captured onto the beads 
was extracted by TRIzol. RT-PCR was performed using a forward primer that 
bound to a sequence within the loop structure of the DI and a reverse primer 
that bound to the PRSseq. As can be seen in Fig. 4.10, when RIPA buffer was 
used, no DI-PRS RNA appeared to be captured by control Dynabeads, but 
significantly less DI-PRS RNA was captured by PP7-Dynabeads, compared to 
when the other buffers were used. In contrast, higher levels of DI-PRS were 
captured by PP7-Dynabeads when Tris Lysis buffer was used, but also some 
non-specific binding was also observed. However, when IPB buffer was used 
relatively high levels of DI-PRS RNA were captured by both PP7-Dynabeads 
and control beads. 
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Fig. 4.10. Testing the effect of the binding buffer on the affinity of the DI-PRS:PP7 
interactions. 300µg PP7-Dynabeads, or Dynabeads that did not contain PP7 (control beads), 
were generated as described in section 4.4.1, washed five times with RIPA, Tris Lysis or IPB 
buffer, and incubated with 8µg DI-PRS RNA (generated by in vitro transcription) in the 
appropriate buffers by rotation for 10min at 4°C. Dynabeads were further washed five times 
with the same buffers used to capture RNA onto the beads. RNase inhibitors were used in all 
steps where DI-PRS RNA was present. The RNA captured was extracted by TRIzol and RT-PCR 
performed using 'A DI loop binding Fwd' primer, which binds to a sequence in the loop of the 
DI RNA, and 'A PRSseq Rev' primer, which binds to the PRS sequence. The φ2.5.DI and φ2.5.DI-
PRS plasmids were used as negative and positive controls for PCR, respectively. 
These results suggest that, whilst RIPA buffer prevents the non-specific binding 
of RNA to Dynabeads, it may also reduce the efficiency of capture of DI-PRS 
RNA by PP7. In contrast, IPB buffer, under these conditions, does not prevent 
non-specific binding. Tris Lysis buffer gave the best results in that it reduced 
non-specific binding (although not preventing it completely) but resulted in the 
highest level of specific capture of the DI-PRS RNA by PP7-V5 Dynabeads.  
4.4.4. Testing the effect of salt in the binding buffer in the affinity 
of the DI-PRS:PP7 interactions 
Another factor which can influence the binding of proteins to RNA is the nature 
and concentration of salts within the binding buffer (McHugh et al., 2014). To 
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test how the salt present in the binding buffer could affect both the specific and 
non-specific capture of DI-PRS by PP7 on Dynabeads, the binding of DI-PRS to 
beads in Tris Lysis buffer containing 0M, 0.15M, 0.4M and 0.75M NaCl was 
investigated as previously described. Briefly, PP7-Dynabeads, or Dynabeads 
that had not captured PP7-V5 (control beads), were washed five times with the 
appropriate buffer and incubated with DI-PRS RNA (generated by in vitro 
transcription), in the presence of RNAse inhibitors, for 10min at 4°C in the same 
buffer. The beads were then washed a further five times with the appropriate 
buffer. The relative amount of DI-PRS RNA captured under the different 
conditions was then estimated by PCR as described above. As can be observed 
in Fig. 4.11, in the absence of NaCl or 0.15M NaCl similar amounts of DI-PRS 
RNA bound to the control and PP7-Dynabeads. However, the amount of non-
specific binding of DI-PRS RNA to the control beads was significantly reduced 
in the presence of 0.4M and 0.75M NaCl. Strikingly, under these conditions the 
specific capture of DI-PRS RNA by the PP7-Dynabeads could now be clearly 
observed. 
 
 
 
Fig. 4.11. Testing the effect of salt in the binding buffer on the affinity of the DI-PRS:PP7 
interactions. Tris Lysis buffers containing 0M, 0.15M, 0.4M or 0.75M were generated. 300µg 
PP7-Dynabeads, or Dynabeads that had not captured PP7-V5 (control beads), were washed five 
times with the appropriate Tris Lysis buffer and incubated with 8µg DI-PRS RNA, generated by 
in vitro transcription, by rotation for 10min at 4°C in the same buffer, in the presence of RNase 
inhibitors. The beads were then washed five times with the appropriate buffer, RNA captured 
onto the beads extracted by TRIzol and RT-PCR performed as described above. φ2.5.DI and 
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φ2.5.DI-PRS plasmids were used as negative and positive controls for PCR, respectively. 
Tris Lysis buffers containing 0.4 or 0.75M NaCl gave the best results in that they 
showed similar amounts of DI-PRS RNA bound to PP7-Dynabeads as Tris Lysis 
buffers containing 0 or 0.15M NaCl, but resulted in the most significant 
reduction of non-specific binding (although not preventing it completely). 
Therefore, in further experiments, a Tris Lysis buffer containing 0.4M NaCl was 
used as the binding buffer to generate PP7-Dynabeads as described above. 
4.4.5. Testing saturation of PP7-V5 onto Dynabeads with DI-PRS 
To determine the amount of DI-PRS RNA needed to saturate PP7-Dynabeads, 
different amounts of DI-PRS RNA (0.96, 4.8 or 19.2µg) were incubated with 
300µg PP7-Dynabeads. The Dynabeads were then washed and the amount of 
DI-PRS RNA present on the Dynabeads estimated by PCR as previously 
described. As shown in Fig. 4.12, the highest levels of DI-PRS RNA were 
detected when PP7-Dynabeads were incubated with 4.8µg DI-PRS. For reasons 
that are unclear, less DI-PRS RNA was captured when the PP7-Dynabeads were 
incubated with 19.2µg DI-PRS RNA, although the amount of non-specific 
binding increased. No non-specific binding of DI-PRS RNA was detected on 
control Dynabeads when they were incubated with 0.96 or 4.8µg DI-PRS. 
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Fig. 4.12. Testing saturation of PP7-V5 onto Dynabeads with DI-PRS. 0.96, 4.8 or 19.2µg DI-
PRS RNA were incubated with 300µg PP7-Dynabeads, or Dynabeads that did not capture PP7 
(control beads) by rotation for 10min at 4°C, in the presence of RNase inhibitors. Dynabeads 
were further washed five times and the amount of DI-PRS captured by the Dynabeads 
determined by PCR as previously described. φ2.5.DI and φ2.5.DI-PRS plasmids were used as 
negative and positive controls for PCR, respectively. 
4.4.6. Testing the effect of pre-incubating Dynabeads with random 
RNA in the non-specific capture of DI-PRS to Dynabeads 
Some non-specific binding of DI-PRS RNA to Dynabeads in the presence of 
0.4M and 0.75M NaCl still occurred (Fig. 4.11). To try and reduce this, I next 
investigated whether pre-incubation of Dynabeads with random RNA blocked 
the non-specific binding sites on Dynabeads for DI-PRS RNA. To test this, prior 
to saturating the Dynabeads with PP7 as previously described, 300µg 
Dynabeads were first incubated with transfer RNA (t-RNA) from wheat germ. 
The beads were then incubated with 4.8µg DI-PRS RNA, or DI RNA, in the 
presence or absence of 24µg t-RNA, and the relative amount of DI-PRS, or DI, 
RNA captured by the beads estimated by PCR as previously described. It can be 
seen from Fig. 4.13 that, pre-incubating with t-RNA, significantly reduced the 
amount of DI-PRS RNA capture by the control beads whilst not reducing the 
specific capture of DI-PRS RNA by PP7-Dynabeads. 
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Fig. 4.13. Pre-incubating Dynabeads with t-RNA reduced non-specific bound DI-PRS to 
Dynabeads. Prior to saturating 300µg Dynabeads with PP7-V5 as previously described, 
Dynabeads were, or were not, incubated with 24µg t-RNA from wheat germ by rotation for 
10min at 22°C. Dynabeads that were not saturated with PP7-V5 were used as control (control 
beads). The beads were then incubated with DI-PRS, or DI, RNA in the presence or absence of 
24µg t-RNA, washed and the relative amount of DI-PRS, or DI, RNA captured by the beads 
estimated by PCR as previously described using 'A DI loop binding Fwd' and 'DI loop binding 
Rev' primers which bind to a sequence in the loop of the DI RNA to detect DI RNA. φ2.5.DI and 
φ2.5.DI-PRS plasmids were used as negative and positive controls for PCR, respectively. 
According to the experiments described above, a protocol was established, and 
used in further experiments, that gave the best conditions for the specific 
capture of DI-PRS RNA by PP7-V5 onto Dynabeads in vitro while reducing non-
specific capture of DI-PRS: 
! Using RNase inhibitors in all steps where RNA is present 
! Incubating the equivalent of 300µg Dynabeads with 24µg t-RNA by rotation 
for 10min at 4°C 
! Incubating Dynabeads with 4.8µg anti-V5 Ab by rotation for 10min at 22°C 
! Washing Dynabeads 5x with Tris Lysis buffer containing 0.4M NaCl 
! Incubating Dynabeads with 36µl cytoplasmic extract of 293T.PP7-V5.puro.8x 
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cells by rotation for 10min at 22°C 
! Washing Dynabeads 5x with Tris Lysis buffer 
! Incubating Dynabeads with 4.8µg DI-PRS RNA, and also 24µg t-RNA, 
diluted in DEPC H2O by rotation for 10min at 4°C 
! Washing Dynabeads 5x with Tris Lysis buffer 
4.5. Step D. Isolating DI-PRS:protein complexes 
Having developed a suitable in vitro protocol to specifically capture DI-PRS by 
PP7-Dynabeads, I next undertook some preliminary investigations to determine 
whether DI-PRS RNA bound to Dynabeads could be used to capture cellular 
RNA-binding proteins, specifically those that were induced by IFN. To this end, 
DI-PRS-containing PP7-Dynabeads generated as described above were 
incubated by rotation for 1h at 4°C with cytoplasmic extracts of A549 cells that 
had, or had not, been treated with IFN for 16h prior to metabolic-labelling with 
35S methionine as illustrated in Fig. 4.14.A. Dynabeads were then washed 5x 
with Tris Lysis buffer, the bound proteins eluted by SDS-PAGE disruption 
buffer and separated by SDS-PAGE. The PAG was stained with Coomassie 
stain (Fig. 4.14.B left panel) prior to exposure to a radiation energy sensor film 
(Fig. 4.14.B right). As can be seen in fig 4.14.B right some bands were present in 
significantly higher amounts in the samples of beads that had been incubated 
with cell extracts treated with IFN. The two bands highlighted by an arrow in 
fig 4.14 were cut from the gel and identified by mass spectrometry (MS) as 
protein kinase RNA-activated (PKR) and interleukin enhancer-binding factor 3 
(ILF3), two proteins known to bind dsRNA (Fig. 4.14.B right). PKR is a 62kDa 
sentinel protein that is induced by IFN and is activated by dsRNA. 
Encouragingly, although PKR could not be identified in the total cell lysate of 
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either IFN-treated or untreated cells (data not shown), Commassie stainable 
amounts of PKR were captured onto the beads from the IFN-treated cell lysate 
but not from untreated cell lysates. However, analysis of the 35S-methionine 
profiles suggested that small amounts of PKR were also captured from the 
untreated cell lysate, presumably due to its basal constitutive expression in 
cells.  
 
 
 
 
 
 
 
 
 
Fig. 4.14. PKR and ILF3 were specifically captured by DI-PRS contained in PP7-Dynabeads 
generated in vitro. A) 300µg PP7-Dynabeads that captured DI-PRS were generated as described 
previously. Dynabeads were further incubated by rotation for 1h at 4°C with 400µl cytoplasmic 
extracts of A549 cells from a confluent monolayer in a 75cm2 flask that had, or had not, been 
treated with IFN for 16h prior to metabollic-labelling with 35S methionine. Dynabeads were 
further washed 5x with Tris Lysis buffer, the bound proteins eluted by SDS-PAGE disruption 
buffer and separated by SDS-PAGE. B) The PAG was stained with Coomassie stain (left panel) 
and then exposed to a radiation energy sensor film (right panel). The two bands highlighted by 
blue arrows in the radiation energy sensor film were cut from the gel and identified by MS as 
PKR and ILF3. Red arrows indicate IgH, IgL and PP7-V5 in the Coomassie stained PAG. The 
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green arrow indicates PKR in the Coomassie stained PAG. 
Although these results strongly suggest that it is possible to specifically capture 
dsRNA-binding proteins with DI-PRS RNA bound to Dynabeads, this 
particular approach was not pursued for a number of reasons. Firstly, the main 
aim of the project was to isolate RNA:protein complexes directly from cells in 
which the IFN-induction cascade had been activated by PIV5 DIs. Secondly, 
there was a significant amount of non-specific binding of proteins to the 
Dynabeads that might mask any specific RNA:protein interactions. Thirdly, the 
presence of the antibody heavy and light chains, as well as PP7, attached to the 
beads might interfere with future MS analysis, especially if a procedure could 
be developed in which proteins captured by DI-PRS RNA could be directly 
released from the beads for MS analysis without the need to cut out the protein 
bands from SDS PAGs. With this latter aim in mind, and the need to develop as 
sensitive technique as possible, it was decided to concentrate on further 
improving the technique for purifying RNA:protein complexes. 
4.6. TAP-tagging purification of RNA:protein complexes using V5-
TEV 
This section describes the development of a purification technique that was 
designed to reduce the amount of non-specifically bound proteins on DI-
PRS:protein complexes captured by PP7 on Dynabeads. Two additional 
purification steps were added to the previously described PP7-based 
purification protocol. Briefly, the aims were to modify the PP7-epitope tag to 
include a TEV protease cleavage sequence between PP7 and the V5 epitope (V5-
TEV-PP7). Following capture of RNA:protein complexes on TEV-PP7-
Dynabeads: 
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1. The RNA:protein complexes would then be cleaved from the Dynabeads by 
incubating the beads with His-tagged TEV protease. Whilst the RNA:protein 
complexes would thus be released into the supernatant, together with PP7 
(no V5-epitope tagged) and His-TEV protease, non-specifically bound 
proteins, and also the anti-V5 Ab heavy and light chains, would remain 
attached to the Dynabeads, and could therefore be simply removed. 
2. To remove His-TEV protease, the supernatant would then be incubated with 
Ni-NTA Dynabeads that would capture His-TEV protease, leaving only 
RNA:protein complexes and PP7 in the supernatant. 
For a schematic diagram of the purification protocol see Fig. 4.15, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.15. Schematic of the TEV-tagging purification of proteins captured by DI-PRS on 
Dynabeads. TEV-PP7-Dynabeads were generated using a cytoplasmic extract of V5-TEV-PP7-
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expressing cells as described in section 4.4. Following capture of RNA:protein complexes on 
TEV-PP7-Dynabeads (PP7-based complex), 1) the beads would be incubated with His-TEV 
protease to cleave the RNA:protein complexes from the Dynabeads. The RNA:protein 
complexes would thus be released into the supernatant, together with PP7 (no V5-epitope 
tagged) and His-TEV protease (TEV supern.). Non-specifically bound proteins, and also the 
anti-V5 Ab heavy and light chains, would remain attached to the Dynabeads and could 
therefore be simply removed (TEV beads). 2) The supernatant (TEV supern.) would then be 
incubated with Ni-NTA Dynabeads which would capture His-TEV, leaving only RNA:protein 
complexes and PP7 in the supernatant (Ni supern.). Ni-NTA Dynabeads, containing His-
TEV(Ni beads), could be simply removed. 
To implement the TEV-based purification of DI-PRS:protein complexes 
captured by TEV-PP7-Dynabeads, the following steps were undertaken: 
A) Generating cell-lines expressing V5-TEV-PP7 
B) V5-TEV-PP7 cleavage by TEV 
C) Purification and cleavage of DI-PRS captured by V5-TEV-PP7 on Dynabeads 
4.6.1. Generating cell-lines stably expressing V5-TEV-PP7 
TEV protease is the 27 kDa catalytic domain of the nuclear inclusion a (Nia) 
protein encoded by the tobacco etch virus (TEV). It recognizes a linear epitope 
of the general form E-X-X-Y-X-Q-(G/S) with high specificity, with cleavage 
occurring between Q and G/S, but the most commonly used sequence is 
ENLYFQG (Kapust et al., 2001). 
In order to have a source of V5-TEV-PP7 to isolate DI-PRS RNA:protein 
complexes, mammalian cell-lines were generated that express V5-TEV-PP7. For 
this, lentiviral transfer vectors, termed pdl'V5-TEV-PP7.puro and pdl'V5-TEV-
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PP7.bla, were constructed so that N-terminal V5-epitope tag was followed by 9 
random aa that, in turn, were followed by the TEV cleavage sequence and the 
PP7 sequence (Fig. 4.16.A). The 9 random aa were added as a spacer to facilitate 
TEV cleavage of the V5 epitope from PP7, as placing the TEV cleavage site too 
close to the V5 epitope sterically hinders cleavage. The lentiviral transfer 
vectors generated also confer resistance to puromycin or blasticidin, 
respectively. Appendix 3 shows the sequence encoding for V5-TEV-PP7 
depicted in Fig. 4.16.A, and Fig. 4.16.B shows a schematic of the V5-TEV-PP7 
construct. 
 
 
 
 
 
 
 
 
Fig. 4.16. Structure of the V5-TEV-PP7 sequence and V5-TEV-PP7 construct. A) Sequence of 
V5-TEV-PP7 in the pdl’V5-TEV-PP7.puro and pdl’V5-TEV-PP7.bla lentiviral transfer vectors. 
The N-terminal V5 epitope tag is followed by 9 random aa that, in turn, are followed by the 
TEV cleavage sequence and the PP7 sequence. B) Illustration of the V5-TEV-PP7 construct. 
293T and A549 cells were transduced with either pdl’V5-TEV-PP7.puro or 
pdl’V5-TEV-PP7.bla. This was because it was anticipated that we would use 
other lentiviruses, with appropriate selection markers, to express additional 
proteins to V5-TEV-PP7 in these cell-lines. Cells were transduced once with the 
lentiviral vectors and the relative levels of expression estimated by Western Blot 
analysis (Fig. 4.17). As can be observed in Fig. 4.17, the V5-TEV-PP7 protein 
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construct expression was detected in all the cell-lines generated (293T.V5-TEV-
PP7.puro, 293T.V5-TEV-PP7.bla, A549.V5-TEV-PP7.puro and A549.V5-TEV-
PP7.bla). 
 
 
 
 
 
 
 
 
 
Fig. 4.17. V5-TEV-PP7 expression in 293T and A549 cells transduced with V5-TEV-PP7 
lentiviral vectors by Western Blot analysis. 293T and A549 cells were transduced once with 
pdl'V5-TEV-PP7.puro or pdl'V5-TEV-PP7.bla lentiviral vectors, and the relative levels of V5-
TEV-PP7 expression in the cell-lines generated were estimated by Western Blot analysis using 
anti-V5 Ab. As a negative control, cells were mock transduced. As a positive control, cells were 
infected with PIV5 W3 wt. at a MOI of 10 pfu/cell. 
Expression of V5-TEV-PP7 in the newly cell-lines generated was also tested by 
immunofluorescence (Fig. 4.18), showing that, as it occurred with PP7-V5-
expressing cells (Fig. 4.6), V5-TEV-PP7 was primarily located in the cell 
cytoplasm. 
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Fig. 4.18. V5-TEV-PP7 expression in 293T and A549 cells transduced with V5-TEV-PP7 
lentiviral vectors by immunofluorescence. Expression of V5-TEV-PP7 in 293T and A549 cells 
transduced with pdl'V5-TEV-PP7.bla or pdl'V5-TEV-PP7.puro lentiviral vectors was established 
by immunofluorescence using anti-V5 Ab. As a negative control, cells were mock infected. As a 
positive control, cells were infected with PIV5 W3 wt at a MOI of 10 pfu/cell. 
4.6.2. V5-TEV-PP7 cleavage by TEV 
Improved purification of RNA:protein complexes captured by DI-PRS on TEV-
PP7-Dynabeads is dependent upon TEV protease efficiently cleaving its target 
sequence to release the RNA:protein complexes into the supernatant. To 
investigate conditions of TEV cleavage, Dynabeads were saturated with anti-V5 
antibody and V5-TEV-PP7 in an analogous fashion as previously described for 
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generating PP7-Dynabeads. The TEV-PP7-Dynabeads were incubated with TEV 
protease diluted either in PBS or in standard TEV reaction buffer (20mM Tris 
HCl, 150 mM NaCl, 1mM DTT, 1mM EDTA, complete EDTA-free protease 
inhibitor cocktail [Roche]) by rotation for 1h at 4°C. Following cleavage, 
Dynabeads and supernatant were separated and the amount of V5-TEV-PP7 
analysed by Western Blot. As can be observed in Fig. 4.19, incubation of TEV-
PP7-Dynabeads in either PBS or TEV reaction buffer led to the complete 
cleavage of V5-TEV-PP7 (Note: TEV cleaves off the V5 tag from PP7, hence PP7 
was not detected in the supernatant). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.19. V5-TEV-PP7 cleavage by TEV. 300µg TEV-PP7-Dynabeads were incubated with 2µg 
TEV protease diluted in PBS or TEV reaction buffer as described above. Following incubation, 
Dynabeads and supernatant were separated and the amount of V5-TEV-P7 analysed by 
Western Blot using an anti-V5 Ab. D: Dynabeads fraction, S: supernatant fraction. 
4.6.2.1. Testing the effect of the incubation time in V5-TEV-PP7 cleavage by 
TEV 
In order to minimize potential loss or degradation of protein:RNA complexes 
captured on Dynabeads during TEV cleavage, I next investigated the time 
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required for efficient TEV cleavage. TEV-PP7-Dynabeads were incubated with 
TEV diluted in PBS for 15min, 1h, 6h or 24h in the conditions previously 
described. Dynabeads were then separated from the supernatants and the 
amount of V5-TEV-PP7 analysed by Western Blot. As can be seen in Fig. 4.20, 
significant amounts of V5-TEV-PP7 remained bound to the Dynabeads after 
15min incubation with TEV, indicating incomplete cleavage of V5-TEV-PP7. In 
contrast, incubating Dynabeads for 1, 6 or 24h with TEV led to complete 
cleavage of V5-TEV-PP7. 
 
 
 
 
 
Fig. 4.20. Testing the effect of the incubation time on V5-TEV-PP7 cleavage by TEV. 300µg 
TEV-PP7-Dynabeads were left incubating with 2µg TEV for 15min, 1h, 6h or 24h in the 
conditions described above. Dynabeads were then separated from the supernatants and the 
amount of V5-TEV-PP7 analysed by Western Blot using an anti-V5 Ab. D: Dynabeads fraction, 
S: supernatant fraction. 
4.6.3. Purification and cleavage of DI-PRS captured by V5-TEV-
PP7 on Dynabeads 
Next, to monitor whether the procedure developed could potentially lead to 
better purification of RNA:protein complexes, TEV-PP7 saturated Dynabeads 
were incubated with in vitro translated DI RNA or DI-PRS RNA as previously 
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described in section 4.4 (an illustration of DI-PRS captured by TEV-PP7-
Dynabeads is in Fig. 4.21.A). Following TEV cleavage, the supernatant was 
separated from Dynabeads. The TEV, which was His tagged, was then removed 
by incubating the supernatant with Ni-NTA Dynabeads (Life Technologies) by 
rotation for 10min at 22°C. Supernatant and Ni-NTA Dynabeads were then 
again separated. The proteins present in selected fractions were visualised by 
PAGE (Fig. 4.21.B). As can be observed, prior to TEV cleavage ('DI-PRS on 
beads'), not only were anti-V5 antibody heavy and light chains, as well as the 
specifically captured V5-TEV-PP7, bound to the Dynabeads but in addition 
there were a lot of proteins non-specifically bound to the Dynabeads. However, 
most of these non-specifically bound proteins, together with the antibody heavy 
and light chains, remained bound to the beads following TEV cleavage ('TEV 
beads'), whilst PP7 was released into the supernatant ('TEV supern.', no V5-
epitope and TEV tagged). Furthermore, incubating the supernatant with Ni-
NTA Dynabeads removed the His-tagged TEV ('Ni beads'), resulting in a 
fraction that primarily contained only PP7 ('Ni supern.'). To confirm that PP7 
was effectively present in the 'Ni supern.', the band highlighted by an arrow in 
Fig. 4.21 was cut from the gel and identified by MS as PP7. 
RT-PCR, as previously described, was then used to determine whether DI-PRS 
RNA was also purified during this procedure (Fig. 4.21.C). Encouragingly, 
significantly more DI-PRS RNA was detected on the Dynabeads prior to TEV 
cleavage ('DI-PRS on beads') than after TEV cleavage. Furthermore, DI-PRS 
RNA was clearly detected in the supernatant fraction from which the His-TEV 
had been removed by Ni-NTA Dynabeads ('Ni supern.'). (Note: it was not 
possible to save samples from every fraction during the purification procedure 
as this would have led to unacceptable sample loss at each step of purification). 
In contrast, in a parallel purification procedure, although control DI RNA was 
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bound by TEV-PP7 Dynabeads ('DI on beads'), this was clearly being bound 
non-specifically as it was not released from the Dynabeads by TEV cleavage 
('Ni supern.'). 
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Fig. 4.21. Purification and cleavage of DI-PRS captured by V5-TEV-PP7 on Dynabeads. A) 
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Illustration of DI-PRS captured by TEV-PP7-Dynabeads. B) 300µg TEV-PP7-Dynabeads were 
incubated with in vitro translated DI or DI-PRS RNA as previously described in section 4.4. 
Following TEV cleavage, the supernatant was separated from Dynabeads. The TEV was then 
removed by incubating the supernatant with Ni-NTA Dynabeads by rotation for 10min at 22°C. 
Supernatant and Ni-NTA Dynabeads were again separated and the proteins present in selected 
fractions were visualised by PAGE. The band highlighted by a red arrow was cut from the gel 
and identified by MS as PP7. C) The DI or DI-PRS RNA present in each fraction was extracted 
by TRIzol and RT-PCR performed to detect DI or DI-PRS as previously described. The φ2.5.DI-
PRS plasmid was used as positive control for PCR. 
These results are proof of principle suggesting that it is possible to purify 
dsRNA-binding proteins with DI-PRS RNA bound to TEV-PP7-Dynabeads by a 
TEV-based protocol that would practically eliminate the presence of proteins 
non-specifically bound to the Dynabeads. It would also eliminate the presence 
of the antibody heavy and light chains that could interfere with future MS 
analysis. 
In summary, a TEV-based protocol was established to purify RNA:protein 
complexes captured by a PP7-based system: 
! Using RNase inhibitors in all steps where RNA is present 
! Using 12µg cytoplasmic extract of 293T.TEV-PP7.puro cells to saturate the 
equivalent of 300µg Dynabeads containing anti-V5 Ab as previously 
described 
! Once proteins have been captured by DI-PRS on TEV-PP7-Dynabeads, 
incubating the equivalent of 300µg Dynabeads with 2µg TEV protease 
diluted in PBS by rotation for 1h at 22°C 
! Once separated from the Dynabeads, incubating the supernatant with 400µg 
Ni-NTA Dynabeads by rotation for 10min at 22°C 
! Separating the supernatant from the Ni-NTA Dynabeads 
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To apply the protocol developed to isolate RNA:protein complexes within cells, 
we also investigated the introduction of DI-PRS RNA into cells. 
4.7. Introducing DI-PRS RNA into cells 
In parallel to the experiments described above, that were concerned with 
improving the methods available for purifying RNA:protein complexes, 
attempts were also being made to develop an appropriate procedure for the 
isolation of RNA:protein complexes that specifically interact with PIV5 DIs 
within cells. 
4.7.1. Transfection of the φ2.5.DI-PRS plasmid into cells 
expressing PP7 
Before trying to capture DI RNA complexes involved in the activation of the 
IFN induction pathway we first needed to know that DI-PRS RNA activated 
innate cell signalling cascades (including the IFN induction cascade). This was 
initially investigated by transfecting the φ2.5.DI-PRS plasmid into PP7-
expressing cells that also express the T7pol (Fig. 4.22). 
 
 
 
 
 
 
 
 
Fig. 4.22. Transfection of the φ2.5.DI-PRS plasmid into cells expressing 
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PP7. Illustration of the method used to introduce DI-PRS RNA into cells by 
transfection of the φ2.5.DI-PRS plasmid into PP7-expressing cells that also 
express T7pol. 
To determine whether DI-PRS RNA generated in this manner activated the IFN 
induction cascade, BSR-T7 cells were co-transfected with the φ2.5.DI-PRS, or the 
φ2.5.DI plasmid, and the pIFNβ.luc plasmid that expresses luciferase under the 
control of the IFNβ promoter. As a positive control for the activation of the IFN-
induction cascade, cells were also co-transfected with the pIFNβ.luc plasmid 
and a ribonucleoprotein (RNP) preparation of mumps virus (MuV), which is a 
powerful activator of the IFN-induction cascade. 24h post-transfection, cells 
were lysed and luminescence assayed (Fig. 4.23.A). Results shown indicate that 
no luciferase induction occurred in cells transfected with either φ2.5.DI or 
φ2.5.DI-PRS plasmid. Surprisingly, cells transfected with MuV RNP were also 
negative. One possible explanation may have been that neither DI nor DI-PRS 
RNA was being generated in the transfected cells. This was unlikely as both 
plasmids had previously been used and proved to generate RNA in the 
presence of T7pol. Another possibility was that luciferase was not induced in 
transfected cells due to a defect of the IFN induction pathway in BSR-T7 cells. 
To test for any defect of the IFN induction in BSR-T7 cells, they were transfected 
with the pIFNβ.luc plasmid and later infected with PIV5-VΔC vM2 (a DI-rich 
stock which is an extremely good inducer of IFN). 24h post-infection, cells were 
lysed and luciferase expression was assayed (Fig. 4.23.B). Strikingly, as can be 
observed in Fig. 4.23.B, no luciferase was generated in cells transfected and later 
infected, indicating that the IFN induction pathway may be impeded in BSR-T7 
cells. Subsequent to these experiments we found that this had already been 
reported by Habjan and colleagues (Habjan et al., 2008), who stated that BSR-T7 
cells are deficient in RIG-I-mediated IFN induction even if the BSR-T7 cells are 
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transfected with a plasmid encoding for RIG-I. For this reason, BSR-T7 cells 
were discarded and 293T cells were used instead. 
To ensure the IFN induction pathway in 293T cells was functional, 293T cells 
were transfected with the pIFNβ.luc plasmid prior to infection with PIV5-VΔC 
vM2. Cells were lysed 24h post-infection and luciferase expression was tested 
(Fig. 4.23.C). High levels of luminescence was observed in cells transfected and 
infected, indicating that the IFN induction pathway had been activated. The 
next step was to test IFN induction by plasmid-derived DI-PRS RNA within 
293T cells. For this, 293T cells were co-transfected with the pIFNβ.luc plasmid, 
φ2.5.DI-PRS or φ2.5.DI, plasmids and the pEMiB plasmid, an uncharacterised 
plasmid obtained from Professor Martin Ryan that expresses T7pol. 24h post-
transfection, cells were lysed and luminescence was tested (Fig. 4.23.D). As can 
be seen in Fig. 4.23.D, almost no luminescence was detected in cells that had 
been co-transfected with φ2.5.DI-PRS or φ2.5.DI plasmids, suggesting that DI 
RNA had not been generated from either of the plasmids. However, this was 
not because the cells had not been successfully transfected with the pEMiB 
plasmid. 
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Fig. 4.23. Luciferase expression generated from cells transfected with the φ2.5.DI-PRS, or 
φ2.5.DI, plasmids. A and D. BSR-T7 cells (A) or 293T cells (D) 70% confluent in a 200mm2 well 
were transfected, or not, with the pIFNβ.luc plasmid and also co-transfected with φ2.5.DI-PRS, 
or φ2.5.DI, plasmid (0.1µg each). 24h post-transfection, cells were lysed and luciferase activity 
was tested. As a positive control for IFN induction, cells were transfected with the pIFNβ.luc 
plasmid and co-transfected with 0.1µg MuV RNP (strain Enders). B and C. BSR-T7 cells (B) or 
293T cells (C) were transfected, or not, with the pIFNβ.luc plasmid and, 24 hours post-
transfection, they were infected, or not, with PIV5-VΔC vM2 at 10 MOI. 24 hours post-infection 
cells were lysed and luciferase activity was tested. RLU: Relative Light Units. 
The pEMiB plasmid contains a pCMV promoter followed by a sequence 
encoding mCherry fluorescent protein, a 2A 'ribosome skipping sequence' and 
then a sequence encoding T7pol (Fig. 4.24.A); fluorescence microscopy of 
transfected cells showed that approximately 20% of transfected cells expressed 
mCherry. Therefore, to test whether functional T7pol was made from the 
pEMiB plasmid, 293T cells were co-transfected with pEMiB, together with the 
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pTM1.GFP plasmid that encodes the green fluorescent protein (GFP) under the 
control of the T7pol promoter. As a control, BSR-T7 cells were also transfected 
with the pTM1.GFP plasmid. 42h post-transfection, cells were examined for the 
expression of mCherry red and GFP expression. As can be seen in Fig. 4.24.B, 
mCherry was expressed at high levels in 293T cells, indicating that the pEMiB 
plasmid was transcribed following transfection. However, although GFP was 
clearly expressed in BSR-T7 cells transfected with the pTM1.GFP plasmid, no 
GFP was expressed in 293T cells co-transfected with pTM1.GFP and the pEMiB 
plasmids, strongly suggesting that functional T7pol was not encoded by the 
pEMiB plasmid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.24. T7pol expression from the pEMiB plasmid. A) Schematic of the sequence of the 
pEMiB plasmid. The pCMV promoter is followed by a sequence encoding mCherry fluorescent 
protein and a 'ribosome skipping sequence' (2A), followed by a sequence encoding T7pol. B) 
70% confluent 293T and BSR-T7 cells in a 200mm2 well were, or were not, transfected with the 
pEMiB plasmid together with the pTM1.GFP plasmid (0.1µg each). 42h post-transfection cells 
were analysed for mCherry and GFP expression. 
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The sequence in the pEMiB plasmid encoding T7pol was published in 1984 and 
it was reported to be functional (Grachev and Pletnev, 1984). Nevertheless, it 
differs by three amino acid residues (R389, H623 and P665) from the 
commercially used sequence. Subsequent to these results Professor Ryan’s 
group confirmed the low efficacy of the T7pol generated by the pEMiB plasmid 
within cells. To solve this, Professor Ryan’s group are currently replacing the 
three amino acids with the ones commercially used (K389, Y623 and L665) and 
are also codon-optimising the sequence for eukaryotic expression. However, 
due to time constraints it was not possible to further investigate this method. 
4.7.2. Transfection of in vitro transcribed DI-PRS RNA into cells 
Given the failure to test the ability of DI-PRS RNA by transfecting the φ2.5.DI-
PRS plasmid into PP7-expressing cells that also express the T7 polymerase, I 
next investigated whether in vitro transcribed DI-PRS RNA activated the IFN 
response. To ensure efficient transfection and monitoring of the activation of 
the IFN induction pathway 293T.pIFNβ.GFP cells were generated using 
lentiviral vectors. This cell line expresses GFP under the control of the IFNβ 
promoter and therefore can be used to test IFN induction. The 293T.pIFNβ.GFP 
cells were transfected with DI-PRS, or DI, RNA generated by in vitro 
transcription, as is illustrated in Fig. 4.25.A. As a positive control, cells were 
also transfected with MuV RNP. To test the role played by blunt-ended dsRNA 
in the activation of the IFN induction, cells were also transfected with DI RNA 
generated by in vitro transcription from the pGEM-Teasy.DI plasmid. The 
pGEM-Teasy.DI plasmid expresses the DI(TrCB) RNA under the control of a 
standard T7 promoter. This plasmid differs from the φ2.5.DI plasmid in that it 
possesses some ‘extra’ nucleotides between the end of the T7 promoter and the 
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beginning of the DI sequence. Therefore, it renders a DI RNA with 'extra' 
nucleotides in the 5’ end so that the RNA structure is not blunt-ended. 42h post-
transfection, GFP expression was observed and is shown in Fig. 4.25.B. As can 
be observed, both DI and DI-PRS RNA transfected in reporter cells induced 
GFP expression, indicating that recognition of the RNAs by cytosolic receptors 
occurred and also that was not affected by the presence of the PRS sequence 
contained in the loop of the copyback DI. In contrast, DI RNA generated from 
the pGEM-Teasy.DI plasmid did not induce high levels of GFP expression, 
highlighting that blunt-ended dsRNA plays an important role in the efficient 
activation of the IFN induction cascade. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.25. IFN induction by transfection of in vitro transcribed DI-PRS and DI RNA into cells. 
A) Illustration showing the introduction of in vitro translated DI-PRS RNA into PP7-expressing 
cells. B) 70% confluent 293T.pIFNβ.GFP cells in a 25cm2 flask were, or not, transfected with 
2.5µg of DI (no blunt ends), DI, or DI-PRS, RNA generated by in vitro transcription from pGEM-
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Teasy.DI, φ2.5.DI and φ2.5.DI-PRS plasmids, respectively. 42h post-transfection, GFP expression 
was observed. As a positive control, cells were transfected with 2.5µg of a RNP preparation of 
MuV. As a negative control, cells were mock transfected. 
4.7.3. Generation of a DI-rich preparation of viruses containing 
DI-PRS genomes 
Generation of a stock of virus containing encapsidated DI-PRS genomes (DI-
PRS viruses) would be the ideal method to introduce of DI-PRS genomes into 
target cells as such a method could potentially lead to the capture of DI-
RNA:protein complexes that activate the induction of innate intracellular 
responses following infection of cells with paramyxovirus. 
Two methods were used to generate a stock of virus containing DI-PRS 
genomes. Firstly, BSR-T7 cells, that constitutively express T7pol, were 
transfected with the φ2.5.DI-PRS plasmid. 24h post-transfection, cells were 
infected with PIV5 W3 wt, to provide the helper proteins required for DI 
replication in trans, at 10 MOI (an illustration of the method is in Fig. 4.26.A). 
30h post-infection, the supernatant was collected, total cell RNA from infected 
cells extracted by TRIzol and the presence of DI genomes containing the PRS 
sequence estimated by PCR as previously described (Fig. 4.26.B). Secondly, as 
encapsidation by proteins encoded by the helper wt virus, of DI-PRS genomes 
generated from a plasmid was likely to be inefficient (as naked DI genomes had 
to compete with the replication and encapsidation of authentic viral genomes 
and antigenomes), in a parallel set of experiments BSR-T7 cells transfected with 
the φ2.5.DI-PRS plasmid were co-transfected with pCAGGS-NP, pCAGGS-L 
and pEF-P plasmids that express NP, L and P proteins, respectively (Fig. 
4.26.B), prior to subsequent infection with wt virus. 
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Fig. 4.26. Generation of a virus preparation containing DI-PRS genomes. A) The φ2.5.DI-PRS 
plasmid was transfected into T7pol-expressing cells to generate DI-PRS. Subsequent infection 
with PIV5 led to virus encapsidation of DI-PRS. B) A 70% confluent 25cm2 flask of BSR-T7 cells 
was transfected with 2.5µg of the φ2.5.DI-PRS plasmid alone (φ2.5.DI-PRS), or also co-
transfected with plasmids constitutively expressing NP, P and L viral proteins (2.5µg φ2.5.DI-
PRS + 6.25µg NP + 0.63µg P + 4.69µg L). 24h post-transfection, cells were infected with PIV5 W3 
wt at 10 MOI. 30h post-infection, virus-containing supernatant was collected. Total cell RNA 
from infected cells was extracted by TRIzol and the amount of DI-PRS genomes estimated by 
PCR as previously described. As a negative control, mock transfected cells were infected. The 
φ2.5.DI-PRS plasmid was used as a positive control for PCR. 
As can be observed in Fig. 4.26.B, DI-PRS genomes could be detected in cells 
A) 
B) 
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transfected with φ2.5.DI-PRS and further infected with PIV5. Surprisingly, 
detection of DI-PRS genomes in cells that had also been co-transfected with P, 
NP and L plasmids was significantly less than in cells that had not been co-
transfected. Previous work in the lab suggested that ectopic viral NP expression 
in cells may inhibit subsequent virus infection. To test if this was the case, 
A549/Npro cells were, or were not, transfected with the pCAGGS-NP plasmid 
and also with the pCMV.GFP plasmid that constitutively expresses GFP in 
mammalian cells. 24h post-transfection, the cells were infected with PIV5 wt. 
24h post-infection, the cells were fixed and prepared for immunofluorescence. 
As can be observed in Fig. 4.27, cells that ectopically expressed PIV5 NP were 
not infected with PIV5 (Fig. 4.27 left and centre, yellow arrows). However, cells 
that did not ectopically express PIV5 NP were infected (Fig. 4.27 right, blue 
arrows). Furthermore, and as can be clearly observed in Fig. 4.27 centre, a 
different pattern of NP localization was observed in PIV5 infected cells vs 
transfected but uninfected cells. In PIV5 infected cells NP (blue arrows) was at 
least partially located in cytoplasmic foci whereas in cells expressing ectopic 
NP, but no P expression, the NP had a more diffuse cytoplasmic distribution 
(yellow arrows), as has been previously observed (Precious et al., 1995). 
Considering these results, no further attempt was made to rescue DI-PRS 
viruses from cells co-infected with P, NP and L plasmids. 
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Fig. 4.27. Ectopic expression of NP protein inhibits further infection. 70% confluent 
A549/Npro cells in a 200mm2 well were transfected with 0.1µg pCAGGS-NP and/or 0.1µg 
pCMV.GFP plasmids that constitutively express viral NP and/or GFP in mammalian cells, 
respectively. 24h post-transfection, cells were infected with PIV5 wt at 10 MOI. 24h post-
infection, cells were fixed and prepared for immunofluorescence using anti -P or -NP Ab. 
Yellow arrows indicate cells expressing ectopic viral NP. Blue arrows indicate cells infected 
with PIV5. 
To increase the proportion of DI-PRS genomes in virus generated by PIV5 
superinfection of BSR-T7 cells transfected with the φ2.5.DI-PRS plasmid, the 
virus stock generated was subjected to sequential passages at high MOI. These 
conditions have been shown to lead to an increase in the DI:ND virus ratio (Von 
Magnus, 1951). As PIV5 DIs have been shown to induce IFN, which would 
inhibit their replication, Vero cells were used for these purposes as they cannot 
produce IFN, thereby facilitating DI replication (Fig. 4.28.A). To determine 
whether DI-PRS genomes increased during sequential virus passage, total RNA 
from infected Vero cells was extracted by TRIzol and the amount of DI-PRS 
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genomes estimated by PCR as previously described (Fig. 4.28.B). An increase in 
signal was observed as the number of the passage increased until vM3, 
indicating that increasing levels of DI-PRS genome-containing viruses had been 
generated by this procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.28. Generation of DI-PRS-rich virus stocks. A) BSR-T7 cells were transfected with 2.5µg 
of the φ2.5.DI-PRS plasmid and, 24h post-transfection, they were infected with PIV5 wt vM0 at 
10 MOI. 30h post-infection, virus-containing supernatant was collected. The virus stock 
generated was subjected to sequential infections at high MOI in Vero cells to increase the DI:ND 
virus ratio. The supernatant generated (called vM1') was used to infect Vero cells (2.5ml supern. 
+ 2.5ml 2% DMEM). 48h post-infection, supernatant collected (vM1) was used to infect new 
Vero cells for 48h and this procedure was repeated over 6 times until virus stock vM6 was 
generated. B) Total RNA from infected cells was extracted by TRIzol and the amount of DI-PRS 
genomes estimated by PCR as previously described. The pCAGGS (empty plasmid) and the 
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φ2.5.DI plasmid were used as negative controls for PCR. The φ2.5.DI-PRS plasmid was used as 
positive control for PCR. 
To test whether the stocks of virus containing DI-PRS genomes activated the 
IFN induction cascade, A549pIFNβ.GFP cells were infected with the various 
virus stocks. 20h post-infection, cells were fixed and prepared for 
immunofluorescence. Disappointingly, as can be seen in Fig. 4.29, GFP 
expression was only induced in a minority of cells regardless of the vM 
preparation used. These results indicated that, even when stocks containing DI-
PRS viruses were successfully generated, the level of DI viruses was not 
sufficient to consider them as DI-rich stocks as they were not good IFN 
inducers. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.29. IFN induction by DI-PRS-containing virus stocks generated after sequential 
passages in Vero cells. 90% confluent A549pIFNβ.GFP cells in a 200mm2 well were infected 
with the stocks of viruses previously obtained from sequential passages in Vero cells (Fig. 4.28) 
diluted 1/10. 20h post-infection, cells were fixed and prepared for immunofluorescence. 
Uninfected cells were used as a negative control. As a positive control, cells were infected with 
PIV5-VΔC vM2. 
Despite repeating this procedure on a number of times, generation of a DI-PRS-
containing stock of virus that was a good IFN inducer was unsuccessful. 
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Possible reasons and solutions for this are commented in the Discussion section. 
4.8. Rescue of viral influenza RNPs containing PRS 
Given the difficulties in generating preparations of DI-PRS viruses, to further 
test and develop the PP7-based purification protocol developed, it was decided 
to use PRS-tagged influenza viruses that had been previously described by 
Professor Ervin Fodor and colleagues (Sir William Dunn School of Pathology, 
University of Oxford) (York et al., 2013). In their approach recombinant 
influenza virus A were generated by reverse genetics that encoded the 
neuraminidase (NA) gene with an inserted PRS sequence in one orientation or 
the other. Thus, depending on the orientation, vRNP (vRNA-PRS influenza A 
virus) or cRNP (cRNA-PRS influenza A virus) could be isolated (York et al., 
2013). Furthermore, they showed that insertion of the PRS sequence did not 
adversely affect either virus growth or genome encapsidation (York et al., 2013). 
Fig. 4.30 depicts the structure of the influenza virus NA gene with the extra PRS 
sequence and its encapsidation into virus particles. 
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Fig. 4.30. Recombinant influenza A viruses containing the PRS sequence into the NA gene. 
NA gene sequences from recombinant influenza A virus containing the PRS sequence (here 
termed PP7) in the orientation to capture cRNPs (cRNA-PRS virus) or vRNPs (vRNA-PRS 
virus) are shown. Adapted from York et al., 2013. 
4.8.1. Test influenza A virus replication in PP7-expressing cells 
In order to use the PRS:PP7 purification method, PRS-tagged influenza A 
viruses must infect cells constitutively expressing PP7. However, potentially the 
binding of PP7 to the PRS sequence during virus infection could inhibit virus 
transcription and replication. To test this possibility, 293T.V5-TEV-PP7.puro 
cells, and also 293T cells, were infected with recombinant vRNA-PRS influenza 
A virus at 10 MOI. 12h post-infection, cells were disrupted and expression of 
the viral NP protein analysed by Western Blot. As can be observed in Fig. 4.31, 
the level of NP protein in infected V5-TEV-PP7-expressing cells was similar to 
the level of NP in 293T cells, indicating that PP7 expression did not inhibit the 
transcription or replication of PRS-tagged influenza A viruses. 
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Fig. 4.31. Influenza A virus transcription and replication in PP7-expressing cells. 
293T.V5-TEV-PP7.puro cells, or 293T cells, in a 90% confluent 75cm2 flask, were 
infected with influenza vRNA virus at 10 MOI. 12h post-infection, cells were 
disrupted and proteins analysed by Western Blot using anti-influenza NP, anti-V5 
and anti β-actin Abs. 
4.8.2. PP7 localization in cells infected with recombinant influenza 
A virus 
Prior to attempting to isolate PRS-tagged-influenza virus RNPs through their 
affinity to PP7, immunofluorescence was used to determine whether there was 
a redistribution of PP7 upon infection of A549.V5-TEV-PP7.puro cells with 
vRNA-PRS influenza A virus, as if such a redistribution was observed it would 
strongly suggest that PP7 was interacting with the genomes of the infecting 
virus. Furthermore, as expression of PP7 may interact with the infecting virus 
genomes, A549.V5-TEV-PP7.puro cells were infected at a very high MOI of 500 
pfu/cell. As controls, A549.V5-TEV-PP7.puro cells were also infected with 
influenza virus wt or mock infected. At 8h post-infection, cells were fixed and 
immunostained for PP7 and NP (Fig. 4.32). As can be seen in Fig. 4.32, PP7 was 
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uniformly distributed in the cytoplasm of uninfected cells. The same pattern of 
distribution was observed in cells infected with influenza A wt virus, and also 
in those cells that did not express PP7 but were infected with vRNA-PRS 
influenza virus. Disappointingly, no change in PP7 localization was observed in 
PP7-expressing cells infected with vRNA-PRS influenza virus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.32. PP7 localization in cells infected with recombinant influenza A virus. 90% confluent 
A549.V5-TEV-PP7.puro cells, and A549 cells in a 24-well plate were infected with influenza 
vRNA virus at 500 MOI. As controls, A549.V5-TEV-PP7.puro cells were also infected with 
influenza A virus wt, or mock infected. 8h post-infection, cells were fixed and stained for 
immunofluorescence using anti-influenza NP and anti-V5 Abs. 
No obvious co-localization of PP7 and NP could be observed, suggesting that 
PP7 had not recognized the PRS RNA in the NA segment of vRNA-PRS 
influenza A virus. 
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4.8.3. Isolation and purification of influenza RNPs captured by 
PP7 on Dynabeads 
To test whether recombinant influenza A RNPs could be purified using a TEV-
tagging protocol following capture by PP7 on Dynabeads, 293T.V5-TEV-
PP7.puro cells in a 75cm2 flask were infected with vRNA-PRS influenza A virus 
at a MOI of 10 pfu/cell. As controls, cells were infected with influenza A virus 
wt or mock infected. At 12h post-infection, cells were lysed using Cell Lysis 
buffer (0.4M NaCl, 20mM TrisHCl pH 7.5, 1mM EDTA, 0.5% IGEPAL, 0.1% 
NaN3, complete EDTA-free protease inhibitor cocktail [Roche], RNase inhibitor 
[Promega]). As replication of influenza A virus occurs in the nucleus of infected 
cells, and to minimize loss of viral RNA, total cell lysates, instead of 
cytoplasmic extracts, from infected cells were obtained. For this, cells were 
resuspended in PBS and centrifuged at 200g for 5min at 4°C. The pellet was 
further resuspended in PBS and centrifuged again. The pellet was added 400µl 
ice-cold cell Lysis buffer (in the presence of RNase inhibitors) by rotation for 1h 
at 4°C. Following incubation, the lysate was centrifuged at 17000g for 5min at 
4°C and the supernatant was then incubated for 2h at 4°C with anti-V5 Ab-
containing Dynabeads that had been pre-incubated with t-RNA as previously 
described (a schematic of the procedure is shown in Fig. 4.33. A). Following 
incubation, Dynabeads were incubated with TEV and the supernatant was then 
separated from the Dynabeads and incubated with Ni-NTA Dynabeads as 
previously described. Supernatant and Dynabeads were then separated and the 
amount of PP7 estimated by PAGE (Fig. 4.33. B). Both anti-V5 Ab heavy and 
light chains were observed in all cases tested before incubating with TEV ('RNP 
on beads'). PP7 could also be observed before cleaving with TEV at ~18kDa (V5-
TEV-PP7) or ~15kDa (PP7, no V5-epitope and TEV tag). However, following 
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incubation with TEV ('TEV supern.'), only PP7, together with TEV protease 
(~35kDa), was observed for all cases. PP7 was also present in the supernatants 
following incubation with Ni-NTA Dynabeads ('Ni supern.'), indicating that 
TEV had been captured by Ni-NTA Dynabeads. A band appeared at ~50kDa, 
possibly due to the presence of a contaminant in the TEV protease solution, as 
the band did not appeared in the Dynabeads before incubation with TEV. 
Disappointingly, no NP protein was detected at Coomassie stainable levels 
when Dynabeads were incubated with a cell lysate from cells infected with 
vRNA-PRS viruses. 
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Fig. 4.33. Isolation and purification of influenza RNPs by PP7 on Dynabeads. A) 
90% confluent 293T.V5-TEV-PP7.puro cells in a 75cm2 flask were infected with 
recombinant influenza vRNA viruses at 10 MOI for 12h. As controls, cells were also 
infected with influenza A virus wt or left uninfected. Following infection, total cell 
lysates were obtained as described previously and incubated with 300µg Dynabeads, 
A) 
B) 
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which had previously been saturated with anti-V5 Ab and t-RNA, by rotation for 2h at 
4°C. B) Dynabeads were then incubated with TEV protease as described in section 4.6, 
the supernatant separated and incubated with 400µg Ni-NTA Dynabeads by rotation 
for 10min at 22°C. Following incubation, the supernatant was separated and the 
proteins present in selected fractions were visualized by PAGE. 
A Western Blot was then performed to test whether vRNP complexes were 
effectively captured (Fig. 4.34). As can be observed, NP protein was present in 
the total cell extract of cells infected with influenza A wt or vRNA-PRS virus. 
Some viral RNPs were bound by TEV-PP7-Dynabeads when cells were infected 
with vRNA-PRS virus, as NP was observed before cleaving with TEV (vRNA in 
'RNP on beads'). However, similar amounts of viral RNPs were also rescued by 
TEV-PP7-Dynabeads when cells were infected with influenza A wt virus (wt in 
'RNP on beads'). Disappointingly, no NP was observed in the supernatant after 
TEV cleavage of TEV-PP7-Dynabeads when cells were infected with vRNA-PRS 
virus (vRNA in 'TEV supern.'), suggesting that all the RNPs detected before 
TEV cleavage were non-specifically bound to Dynabeads. 800µl of total cell 
extract were incubated with 2400µg Dynabeads, and the equivalent of 60µg 
Dynabeads were loaded onto the gel as 'RNP on beads'. 2µl of total cell extract 
were loaded onto the gel ('total cell extract'). Considering that the amount of NP 
protein in 'RNP on beads' in the W/B is slightly less than half of that in 'total cell 
extract' (Fig. 4.34 left), a rough estimate for the proportion of RNPs rescued by 
Dynabeads with respect to the total RNPs incubated with them was calculated 
as less than 5%. 
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Fig. 4.34. Isolation and purification of influenza RNPs by PP7 on Dynabeads by Western 
Blot. Viral NP and V5-TEV-PP7 presence in selected fractions of the experiment in Fig. 4.32 
were analysed by Western Blot using anti-V5 and anti-influenza A NP Abs. 
Disappointingly, despite repeating this experiment on a number of occasions, 
influenza viral RNP complexes containing the PRS sequence were not 
specifically captured using the V5-tagged PP7-based protocol developed. Due 
to time constraints, it was not possible to further investigate the rescue of 
influenza RNP complexes. Possible reasons and solutions for this are 
commented in the Discussion section. 
4.9. Discussion 
4.9.1. Developing a protocol based on PP7:PRS RNA interactions 
to study the proteins involved in RNA:protein complexes 
Distinct types of RNA play essential roles in the proper functioning of cells and 
they normally act bound to proteins forming part of macromolecular 
complexes, such as ribosomes or spliceosomes (Jones et al., 2001). It is therefore 
fundamental to understand the role played by RNA:protein interactions in the 
formation and functions of such macromolecule complexes. Our knowledge of 
specific RNA:protein interactions has increased considerably over the recent 
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years. Common techniques to study proteins involved in RNA:protein 
complexes are mass spectroscopy to identify the proteins in the complex and X-
ray crystallography and nuclear magnetic resonance (NMR) to investigate their 
structure. However, before such techniques can be employed, the desired 
RNA:protein complexes must be at least partially purified, and the techniques 
used to purify such complexes are often laborious and time–consuming. The 
main aim of my research project was to develop a simple purification protocol 
to isolate highly purified preparations of the RNA:protein complexes under 
investigation. The protocol was based on the interaction of PP7 with PRS that 
has a stem-loop structure that is only recognized with high affinity by PP7. 
Indeed, in general, the interaction of bacteriophage coat proteins with their 
cognate binding sites are highly specific. Thus, whilst PP7 binds with high 
affinity to the PRS on the bacteriophage Pseudomonas aeruginosa, it does not bind 
to a related sequence on the bacteriophage MS2, which only differs from the 
PRS in one bulged adenosine and the sequence of the loop. In contrast, the MS2 
coat protein binds to its cognate sequence with high affinity but not to PRS. 
(Gesnel et al., 2009). This highly specific interaction of PP7 with PRS has already 
been used to identify cellular and viral proteins that interact with specific RNAs 
(Gesnel et al., 2009; York et al., 2013). 
The aim of the initial part of the work was to develop a protocol that would 
result in the isolation of highly purified RNA:protein complexes, with the 
minimum of contaminating material. Therefore initially I tested the effect that 
different binding buffers, containing either ionic or non-ionic detergents, had 
on the efficiency of rescue of DI-PRS RNA by PP7 on Dynabeads in vitro. Whilst 
the use of RIPA buffer, that contains the ionic detergents sodium dodecyl 
sulphate (SDS) and sodium deoxycholate (DOC), minimized the amount of 
non-specific binding of RNA to Dynabeads, there was also a significant 
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reduction in the efficiency of capture of DI-PRS RNA by PP7-Dynabeads. It has 
been reported that SDS can disrupt protein:nucleic acid complexes when used 
at a concentration of 2% or more (Metelev et al., 2003). In the experiments 
reported here, SDS and DOC were used at the concentrations of 0.05% and 0.5% 
respectively. It therefore seems likely that these relatively low concentrations 
deleteriously affect PP7:PRS RNA interactions. Another reason for not using 
ionic detergents is that they disrupt cellular membranes, including the nuclear 
membrane, resulting in the presence of DNA in the cell lysate, which increased 
the viscosity of the extract making it more difficult to process the Dynabeads 
than when IPB or Tris lysis buffer were used, and thus also potentially 
increasing the amount of non-specific binding of proteins. 
When IPB buffer or Tris Lysis buffer were used, high efficiency of rescue of DI-
PRS RNA by PP7-Dynabeads was observed. Both IPB and Tris Lysis buffer 
contain octylphenoxypolyethoxyethanol, also known commercially as NP-40, a 
non-ionic detergent. Non-ionic detergents are less harsh than ionic detergents 
and are preferred for immunoprecipitation protocols. Two variables that can 
affect immunoprecipitation efficiency using beads are the concentrations of 
non-ionic detergents and salts in the binding buffer. Non-ionic detergents alter 
hydrophobic interactions, thereby reducing low affinity, non-specific, binding 
of molecules to beads. NP-40 concentration was 0.1% in IPB buffer in contrast to 
0.5% in Tris Lysis buffer. This more stringent condition for Tris Lysis buffer 
could explain the lower level of non-specific binding of RNA to Dynabeads 
observed when Tris Lysis buffer was used when compared to the level 
observed for IPB buffer. Presence of salts in the binding buffer increases ionic 
strength and this affects low affinity, ionic interactions of molecules with other 
molecules or with beads. However, this condition seemed to play a less 
important role in terms of the interaction with non-specific binding of RNA to 
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Dynabeads compared to the presence of non-ionic detergents in the binding 
buffer, as concentration of NaCl was as high as 0.65M in IPB buffer whilst it 
was 0.4M in Tris Lysis buffer. Nevertheless, the combination of 0.5% NP-40 and 
0.4M NaCl in Tris Lysis buffer gave the best results concerning specific capture 
of DI-PRS RNA to PP7-Dynabeads. Moreover, the effect of salt concentration 
was also tested, and it was observed that increasing salt concentration to levels 
higher than 0.4M did not result in greater reduction of non-specific binding of 
DI-PRS RNA. In view of these results, a binding buffer containing 0.5% NP-40 
and 0.4M NaCl was selected to be used in experiments to capture RNA:protein 
complexes by PP7 on Dynabeads. 
Some non-specific binding of RNA to Dynabeads still occurred after 
optimization of the binding buffer and, to try and reduce this further I 
investigated blocking the non-specific binding sites for RNA in Dynabeads by 
pre-incubating them with random RNA. In an analogous fashion, Dynabeads 
are pre-incubated with proteins, such as BSA. I therefore pre-incubated 
Dynabeads with t-RNA from wheat germ before incubating them in the 
presence of carrier t-RNA with a cytoplasmic extract containing PP7 during the 
generation of PP7-DI-PRS RNA Dynabeads. This resulted in a considerable 
reduction (although not complete) of RNA non-specifically bound to 
Dynabeads. 
4.9.2. TAP-tagging purification using V5-TEV 
The ultimate aim of these studies was to use mass spectroscopy to identify the 
proteins present in RNA:protein complexes captured by, and subsequently 
eluted from, Dynabeads. However, as well as the problem of non-specific 
binding of proteins to Dynabeads, there was also the potential problem that if 
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large amounts of IgG heavy and lights chains, from the anti-V5 antibody used 
to capture the V5 tagged PP7, were present in the samples to be analysed they 
would interfere with the analysis. One possible method to avoid presence of Ab 
heavy and light chains is to covalently link, or cross-link, the Ab to the beads. 
However, this method can negatively affect the efficiency of 
immunoprecipitation. As an alternative method, a tap-tagging purification 
system based on V5-TEV was designed to release the RNA:protein complexes 
from the Dynabeads. This has the added advantage that it also can be used to 
significantly reduce the amount of non-specific proteins present in the eluted 
samples. Cell lines that constitutively expressed V5-TEV-PP7 were generated 
and the optimal conditions for the tap-tagging purification were determined. 
This procedure looks extremely promising for further development. Thus, 
following the capture of DI-PRS RNA by TEV-PP7, PP7:RNA:protein complexes 
were released from the Dynabeads by incubation with His-TEV and then the 
His-TEV was removed with Ni-NTA Dynabeads. As a consequence, no trace of 
proteins that bound non-specifically to the Dynabeads or IgG heavy and light 
chains could be detected in the supernatant that contain PP7 and the captured 
DI-PRS RNA. 
The tap-tagging purification protocol developed is not limited to the isolation of 
DI-PRS RNA-binding proteins. Using very similar protocols to those I 
developed, the techniques can be used to identify protein:protein interactions. 
For example, ongoing work in our laboratory is using this tap-tagging method 
to identify cell host proteins that are the targets of viral IFN antagonists. 
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4.9.3. Failure to amplify viruses containing DI-PRS that induce 
IFN 
Generation of a stock of PIV5 containing encapsidated DI-PRS genomes was 
intended as a method to introduce DI-PRS genomes into PP7-expressing cells in 
order to capture DI-PRS RNA:protein complexes that activate the induction of 
innate intracellular responses following viral infection. For this, BSR-T7 cells 
transfected with the φ2.5.DI-PRS plasmid were subsequently infected with wt 
PIV5, and the virus stock generated subjected to sequential passages in Vero 
cells at high MOI in an attempt to amplify DI-PRS further. Disappointingly, 
despite observing a slight amplification in the number of DI-PRS genomes as 
the virus passage number increased (Fig. 4.28), the IFN induction cascade was 
only activated in a very small number of cells regardless of the virus stock used. 
Unfortunately, despite repeated attempts to generate a virus stock containing 
large numbers of DI-PRS genomes, no preparation of DI-PRS virus was 
obtained that activated the IFN induction cascade. 
Reasons for the failure to generate a DI-PRS-rich stock of PIV5 are not known. 
As already stated, the φ2.5.DI plasmid encodes the most prominent copyback 
DI genome found in a PIV5-VΔC vM2 preparation (Killip et al., 2013). This DI 
genome is 1428 nt long including a 223 bp long dsRNA stem, and is therefore in 
accordance with the 'rule of six'. This rule states that RNA genomes whose 
nucleotide number is multiple of six are more efficiently replicated (Calain and 
Roux, 1993). The 'rule of six' is based on the stoichiometry of the encapsidation 
process of the viral genome. In the encapsidation process, which occurs 
concurrent to the generation of new viral genomes or antigenomes, each NP 
protein binds 6 nucleotides. This rule has proved to be valid for many 
paramyxoviruses, although it is not known whether it is valid for PIV5. In fact, 
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the rule is not strict for PIV5 DI genomes, as DI genomes whose nucleotide 
number is not a multiple of six have been found in DI-rich stocks of PIV5-VΔC 
and PIV5 wt (Killip et al., 2013). Nevertheless, it has been observed that DIs 
genomes that are divisible by six replicate more efficiently than those that do 
not (Murphy and Parks, 1997). The DI-PRS genome expressed from the φ2.5.DI-
PRS plasmid also obeys the rule. This can have two consequences. First, if all 
the genome was encapsidated, replication of the DI would occur, as the viral 
polymerase encountered no difficulty in reading along the genome. However, a 
second consequence is that it is possible that, even when DI-PRS obeys the rule, 
a stable PRS stem-loop structure would be formed. In this case, the rest of the 
DI genome would fall out-of-phase, affecting encapsidation. Although PRS 
would be exposed for interaction with PP7, this would affect DI replication, as 
the viral polymerase would find an obstacle to read along the DI genome. For 
influenza viruses, the 'rule of six' seems not to be strict. It appears that PRS-
containing influenza NA RNP complexes had the PRS structure exposed for 
interaction and were captured by PP7 (York, 2014). This will be commented 
later. 
Paramyxovirus RNA synthesis requires the viral phosphoprotein (P), large 
protein (L) and nucleoprotein (NP). It has been observed that replication and 
transcription efficiency of PIV5 W3 was low compared to similar PIV5 strains, 
and this was related to P protein phosphorylation (Timani et al., 2008). In fact, 
after an initial phase of infection, S157 in the P protein becomes phosphorylated 
by the cellular kinase Polo-like kinase 1 (PLK1) and this decreases viral gene 
expression, and also cytokine expression, in infected cells (Sun et al., 2009). It is 
possible that, apart from phosphorylation, PIV5 W3 regulates viral gene 
expression by sumoylation (Sun et al., 2011) or ubiquitination of the P protein. 
This could be a more plausible reason for failure in the generation of a DI-rich 
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stock of PIV5 viruses, as experiments in this research were performed using 
PIV5 W3. We were not aware of this at the time the experiments were 
performed, as failure in PIV5 W3 replication/transcription had only been 
observed in minireplicons. Further work on this is being performed in our 
laboratory at the time of submission of this thesis. However, due to lack of time, 
the impact this issue had in the rescue of viruses containing DI-PRS genome 
was not further investigated. Nevertheless, in the light of our understanding, 
CPI+ virus would be a better candidate to generate DI-rich stocks of virus. CPI+ 
is a PIV5 strain isolated from a dog infected with PIV5 (Southern et al., 1991). 
Unpublished data suggests that there is a critical modification in the CPI+ P 
protein, S157F, which would prevent P phosphorylation and, therefore, 
decrease in the replication/transcription efficiency. With all this, transfection of 
BSR-T7 cells with the φ2.5.DI-PRS plasmid and later infection with CPI+ at high 
MOI would potentially lead to the generation of viruses containing DI-PRS. To 
enhance replication and encapsidation of DI-PRS genomes, cells could be co-
transfected with plasmids encoding for PIV5 W3 NP and L proteins and also, to 
avoid decrease in viral replication/transcription, a plasmid encoding for PIV5 
CPI+ P protein. 
In view of unsuccessful rescue of viruses containing DI-PRS, attempts to 
generate such stock were made using a different strategy. It would be extremely 
useful to have a selectable marker, such as a gene encoding for a fluorescent 
protein, contained in the DI genome to generate DI-containing viruses as 
previously described. Therefore, cells infected with such stock of viruses can be 
monitored. Cells presenting fluorescence would be selected, and stocks of 
viruses derived from those infected cells would be potentially enriched in DI-
containing viruses. However, DI(TrCB) genomes cannot be used for this 
strategy, as an antigenome promoter does not lead to mRNA transcription. 
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Instead, this approach was performed using a plasmid containing a DI(LeCB) 
genome. This plasmid was provided by Professor Steve Goodbourn and a 
schematic of it can be seen in Fig. 4.35. It basically consists on the φ2.5 promoter 
followed by a hepatitis D virus (HDV) ribozyme sequence. The HDV ribozyme 
sequence is, in turn, followed by a DI(LeCB) genome sequence plus a HDV 
ribozyme and a T7 terminator sequences. The DI(LeCB) genome includes a 
Leader (Le) sequence that is essential to start transcription by the viral 
polymerase and forms one 'arm' of the ds stem component of the DI. It is 
immediately followed by a sequence encoding for mCherry that forms part of 
the loop of the DI structure and, in turn, is followed by an L sequence that 
terminates transcription by the viral polymerase. A sequence complementary to 
the Le sequence forms the other 'arm' of the ds stem. The plasmid was tested in 
several cell lines i.e. 293T, BSR-T7, A549 and Hep2 cells. Those cells were 
transfected with the plasmid encoding for DI(LeCB) and also, when required, 
co-transfected with a plasmid encoding for a functional T7pol (also provided by 
Professor Steve Goodbourn). 24h post-infection, cells were infected with PIV5 at 
a MOI of 10pfu/cell. Disappointingly, no mCherry was observed in the cells 
after 24 and 48h of infection. A second experiment was performed to further 
test the plasmid encoding for DI(LeCB), this time by infecting BSR-T7 cells with 
PIV5 at 10pfu/cell and, after 12h, transfecting them with the plasmid. An 
ongoing replication and encapsidation of viral genome would potentially help 
encapsidation of the DI genome. However, no mCherry was observed after 24 
and 48h of infection. Reasons for failure could be related to the use of PIV5 W3 
in these experiments. For reasons previously commented, such stock should be 
avoided in experiments that require multiple replication and transcription of 
the viral genomes. Instead, generation of stocks of virus containing the 
mCherry-DI(LeCB) genome should be performed using CPI+ stocks of viruses. 
To enhance replication and encapsidation of DIs, BSR-T7 cells could be co-
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transfected with plasmids encoding for viral PIV5 NP and L proteins, and CPI+ 
P proteins. mCherry expression in BSR-T7 cells, and also in cells infected with 
the virus stocks generated, would indicate that DI(LeCB) genomes are being 
generated and encapsidated into viral particles. If successful, this technique 
would facilitate the generation of stocks of viruses rich in DI genomes. A 
fluorescent marker in the DI genomes could serve to monitor the cells infected, 
that could facilitate a better understanding of infection by DI viruses. 
 
 
 
 
 
 
Fig. 4.35. Structure of the plasmid encoding for a DI(LeCB) genome containing the mCherry 
sequence. The DI(LeCB), under the control of the φ2.5 promoter, is preceded by a HDV 
ribozyme (HDR) sequence. It is followed by another HDR sequence and a T7 termination 
sequence. The ribozyme sequences cut the copyback DI sequence so that a blunt-ended stem-
loop structure is generated. A Leader (Le) forms the first 'arm' of the ds stem of the DI structure 
and starts transcription by the viral polymerase. It is followed by a mCherry sequence that is 
contained in the loop of the copyback DI that, in turn, is followed by an L sequence that 
terminates transcription. A sequence complementary to the Le sequence forms the other 'arm' of 
the ds stem. 
It has fairly recently been discovered that viral genomes containing high 
frequency of CpG dinucleotides are more readily recognized by host receptors 
and this leads to an inhibition of viral replication (Atkinson et al., 2014; Tulloch 
et al., 2014). The DI(TrCB) sequence shows a frequency of CpG dinucleotides 
that is 50% of the expected value calculated from its mononucleotide 
composition (based on the number of G and C nucleotides). Although a low 
CpG ratio, it should be potentially possible to improve replication efficiency by 
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modifying the copyback DI sequence so that it contains a lower frequency of 
CpG motifs. This could be translated into an improvement in the chances of 
virus rescue. 
4.9.4. Failure in the ability to pull down influenza RNPs 
Previously to this research, Dr Ashley York isolated influenza NA-PRS vRNP 
and cRNP complexes (York, 2014). For this, he infected cells stably expressing 
PP7 protein His-tagged with vRNA-PRS, and cRNA-PRS, influenza viruses and 
separated the viral NA vRNP and cRNP complexes formed using a Ni-NTA 
affinity purification method. On average, the yield of NA vRNA captured of 
total vRNA from cell lysates was 11.8%, and that of cRNP captured was 20%. 
In this research, we wanted to further test the PP7-based purification protocol 
developed using PRS-tagged influenza viruses. Successful capture of influenza 
NA RNP complexes formed within cells following infection would be proof of 
principle showing that the protocol developed can successfully work. 
Unfortunately, vRNA-PRS RNPs were non-specifically captured by PP7-
Dynabeads, as influenza wt RNPs were also captured. Nevertheless, the yield of 
NA vRNA captured of total vRNA from the cell lysate was less than 5%. In our 
approach, we used a V5-epitope tag purification protocol instead of a His-
tagged-based protocol used by Dr Ashley York. Therefore, it is possible that, for 
unknown reasons, the differences among V5 tag and His tag affect the rescue of 
influenza RNPs. 
To prevent presence of IgG heavy and light chains in future analysis, and also 
to avoid presence of non-specifically bound proteins to Dynabeads, influenza 
RNP complexes captured by PP7-Dynabeads were further subjected to tap-
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tagging purification using TEV protease. Unfortunately, none of the RNP 
complexes previously observed were present in the supernatant after 
incubation of Dynabeads with TEV (Section 4.8.3). We already showed that the 
PRS sequence is recognized by PP7 in vitro (Section 4.4.2). However, binding of 
influenza NA RNPs containing the PRS sequence to PP7 within cells did not 
occur, and reasons for this are unclear. Dr Ashley York showed capture of 
influenza NA RNPs after Ni-NTA affinity purification (York, 2014). However, a 
high background of proteins were also rescued and, to further purify the 
influenza NA RNPs and avoid proteins non-specifically captured, samples were 
subjected to density gradient ultracentrifugation. Following ultracentrifugation, 
results shown in York, 2014 revealed that the total yield of specific capture of 
NA vRNP and cRNP complexes was lower than 10% in each case. This could 
indicate that a good specific capture may not have occurred. It is possible that, 
as compared with what occurred in the experiment we performed in Section 
4.8.3, there was no specific interaction of PRS-containing viral RNPs with PP7, 
and the viral RNP complexes captured were non-specifically bound. It is 
therefore likely that the PRS sequence in influenza NA RNPs was not exposed 
for interaction with PP7. Unfortunately, we did not have time to investigate this 
further.
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CHAPTER 5: CONCLUSIONS 
Work presented here led to the identification of distinct cytokines that, together 
with IFNβ, are induced within cells in response to infection with PIV5 stocks 
rich in DI viruses. Further investigations are needed to know which other 
cytokines are also induced by PIV5 DIs. A better understanding of how DI 
genomes of different viruses modulate the host immune response could lead to 
the use of DIs as therapeutic agents in a wide range of medical applications and 
diseases. 
This research also led to the development of a simple protocol, based on the 
interaction of PP7 with its cognate RNA binding site, termed PRS, to isolate 
specific RNA:protein complexes. Using this protocol in in vitro pull down 
assays, ILF3 and PKR, two proteins known to be induced by IFN and bind 
dsRNA, were successfully captured. The methodology was complemented by a 
tap-tagging purification system, based on TEV protease, that resulted in a 
significant decrease in the amount of non-specifically captured proteins that 
could interfere with subsequent analysis. Purification systems based on the one 
developed can be applied to the study of other biological complexes and, in 
fact, have been used in our laboratory to investigate the interaction of viral IFN 
antagonists with cellular proteins. 
The generation of stocks of viruses containing DI-PRS genomes could have 
been a major step forward in our investigations into how DIs activate innate 
intracellular signalling cascades within cells. The failure in generating such 
virus stocks may have been related to the fact that the W3 strain of PIV5 was 
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used for these experiments. As it is now known that W3 transcription and 
replication is specifically switched off after 18-24h p.i., but other PIV5 strains, 
such as CPI+, are not, attempts to generate DI-PRS genomes should be 
undertaken using the CPI+ strain of PIV5.  
Reasons for failure to capture PRS-tagged influenza RNPs using the PP7 
purification system developed are unknown and need to be investigated. 
In conclusion, a promising protocol for the purification of RNA:protein and 
protein:protein complexes was developed that could be further modified in 
many diverse studies aimed at better understand the molecular basis of many 
important biological processes. 
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Appendix 1. Sequence of the φ2.5.DI plasmid 
 
. partial NcoI site (lacks a C in 5’)  
. φ2.5 T7 promoter 
. PstI sites 
. ribozyme sequence 
. T7 terminator sequence 
. XbaI site 
 
5' 
CATgGCAGTAATACGACTCACTATTACCAAGGGGAAAACCAAGATTAATCCTCTTCTTT
TTTCTTAAACTAATTCTGATTCTTGATATGTTTAGATTTCCTCGCCATCGATCCCGCGGTC
TATTTCTTCATTAATATTTATATCAATAAACTCTGTTGACTCCCTTTGATCCATTGGATCG
TGACAATAGACTACACAACCTAATGCTTTCCAGATTTGCTTTTGGATAGGTCTGGTTGGA
TCGATATTATGGAACGGAGGCGCCGCCATGACTGACATATGAATGACAGCTTGTGTAG
AATTCATCATCAATCGAGTCGGCCCAAGGACTTGCAGTTTAGTACATGTAGATTTGGAA
TCAAGTGCAAGCTTGAATCAACAATGCCTGTCAAAGCCGATGATTAATGCTATCATCAC
TGCTACAACTGTTTTGTGCCCTCATGGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTT
ACTGGGTTTAGTGCTTTGATCACTTTCTTGTGGTGCTACTTTGAGAGAATCACTGTTCTTA
GGAGCACATATTCTGATCCAGCTAATCATGAGGTTTTATTTAATTTGTATCCTTGCCAAC
AACTTTGCATTCCAGACTGTCTCGCAGGCAACAGGAATGGCGATGACTTTAACTGATCA
ATGGTTTACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTGAAGC
AGGAACGTATCGTAGCAGAAGCAATTGATAGGGTGGTTCTAGGAGAAAATGCTCTATT
TAATTCGAGTGATAATGAATTAATTCTCAAATGTGGAGGGACACCAAATGCACGGAAT
CTCATCGATATCGAGCCAGTCGCAACTTTCATAGAATTTGAACAATTGATCTGCACAAT
GTTGACAACCCACTTGAAGGAAATAATTGATATAACAAGGTCTGGAACCCAGGATTAT
GAAAGTTTATTACTCACTCCTTACAATTTAGGTCTTCTTGGTAAAATCAGTACGATAGTG
AGATTATTAACAGAAAGGATTCTAAATCATACTATCAGGAATTGGTTGATCCTCCCACC
TTCGCTCCGGATGATCGTGAAGCAGGACTTGGAATTCGGCATATTCAGGATTACTTCCA
TCCTCAATTCTGATCGGTTCCTGAAGCTTTCTCCAAATAGGAAATACTTGATTGCACAAT
TAACTGCAGGCTACATTAGGAAATTGATTGAGGGGGATTGCAATATCGATCTAACCAG
ACCTATCCAAAAGCAAATCTGGAAAGCATTAGGTTGTGTAGTCTATTGTCACGATCCAA
TGGATCAAAGGGAGTCAACAGAGTTTATTGATATAAATATTAATGAAGAAATAGACCG
CGGGATCGATGGCGAGGAAATCTAAACATATCAAGAATCAGAATTAGTTTAAGAAAAA
AGAAGAGGATTAATCTTGGTTTTCCCCTTGGTGGGTCGGCATGGCATCTCCACCTCCTCG
CGGTCCGACCTGGGCATCCGAAGGAGGACGCACGTCCACTCGGATGGCTAAGGGAGCG
GCCGGGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCG
CTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTC
TAGAAATTCACCCCACCAGTGCAGGCTGCCTATCAGAAAGTGGTGGCTGGTGTGGCTA
ATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGG
TTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCAT
CTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAATGATGTATTTAAATTATTTCT
GAATATTTTACTAAAAAGGGAATGTGGGAGGTCAGTGCATTTAAAACATAAAGAAATG
AAGAGCTAGTTCAAACCTTGGGAAAATACACTATATCTTAAACTCCATGAAAGAAGGT
GAGGCTGCAAACAGCTAATGCACATTGGCAACAGCCCTGATGCCTATGCCTTATTCATC
CCTCAGAAAAGGATTCAAGTAGAGGCTTGATTTGGAGGTTAAAGTTTTGCTATGCTGTA
TTTTACATTACTTATTGTTTTAGCTGTCCTCATGAATGTCTTTTCACTACCCATTTGCTTAT
CCTGCATCTCTCAGCCTTGACTCCACTCAGTTCTCTTGCTTAGAGATACCACCTTTCCCCT
GAAGTGTTCCTTCCATGTTTTACGGCGAGATGGTTTCTCCTCGCCTGGCCACTCAGCCTT
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AGTTGTCTCTGTTGTCTTATAGAGGTCTACTTGAAGAAGGAAAAACAGGGGGCATGGTT
TGACTGTCCTGTGAGCCCTTCTTCCCTGCCTCCCCCACTCACAGTGACCCGGAATCTGCA
GCCCAAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTT
ACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGA
GGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTG
ATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTC
AGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCG
CTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACC
GTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACG
AAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTA
GACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTA
AATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAAT
ATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTG
CGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCT
GAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGA
TCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGC
TATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATA
CACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGA
TGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCG
GCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAA
CATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATA
CCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAA
CTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGA
GGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTG
CTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCA
GATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGG
ATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT
GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAA
AAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGT
TTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCT
TTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAG
CGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAAC
TCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGT
GGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGC
AGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTA
CACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGG
AGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAG
GGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCT
GACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCC
AGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCA 
3' 
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Appendix 2. Sequence of φ2.5-DI-PRS plasmid 
 
. partial NcoI site (lacks a C in 5’)  
. φ2.5 T7 promoter 
. PstI sites 
. ribozyme sequence 
. T7 terminator sequence 
. XbaI site 
. PRS sequence 
 
5' 
CATgGCAGTAATACGACTCACTATTACCAAGGGGAAAACCAAGATTAATCCTCTTCTTT
TTTCTTAAACTAATTCTGATTCTTGATATGTTTAGATTTCCTCGCCATCGATCCCGCGGTC
TATTTCTTCATTAATATTTATATCAATAAACTCTGTTGACTCCCTTTGATCCATTGGATCG
TGACAATAGACTACACAACCTAATGCTTTCCAGATTTGCTTTTGGATAGGTCTGGTTGGA
TCGATATTATGGAACGGAGGCGCCGCCATGACTGACATATGAATGACAGCTTGTGTAG
AATTCATCATCAATCGAGTCGGCCCAAGGACTTGCAGTTTAGTACATGTAGATTTGGAA
TCAAGTGCAAGCTTGAATCAACAATGCCTGTCAAAGCCGATGATTAATGCTATCATCAC
TGCTACAACTGTTTTGTGCCCTCATGGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTT
ACTGGGTTTAGTGCTTTGATCACTTTCTTGTGGTGCTACTTTGAGAGAATCACTGTTCTTA
GGAGCACATATTCTGATCCAGCTAATCATGAGGTTTTATTTAATTTGTATCCTTGCCAAC
AACTTTGCATTCCAGACTGTCTCGCAGGCAACAGGAATGGCGATGACTTTAACTGATCA
ATGGTTTACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTGAAGC
AGGAACGTATCGTAGCAGAAGCAATTGATAGGGTGGTTCTAGGAGAAAATGCTCTATT
TAATTCGAGTGATAATGAATTAATTCTCAAATGTGGAGGGACACCAAATGCACGGAAT
CTCATCGATATCGAGCCAGTCGCAACTTTCATAGAATTTGAACAATTGATCTGCACAAT
GTTGACAACCCACTTGAAGGAAATAATTGATATAACAAGGTCTGGAACCCAGGATTAT
GAAAGTTTATTACTCACTCCTTACAATTTAGGTCTTCTTGGTAAAATCAGTACGATAGTG
AGATTATTAACAGAAAGGATTCTAAATCATACTATCAGGAATTGGTTGATCCTCCCACC
TTCGCTCCGGATGATCGTGAAGCAGGACTTGGAATTCGGCATATTCAGGATTACTTCCA
TCCTCAATTCTGATCGGTTCCTGAAGCTTTCTCCAAATAGGAAATACTTGATTGCACAAT
TAACTGCAGtaaggagtttatatggaaacccttaGCTACATTAGGAAATTGATTGAGGGGGATTGCAA
TATCGATCTAACCAGACCTATCCAAAAGCAAATCTGGAAAGCATTAGGTTGTGTAGTCT
ATTGTCACGATCCAATGGATCAAAGGGAGTCAACAGAGTTTATTGATATAAATATTAAT
GAAGAAATAGACCGCGGGATCGATGGCGAGGAAATCTAAACATATCAAGAATCAGAA
TTAGTTTAAGAAAAAAGAAGAGGATTAATCTTGGTTTTCCCCTTGGTGGGTCGGCATGG
CATCTCCACCTCCTCGCGGTCCGACCTGGGCATCCGAAGGAGGACGCACGTCCACTCG
GATGGCTAAGGGAGCGGCCGGGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGA
GTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGG
TCTTGAGGGGTTTTTTCTAGAAATTCACCCCACCAGTGCAGGCTGCCTATCAGAAAGTG
GTGGCTGGTGTGGCTAATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGTC
CAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTAT
GAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAATGA
TGTATTTAAATTATTTCTGAATATTTTACTAAAAAGGGAATGTGGGAGGTCAGTGCATTT
AAAACATAAAGAAATGAAGAGCTAGTTCAAACCTTGGGAAAATACACTATATCTTAAA
CTCCATGAAAGAAGGTGAGGCTGCAAACAGCTAATGCACATTGGCAACAGCCCTGATG
CCTATGCCTTATTCATCCCTCAGAAAAGGATTCAAGTAGAGGCTTGATTTGGAGGTTAA
AGTTTTGCTATGCTGTATTTTACATTACTTATTGTTTTAGCTGTCCTCATGAATGTCTTTTC
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ACTACCCATTTGCTTATCCTGCATCTCTCAGCCTTGACTCCACTCAGTTCTCTTGCTTAGA
GATACCACCTTTCCCCTGAAGTGTTCCTTCCATGTTTTACGGCGAGATGGTTTCTCCTCG
CCTGGCCACTCAGCCTTAGTTGTCTCTGTTGTCTTATAGAGGTCTACTTGAAGAAGGAAA
AACAGGGGGCATGGTTTGACTGTCCTGTGAGCCCTTCTTCCCTGCCTCCCCCACTCACAG
TGACCCGGAATCTGCAGCCCAAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTG
GGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCT
GGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAA
TGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCG
CATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGAC
ACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTAC
AGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACC
GAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGA
TAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCT
ATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGA
TAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGC
CCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTG
AAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATC
TCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGC
ACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCA
ACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAG
AAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCAT
GAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTA
ACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGA
GCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCA
ACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATT
AATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCG
GCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATT
GCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGA
GTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGAT
TAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACT
TCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAAT
CCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGC
TACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACT
GGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCA
CCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGT
GGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTAC
CGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGA
GCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCAC
GCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGG
AGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGG
TTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTA
TGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCT
CA 
3' 
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Appendix 3. Sequence of the V5-TEV-PP7 construct 
 
 
 
